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Abstract 
The global pharmaceutical industry is characterized for being highly competitive and for having though 
market regulations. Therefore, companies whose seek to generate value and continue with a strategic 
position in the market, look for different and smart ways to achieve the objective. In this industry, 
Mergers and Acquisitions are very supported by practitioners and managers, since it enhance the 
productivity of the company and the shareholder value. Merck & Co., Inc and Schering-Plough 
Corporation are an example of the merger of two companies that brought and incorporated different 
capabilities in an efficient way, therefore taking advantage of new opportunities in the different 
segments of the pharmaceutical industry.  
The goal of this dissertation is to do the historical financial analyze and estimate the enterprise value of 
both companies as if they were optimally managed; and assess the value of the merged entity and the 
synergies created. Last it is proposed an acquisition mode and optimal price for the deal to be accepted.  
Through the Literature Review it is presented explained the different valuation methods and M&A 
concepts and applications.   
This work showed that Merck & Co., Inc and Schering-Plough Corporation were undervalued during 
2008, and the merger will create value of both companies. The estimated synergies, approximately $ 84 
billion, represent 26 percent of the merged entity enterprise value. The company’s share price, by the 
end of 2008 was 30.4 and 17.03, Merck and Schering-Plough, respectively. As a result of all the 
valuation factors, the premium offered to Schering-Plough was 30 percent over the company’s average 
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1. Introduction 
The emphasis of this master thesis is on Mergers and Acquisitions (M&A). The objective of the thesis is 
to evaluate the merger of two companies and give reasonable reasons for their consolidation. The thesis 
focuses on the real case of merger of two biopharmaceutical companies, Merck & Co., Inc and 
Schering-Plough Corporation in 2008. Since the merger occurred in 2008 it will be analyzed as the 
present time began in the end of 2008, time when both companies expressed a desire to merge, therefore 
all financial and market information will be from the same year. 
The pharmaceutical industry is characterized for having innumerous opportunities that can be captured 
when two pharmaceutical companies merge, since the different companies can combine different 
capabilities that leverage their competitive advantage. Hereby, in this thesis one will demonstrate the 
opportunities that Merck & Co., Inc and Schering-Plough Corporation will gain with the merger.  
The thesis will initiate with the industry and company analysis of Merck & Co., Inc and Schering-
Plough Corporation. This framework in the pharmaceutical industry will provide information of how the 
industry works and their segments. The company analysis section will present Merck & Co., Inc and 
Schering-Plough Corporation, sales performance and main costs that affect their operations. 
The thesis will have a literature review chapter to present the various valuations models and the proper 
model to value these companies. The literature review will also focus on M&A, crucial notions that are 
important to understand and proceed with the consolidation of two companies.  
Proceeding there will be a chapter dedicated to the performance in the stock market of Merck and 
Schering-Plough in order to compare both companies share price.  
The performance forecast will be separated in different chapters, where there will be the standalone 
valuation forecast for Merck and Schering-Plough, in this chapter it is applied expectations for both 
companies. Hereafter, the merger of the companies; the valuation will be done with the same valuation 
method. In the merger it will be stretched the opportunities that the merged entity will have and applied 
in the valuation.  
At the end, there will be an acquisition offer and the market reaction for this merger.    
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2. Industry and Company Analysis 
2.1. Overview of the Pharmaceutical Industry 
The pharmaceutical market is worth 781 US$ billion
1
 corresponding to a GDP expenditure
2
 global 
average of 6 percent (Figure 1) and it is represented by two general product segments (Figure 2). The 
pharmaceutical industry is considered high technology sector with the greatest value added per person 
employed. It also represents the highest global business R&D investments to net sales and the highest 
total world manufacturing value added
3
. The average growth rate of the industry in the past 5 years 




Figure 1: Top 15 countries according to healthcare spending in 2008 as a % of GDP 
As mentioned previously the market is divided in two general segments, originally protected and never 
protected segment. The originally protected segment is formed by pharmaceutical and biotechnological 
companies. The last segment, never protected, is formed by generic companies and pharmaceutical 
companies that produce health care products. 
Pharmaceutical and Biotechnological companies develop, produce and market medicines; due to the 
long years (10 to 12 years) it takes to develop and market a new medicines these are legally protected 
with a patent. The difference between the two types of companies is that biopharmaceutical companies 
focus their work on finding medicines working with human molecules, instead of chemical molecules.  
This area of the pharmaceutical industry is considered the new challenge of the business since patients 
interact in the studies and it will be possible to create personalized medicines. The United States market 
has approximately 75 percent of the global revenues and R&D expenditure.  
                                                          
1
 “Total Unaudited and audited Global Pharmaceutical market in 2008”, IMS Health Market Prognosis, March 2010 
2 Sheppard, A. (2010) “Generic Medicines: Essential contributors to the long-term health of society”, Sector Sustainability 
Challenges in Europe, IMS Health 
3 EPFIA (2008) “The Pharmaceutical Industry in Figures” 
4 “Total Unaudited and audited Global Pharmaceutical market from 2003 to 2008”, IMA Health Market Prognosis, March 2010 
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Figure 2: Pharmaceutical Market Segmentation 
Generic companies, as the name already says sell generics. Generics is the term used to define the drug 
segment that is similar to a branded medicines in terms of effectiveness and quality features, dosage to 
be taken, route of administration and strength, this segment can only be commercialized when the 
intellectual property protection of originally branded drugs achieves to its end.  This segment is the 
fastest growing segment and it has been gaining strength among the markets, as governments increase 
their efforts to reduce health expenditure. In volume terms, generics raised 46 percent in the key markets 
during five years (2002-2007), but in value terms it grew 2 percent, from 12 to 14 percent (during the 
period of 2002 to 2006), in the global pharmaceutical market (Appendix 2). 
By 2007, the greatest market in the world is represented by North American market (USA& Canada) 
with 45.9 percent market share and it is worth $311.8 billion in sales, followed by Europe and Japan 
(Figure 3). Although the greatest market, the European market outpaced the US market in terms of 
growth rate, 7.1 percent and 4.4 percent, respectively, but the fastest  growing market is the Asian 
market with 15 percent growth rate.  According to the statistics of IMS Health, it is expected that, 
between 2008 and 2013, US market might enter in a small recession [(1) to 2 percent], and the 
remaining markets will continue to grow (Appendix 1). 
The pharmaceutical industry is a highly regulated industry and an industry where other players besides 
the manufacture play a big role. 
Figure 3: Breakdown of the world – Pharmaceutical Market – 2007 Sales 
Source: IMS Health, February 2008 (data relate to the 2007 audited market at ex-factory prices) 
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Distribution margins, in one of the examples where it is possible to see how many players influence the 
final price of medicines (Appendix 3). Normally, distribution margins are fixed by governments (mainly 
in European countries), and approximately 35 percent of retail price reverts to governments and 
distributors (pharmacists and wholesales). VAT rates are not standardized within countries, according to 
EU Member States requirement, it must be at least 15 percent, but it varies from country to country. 
Pharmaceutical Development Cost are very high due to great length and riskiness that involves the 
process of research and development of medicines, 10 to 12 years (Appendix 4), approximately, and the 
improvement of societies and patients that are requiring more complex and suitable medicines (Table 1). 
In 2007, it was estimated an average cost of spending for a new medicine, biological or chemical, of 
$1.318 million. The high cost of R&D demonstrates the high necessity for investments in 
pharmaceutical companies, which tend to be sponsored by their own financial capacities.  
Table 1: Ranking of Industry Sectors by aggregate R&D from the world top 1,400 companies in the 2007 EU Scorecard – 2006 
Source: EPFIA; The Pharmaceutical Industry in Figures (2008) 
 
The European pharmaceutical companies have been for a 
long time the main region where new medicines were 
invented, reaching during five years (1960 – 1965) a pick 
of 65% share of the market. But since 2003, United States 
pharmaceutical companies surpassed EU firms, being the 
leading market in inventing new molecules (Figure 4).                                                                                                                    
                                                                                           Figure 4: New Chemical or Biological Entities (1988 – 2007) 
Sector                                                   
(according to the ICB)
R&D investment (€ 
million)




Pharmaceutical & Biotechnology 70.523,5 19.3 15.9
Technology hardware & Equipment 64.351,5 17.6 8.6
Automobiles & parts 60.807,1 16.6 4.2
Electronic & electrical Equipment 27.138,9 7.4 4.4
Software and computer services 26.522,8 4.7 3.1
Chemicals 17.186,0 4.7 3.1
Aerospace & Defence 15.991,3 4.4 4.8
Leisure goods 14.208,6 3.9 6.5
Industrial engineering 9.319,3 2.5 2.7
General industrials 8.867,6 2.4 2.1
Fixed line telecommunications 7.283,1 2.0 1.6
Health care equipment & services 6.446,1 1.8 6.8
Oil & gas producers 4.923,7 .13 0.3
Food producers 3.918,5 1.1 2.2
Household goods 3.911,9 1.1 1.6
Others (22 sectors) 24.243,9 6.6 0.9
Grand Total (37 sectors)* 365.643,8 100,00 3.4
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2.2. Merck & Co 
Merck operates in the pharmaceutical industry, focused on research and development of pharmaceutical 
products. The Merck family entered in the 
pharmaceutical business in 1668 through a pharmacy 
and the persistency in discovering and developing 
medicines has maintained the company operations 
until the present day
5
.                                                                                                                      
According to IMS Health data in 2008, Merck 
Corporation ranked in eight in the top 15 Global 
Pharmaceutical Corporations (Figure 5).                                                                       
                                                                                                                                                                                   
Figure 5: Top 10 Global Corporation 
The company separates its business into two product basis operations, Pharmaceutical segment and the 
Vaccines and Infectious Diseases segment, reporting results in this matter. Pharmaceutical products are 
human health pharmaceutical products used in therapeutics and for prevention of human disorders. 
Vaccines and Infectious Diseases products include products related to both, vaccines for human health, 
such as preventive pediatric, adolescent and adult vaccines that have to be administrated by medical 
professionals; and infectious diseases medicines. 
Operating results of the Company have been increasing during the years enhancing Merck’s’ presence 
in the market (Figure 6 and 7). Although the positive performance in 2008, the company faced a decline 





, which lost exclusivity (patents) in 2008 and 2006, respectively. The decline in the current year 
was not greater due to increase of sales of three products, Januvia, Janumet and Insentress
8
.  Merck 
performed better in markets outside the United States, having an enlargement of 10 percent in sales, 
while in the domestic market sales decreased 9 percent, compared to 2007. 
                                                          
5 Information taken in the Portuguese Merck official website, on November 29th, 
http://www.msd.pt/content/corporate/about/pt_historia.html 
6 Fosamax is used for the treatment and prevention of osteoporosis. Fosamax and Fosamax Plus D lost their patent in the 
United States in February 2008 and April 2008, respectively.  
7 Zocor, used to modify cholesterol, lost exclusivity to the United States Market in 2006. 
8 Januvia and Janumet are medicines used for the treatment of diabetes type 2. Isentress is an antiretroviral therapy for the 
treatment of HIV infection 
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                    Figure 6: Merck Performance                                      Figure 7: Segments Revenue Performance 
The main focus of the company is on innovation and customer value, facing the challenges of the 
market, in this way the company has the ability to continue to grow and prepare itself for future trends. 
Merck develops its business with internal and external R&D programs; the objective is to optimize its 
portfolio by focusing only on the company core competencies, outsourcing its non-core competencies 
and investing in opportunities such as Merck BioVentures
9
, growing emerging markets, like China, and 
business development. 
In the same year, Merck announced a global restructuring program which aimes to the enhance 
competitiveness, cost reduction and efficiency enlargement. The guidelines of the project go through 
extensive use of outside technology, in order the company to focus only on its core competencies, as 
previously mentioned, centralize marketing and sales operations, reinforce and streamline operations. 
“The company expected to eliminate 6,800 employees and 400 vacancies, 40 percent being in the 
United States, by the end of 2011. The program would yield a pretax cost of $1.8 to $2.0 billion by 




In the beginning of 2008, the company had nine products in Phase III clinical development and it was 
anticipating to submit three New Drug Applications (“NDA”) with the U.S. Food and drug 
Administration (“FDA”) in 2009 (Appendix 5.1).  
 
                                                          
9 New division of the company that focused on an unique technology platform for follow-on and novel biologics 
10 Stated in the Annual Report of 2008 about the Restructuring Program.  
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2.2.1. Prescription Pharmaceutical Segment  
Prescription Pharmaceutical products are sold through prescriptions and the company sells them to drug 
wholesalers and retailers, hospitals, government agencies and managed health care providers (pharmacy 
benefit managers, health maintenance providers and other institutions).  
Sales of this segment had a decline of 1% in 2008 and 2007 due to the end of exclusivity of the products 
previously mention. Part of the decline felt in the pharmaceutical segment was offset by an increase of 
sales of Januvia, Janumet, Singulair
11
 and Cozaar/Vaseretic. Singulair was one of the medicines with a 
higher growth rate of 19% in the segment, in 2007; this rose was due to increase of volume sales in 
Europe and Japan. Januvia was also an important medicine in the company portfolio since it started 
with sales in 2006 of $42.9 million, $667.5 million in 2007 to $1.4 billion in 2008. (Appendix 5.2) 
2.2.2. Vaccines and Infectious Diseases Segments  
Vaccines and infectious diseases products cannot be sold directly to the public by retailers due to the 
fact that they have to be administrated by professionals; therefore this segment has different distribution 
networks then the Pharmaceutical products. Vaccines distribution network are physicians, wholesalers, 
physician distributors and government entities. Infectious Diseases products are distributed to 
wholesalers and retailers, hospitals and governments agencies. 
In 2007, sales of this segment grew 48 percent
 12
 driven by strong performance of four products, 
Gardasil, Varivax, Rotateq and Zostax. Contrary to 2007, a small decline from $4.3 billion to $4.2 
billion was experienced in 2008 and the main factor was the Gardasil and Varivax reduction of sales.  
2.2.3. Costs, Expenses and Others  
Merck reduced its cost by 33% in 2008 in comparison with 2007. This reduction was influenced by the 
2008 restructuring program implemented in the company and it had different effects in different areas of 
the company. The higher decrease was seen in Materials and Production costs and Equity Income from 









                                                          
11 Medicine for astham and seasonal and perennial allergic rhinitis treatment. 
12 Sales of 2006 were 2.2 billion.  
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Materials and Production costs were reduced to align with the reduction of costs of the restructuring 
program. Respectively to the restructuring program $132.2 million were costs related to material and 
production, where $88.7 million were associated with the closure of facilities and $34.5 million of asset 
write-offs and others.  The Company gross margin was 76.6 percent compared to 74.6 percent in 2008 
and 2007, respectively. Changes in the product mix in 2008, decline of Fosamax sales, influenced the 
gross margin. 
Marketing and administrative expenses and research and development (R&D) had each a decline in 
costs of 2 percent in 2008. The cost reduced in marketing and administrative were the reduction of 
future legal defense costs and reduction of the cost base, like sales force. R&D reduction costs reflect 
closure of facilities, associated with the restructuring program.  
The reduction in Equity Income from Affiliates reflects a decrease in partnerships, more specifically 
some partnership with Schering-Plough Corporation and reduction in returns of other partnerships. 
2.2.4. Capital Structure 
From 2004 to 2008, Merck presents a slightly stable capital structure. During the 5 historical years 
(2004 to 2008) the debt to capital varied from 59 to 62 percent. The company does not provide 
information about their choices and reasons for the different sources of finance, therefore one cannot 






($ in millions) 2008 Change 2007 Change 2006
Materials and production 5.582,5$           -9% 6.140,7$          2% 6.001,1$        
Marketing and administrative 7.377,0 -2% 7.556,7 -7% 8.165,4
Research and Development 4.805,3 -2% 4.882,8 2% 4.782,9
Restructuring costs 1.032,5 * 327,1 * 142,3
Equity income from affiliates -2.560,6 -14% -2.976,5 30% -2.294,4
U.S Vioxx Settlement Agreement charge - * 4.850,5 - -
Other (income) expense, net -2.194,2 * 46,2 * -382,7
14042,5 -33% 20827,5 27% 16414,6
*100% or greater
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2.3. Schering-Plough Corporation   
Schering AG was created in 1851 by Ernst Christian F. Schering in Germany and Plough was a 
Memphis company formed in 1908 by Abe Plough. In 1971, the companies merged originating 
Schering-Plough Corporation, becoming a United States based company. 
The company is an “innovation-driven science-centered global health care company”, which focus its 
operations in three customer segments, such as prescription, consumer health care and animal health. 
Although Schering-Plough is presence in all the stages of product development, discovering, developing 
and manufacturing pharmaceutical products, it also tried to have external programs to enhance 
innovation through partnering, in-licensing and acquisition. Its main R&D activities were focused in the 
prescription segment, but it also had crucial applications for the other two segments.   
By 2003, with the new management the company strategy was to focus on creating undiscovered 
therapies and treatments for medical needs and that have commercial value, therefore investing 
significant funds in scientific research, a six-to-eight year strategic plan denominated by Action Agenda. 
The goal of this plan was to build strategic and long-term value for shareholders and patients that 
depend upon the company’s medicines.  This corresponds to growing sales, control costs and 
investments in R&D as mention previously.  
 According to IMS Health data in 2005, the company accounted for 1.4 percent market share of the 
United States market, being the seventeenth biggest pharmaceutical company in the world.  
In 2008, Schering-Plough net sales were $18.billion, having an increase of 46 percent compared to 
2007.  According to annual report of the company this increase was generated by greater sales of 
pharmaceutical products such as Nasonex, Remicade and Temodar, as well as greater sales by the 
Animal Health segment and the Organon BioSciences N.V.
13
 (OBS) products.  Some products, such as 
Vytorin and Zetia, had a decreased of 11 percent of global net sales. Net sales outside the domestic 
market accounted for 70 percent of consolidated net sales. (Appendix 6.1)   
                                                          
13  Organon BioSciences N.V. was purchased from Akzo in 2007. This purchase gave the Schering-Plough  
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                    Figure 8: Schering-Plough Performance                                           Figure 9: Segments Revenue Forecast 
2.3.1. Prescription Pharmaceuticals Segment 
Prescription Pharmaceutical products are medicines created for therapeutic treatments that need to be 
prescribed by a profession to be used. Sales of this segment increased from $10.773 to $14.253 million, 
corresponding to an enhanced of 40 percent in 2008 compared to 2007. In 2007, the segment had also an 
increase of 19 percent in sales.   
Organon, the human health business of OBS, bought in late 2007, has been one of the main contributors 
to the sales increase, totalizing in 2008 and 2007 an amount of $3.5 billion and $409 million, 
respectively. Remicade
14
 grew 28 and 33 percent in 2008 and 2007, contributed by a favorable impact 
from foreign exchange, higher market growth and penetration in certain markets. 
Greater drop in sales was seen by Rebetol
15
 with (6) and (11) percent in 2008 and 2007, respectively, 
due to sales reduction in Japan and the increase of generics competition. 
2.3.2. Animal Health Segment 
Animal health products are medicines used for animal therapeutic treatments. In terms of percentage it 
was the segment with higher growth rate from 2007 to 2008, 138 percent, this great increase was driven 
by the acquisition of OBS, contribution of $1.9 billion in sales, since this company has a high focus on 
the animal health segment treatments.  Global sales grew in a solid way in all geographic areas the 
company was present but it also enlarged the competition, the later was driven mainly by generics.   
                                                          
14 Drug administrated for the treatment of immune-mediated inflammatory disorders like rheumatoid. 
15 The combination of Rebetol and Intron A are used for Hepatitis C treatment. 
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2.3.3. Consumer Health Segment  
Having only three product lines in this segment, this also had an increase of 1 percent ($10 million) in 
2008, compared to the previous year.  MiraLAX, launched in 2007, was the main contributor to sales 
increase in the segment, being offset by a decrease of 12 percent OTC Claritin
16
 sales. Contrary to 2008, 
in 2007 the segment had an increase of 13 percent compared to the previous year which the main 
contribution was given by OTC Claritin, with an increase of 18 percent in sales.  
The consumer health care segment is a very competitive segment that requires constant introductions of 
new and innovative products in the market and strong advertisings to costumers.  
2.1.1. Costs, Expenses and Others 
Schering-Plough gross margin was 65.3 percent in 2007 and 60.5 percent in 2008. The reduction in 
gross margin in 2008 and 2007 compared to 2006 was due to the impact of $1.4 from purchase 
accounting adjustments included in costs of sales derived by the amortization of fair values of 
inventories billion and $326 million from intangible assets acquired with OBS transaction.  
R&D and selling, general and administrative expenses (SG&A) suffered an increase of 20.6 percent and 
24.8 percent in 2008 and 2007 mainly due to OBS acquisition. Expenses in SG&A rose due to  OBS 
acquisition, ongoing investments in emerging markets, greater promotion spending and unfavorable 
impact of foreign exchange. R&D expenses were not only influenced by OBS acquisition but also by 
the increase of clinical trials and related activities and investments in R&D that enhance and expand the 
company pipeline.  
2.1.2. Capital Structure 
From 2004 to 2008, Schering-Plough does not present a stable capital structure. From 2004 to 2006 the 
debt to capital ratio was 52 percent, approximately, but in 2007 and 2008 the ratio increased to 64 and 
63, respectively. The company states in its 2008 10-K report that it must maintain a debt to capital ratio 
of 65 percent in 2009 and 60 percent thereafter (Appendix 6.2). 
 
Having into account the different characteristics of the industry, Merck & Co., Inc and Schering-Plough 
Corporation, one will chose the most appropriate method to value the two companies.  
                                                          
16 First RX-to-OTC switch in the laxative category. 
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3. Literature Review  
Through the Literature Review it is going to be explained different valuation methods and the mergers 
and acquisitions (M&A) concept and methodology. 
Regardless of the companies that are going to be valued it is crucial to bear in mind that the value of a 
project is the sum of future cash flows expected discounted by a proper discount rate. 
To valuate these companies we have to evaluate the different methodologies and find the most suitable 
for the companies that are being valued. The method of Discounted Cash Flows, the Adjusted Present 
Value and the method of Comparables are going to be the three main methodologies discussed through 
this Literature Review.  
3.1. Valuation  
 “There are those who are disingenuous enough to argue that value is in the eye of the beholder, and that 
any price can be justified if there are other investors willing to pay that price. Perceptions need to be 
backed up by reality, which implies that is the paid for any asset should reflect the cash flows it is 
expected to generate.”
17
 (Damodaran, 2002) 
This sentence stretches the importance of valuing companies according to cash flows they generate. 
3.1.1. Cash Flows  
Damodaran (2002) presents the value of an asset as its capacity to generate cash flows. To value cash 
flows (CFs) it is crucial that CFs is valued prior to taxes, debt payments and reinvestment needs. When 
valuing equity, Cash flows to equity must be without debt payments. 
3.1.1.1.  Types of Cash Flows  
As it seen so far, there are different cash flows depending on the valuation that is being chosen to 
estimate the company value, different CFs have to be computed. 
 Dividends are the only CFs that is received when an investor buys a stake of a company publically. 
The model to evaluate equity is named as dividend discount model, which the value of the stock is 
the present value of the dividend payment.  
                                                          
17 Damodaran, A. (2002), Investment Valuation, Tool and Techniques for Determining the Value of Any Asset, University 
Edition, Second Edition, John Wiley & Sons, Inc., New York 
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 Free Cash Flow to the Firm (FCFF) is the group of all cash flows that are generated by the firm 
operations. All claim holders cash flows must be included and those are stockholders, bondholders 
and preferred stockholders. 
 Free Cash Flow to Equity (FCFE) is defined as the remaining cash flow after paying debt 
obligations, capital expenditure, tax issues and working capital.  
3.1.1.2. Terminal Value 
According to Damodaran (2002) firms “do not last forever” and it is necessary to establish a moment in 
the future to estimate its liquidation value. In assessing the terminal value it is imposed a closure in the 
Discounted Cash Flow Valuation (methodology that will be explained in the next section). Assuming a 
constant nominal rate in perpetuity, Kaplan et al. (1996) reinforces that depreciation and amortization 
must be seen as means of comparison with CAPEX, and CAPEX should be as high as those two costs.  
3.1.1.3. Growth rate (GR)  
According to Damodaran (2002), when estimating growth rate (GR) it is important to have into account, 
the historical performance of the company, since the past information can be valuable information to the 
estimation of growth. The growth rate can be calculated simply by doing the product of reinvestment 
rate (2.1) and the return on capital (2.2).  
                   
                                                 




      
          




Reinvestment rate accounts for how much a firm is going to generate future growth. Although not the 
most accurate estimation it is used the most recent financial statements of the company to forecast
18
. 
Damodaran (2005) states that the higher reinvestment rate will increase the growth rate. The return on 
invested capital (ROIC) is based upon the firm’s operating incomes on existing investments divided by 
the total capital (Damodaran, 2005).  By the formula, it is clear that the growth and reinvestment rate are 
linked, estimating one will influence the estimation of the other, so in order to grow at greater rate it is 
necessary to reinvest intensively (Damodaran, 2002). Growth is also directly related with ROIC, the 
quality of the investment will be reflected in the growth of the company.   
                                                          
18 http://olesiafx.com/economics/day-200706-15.html 
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3.1.2. Approaches to Valuation  
3.1.2.1. Adjusted Present Value and Discounted Cash Flow Methodologies    
Considered for a long time one of the best methods to value assets (for instance a factory, business, 
product line or market position) was the Discounted Cash Flow (DCF) methodology (Luehrman, 1997) 
The DCF methodology values any asset as the expected future cash flows (CFs) of a project. But to find 
the present value of the CF, it is necessary to discount them at a proper discount rate. The discount rate 
will be related with the riskiness of the estimated cash flows, with higher rates for riskier assets and 
lower rates for safer projects.
19
  
The DCF approach with the Weighted Average Cost of Capital (WACC) (2.3), it’s used to obtain the 
firm value by discounting the FCFF with the WACC rate, which is the cost of the different components 
of financing used by the firm, weighted by their market value proportion. (Damodaran, 2002)  
     
 
   
      
 
   
               
(2.3)
 
The value of the firm can also be derived by valuing the different pieces of the firm separately. This 
approach is called Adjusted Present Value (APV), where the firm value is the sum of two pieces. The 
first piece is the value of the firm as unlevered firm (2.4), all-equity financed; and the second piece is 
the value added by a firm’s choice of capital structure, in order words the financing side (2.5), which 
comes in the form of interest tax shield (Kaplan, S et al., 1996). The valuation must contain the tax 
shields valuation since the company pays taxes and interests, so it is crucial to taken into consideration.  
                                 ∑
     
      
  
           
      
   
(2.4) 
Interest tax shields will reduce taxable income by the amount of the interest and consequently the tax 
bill by the amount of interest times the tax rate. As with the all-equity financed part the tax shields must 
be discounted at an “appropriate rate” to reflect its risk (Luehrman, 1997). The common discount rate is 
the cost of debt since tax shields are as uncertain as principal and interest payments.  The author also 
states that in the terminal horizon, indebtedness will grow as the company grows so the growth rate will 
be the same as the one applied in the equity side.  
                            ∑
             
      
  
                   
      
   
(2.5) 
                                                          
19 Damodaran, Aswath, Investment Valuation, Tools and Techniques for Determining the Value of Any Asset; University 
Edition, Second Edition, 2002 
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The cost of financial distress (CFD) (2.6) is a way to adjust the company’s value to the likelihood of the 
company to enter in hazard, being unable to deliver its terminal value or simply the forecasted cash 
flows. According to Damodaran (2002) the present value of the distress is multiplied by the probability 
of distress. In the pharmaceutical industry, it is assumed 27% of losses in case of distress, according to 
Korteweg (2007) research paper for the health industry. 
                                                                                
(2.6)
 
According to Copeland et al. (2000) and Damodaran (2002), the value of the company (2.7) is the sum 
of the different components described previously.   
                          
           
    
                
(2.7)
 
Although a good method when it was discovered, currently the WACC approach is considered obsolete 
by many researches. To substitute the WACC it is presented the APV, whereas many researches support 
the usage of the later due to its versatility, reliability and its lower propensities to serious errors 
(Luehrman, 1997). 
Luehrman reinforces the idea by saying that “APV always works when WACC does, and sometimes 
when it doesn’t, because it requires fewer restrictive assumptions. APV’s power lies in added 
managerially relevant information it can provide. APV can help managers analyze not only how much 
an asset is worth but also where the value comes from.” 
3.1.2.1.1. Compressed Adjusted Present Value   
Kaplan et al. introduced in their study a version of the APV methodology to be applied where it is used 
the FCFs of an all equity financed firm and the interest tax shields at the same unlevered, all-equity 
financed firm. This methodology will discount all the capital cash flows to an equity discount rate. 
3.1.2.2. The method of Comparables/Multiples  
The method of comparables is a methodology based on relative valuations. The value of an asset is 
based on how similar assets are priced in the marketplace.  
According to Steven Kaplan et al. (1996), the value of a company through multiples is obtained by 
multiplying the ratio or multiple from the comparable companies by the performance measure of the 
company being valued. Aswath Damodaran (2002) claims the value of the asset through multiples is 
derived from the pricing of comparable assets, standardized using common variable such as earnings, 
cash flows, book value, or revenues. 
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The most widely used multiple analysis are Earnings, Book Value and Revenue Multiples. To determine 
the Market Value of Equity the multiples analyzed are the Price-earnings ratio (PE), Price-book value 
(PBV) and Price-Sales ratio and to estimate the Value of the business analysts use FV
20
/EBITDA, 
Tobin’s Q and the Value-sales ratio (FV/Sales). (Damodaran 2002) 
Kaplan et al. assert after the analysis of 51 highly leverage transactions (HLT) that although some of the 
“comparable” or multiple methods performed well on an average basis, the DCF methods were more 
reliable because they return estimation. Kaplan et al. findings also asserts that most reliable estimates 
were those obtained by using the DCF and the comparable methods together, being more efficient to 
perform an analysis with both methods for the sample being studied.
21
 
When using Multiples and a methodology based on Cash flows in the same sample it is important to 
employ Multiples based on EBITDA- Kaplan et al. – in order to obtain a comparability factor.  
Kaplan concludes that to employ the multiple method, comparable companies need to have similar 
trends. These companies need to grow at the same rate and have the same risk profile. It’s also expected 
that these companies vary their value in a direct proportion with changes in performance measures, for 
instance EBITDA.  
3.1.3. Discount Rates  
After explaining the three different methodologies that can be applied when valuing a company, cannot 
be forgotten the different rates that are used by the different methodologies already presented. In this 
section, it will be stretched these rates and highlight their major differences. 
The Adjusted Present Value Methodology employs a discount rate directly to the company cash flows 
as if the company was entirely equity financed, for this reason the rate employed is an “opportunity cost 
of capital” (Luehrman, 1997), the unlevered cost of equity, and a Cost of Debt to discount the tax 
shields. 
According to Luehrman (1997) the Discount Cash Flow Model with WACC can be applied to 
companies where exists constant ratio of debt to total capital. Expected Cash Flows that are already 
known and those CFs are discounted using a weighted average cost of capital, that has into account debt 
and equity.  
                                                          
20 Firm Value 
21 It’s important to retain that in the HLT analysis the DCF approached with the WACC couldn’t been applied due to one of its 
assumptions that states that companies must have constant debt ratios, which was not the case. 
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3.1.3.1. Cost of Equity – CAPM  
Aswath Damodaran presents the cost of equity (Re) as the required rate on equity investments in a firm 
by the investors. According with the Capital Asset Pricing Model (CAPM) which the Re  formula(2.8) 
lays on the principle that investors are individuals with diversified portfolios, diversification is a way of 
reducing the risk, in this sense investors are only exposed to Market Risk. Investors hold a small 
portfolio of assets, between 10 to 20, reducing their exposure to risk, due to reduction of marginal 
benefits gained with the increase of portfolio diversification. 
The CAPM assumes that investments are “infinitely divisible”, being the investors able to purchase an 
asset by any of its fraction; they are well informed, they have access to all information of the market (no 
asymmetry) and finally that there is no transaction costs, every asset in the market can be traded. 
CAPM incorporates three elements, a Risk-free rate (Rf), a Risk Premium (Rp = Rm – Rf) and an 
unlevered beta (β
u
) or systematic risk (Luehrman, 1997) that measure the company’s exposure to the 
market risk.  





 stated in his study and as we can see by the equation in the CAPM the “return 
and the systematic risk go together” and it’s not possible to work with one without the other. 
3.1.3.2. Risk Free rate 
“Academics and practitioners have long used government security rates as risk free rates, though there 
have been differences on whether to use short term or long-term rates” Aswath Damoradaran (2008) 
states in his paper. 
As Damodaran shows in his findings, the majority of risk and return models takes as a starting point an 
asset as risk free, and use it to calculate the risk and return of other assets. The importance in this section 
is to clarify how to choose the appropriate risk free for the valuation of Merck and Schering-Plough. 
The expected return of any risky investments is based on the risk free rate of the riskless asset and later 
added the expected equity premium, which is also based on the risk free rate (in section 2.1.3.4 it’s 
going to be more detailed this relationship). To have a risk free asset means that returns that are 
expected to be generated by the asset are equal to actual returns. The risk would be the variance between 
actual returns and the expected return, and in this case the risk would be null.  
                                                          
22 “Jason MacQueen: Beta Is Dead! Long Live Beta!,  Quanted, Ltd” 
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           18 |  
For Aswath Damodaran it’s crucial to estimate properly the risk free rate due to great dependency of the 
cost of equity, as seen in the section 3.1, and cost of debt have on it.  In case of the cost of debt, to 
compose it, it is added the default spread (risk premium), being the latter dependent on the credit risk of 
the company.  
The risk free rate has also influence upon the company’s growth, the greater the risk free rate the 
smaller will growth be, since the value of growth assets will decrease. In this sense, mature companies 
would have a greater rate than growth companies.  
But to use the risk free rate it’s imposed some requirements: 
 The riskless securities may have no default risk. Being so, only government securities may be 
chosen, since governments are the only entities that are able to “fulfill promises”. 
 Securities with risk free rates may not have reinvestment risk. If a security has reinvestment risk 
it means that in maturity the value of the Treasury bill rate is uncertain. 
To have a proper use of risk free rate, valuation should be done with zero-coupon default-free bonds 
maturing in the same period has the asset of the company. The risk free rate may also vary among 
countries, since different each country has its own inflation rate, having countries with high inflation 
rates a higher risk free rate for the same maturity, therefore, securities should be measured in the same 
currency. 
3.1.3.2.1. Real and Nominal Risk Free  
What determines whenever it is used the real or the nominal risk free rate is the inflation of a specific 
country (Damodaran, 2008). In a market where inflation is unstable and high, company valuation should 
be done with real rates. In this sense, the discount rates should also be real rates.  
Government bonds are not based on real rates, instead returns are risk free rate in nominal terms, 
accounting for inflation. To obtain the value of the real rate it is simply subtracted to the nominal rate 
the expected inflation.  
Another option for obtaining a real risk free rate is through the inflation-indexed treasuries. The 
inflation-indexed treasury (TIPs) presents a guaranteed real return but not a guaranteed nominal return.   
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3.1.3.3. Beta 
According to Rosenberg B. and Rudd, A. (1998)  al. beta (β) is the key variable in the CAPM and it has 
been used as a measure of risk by the investment community. The authors also state that the value of β 
can be derived by observing relationship between the market trend and the stock price of the company.  
The value of β (of a stock) has a direct relationship with the proportion of excess stock return when 
compared to the excess return on the market, in other words, the higher the excess stock return 
compared with the excess market return, the higher will be the β estimation of the stock.  In this line of 
thought, β would be an estimation of “historical alignment of stock price with the market” and it can be 
used to estimate future trends of risk.  
Since β is based on historical data is crucial to bear that some levels of risk may have occurred in 
abnormal situations (chance events) causing the stock price to move with market. In case these events 
occurred frequently, the stock value will have a β estimation with misleading values, having an 
unreliable predictor. These estimations problems are named as “estimation error” and have to be 
considered. 
Aswath Damodaran (2002) suggests a second method to estimate betas through the fundamentals of the 
business. The author claims that β is a pure reflection of decisions on which business the company 
should be in, the level of operating leverage to be applied in the business and the proper financial 
leverage for the company.  
A third way to have the value of beta is estimating the risk parameters from accounting earnings rather 
from than traded prices. Since variations in earnings in the company reflect the variations in earnings of 
the market, from the same period, the value of β can be estimated easily to be used in the Capital Asset 
Pricing Model. 
Rosenberg B. and Rudd, A. (1998) concluded in their paper that despite the errors that can appear from 
the beta estimation, this variable is so far the best risk estimator.  
Although, these authors support the use of β, Fama E. and French, K. (FF) (1996) caught the attention of 
practitioners introducing two arguments against CAPM model, more specifically against the usage of β. 
The authors argue in their paper that one premises of CAPM (β is the only parameter that explains the 
expected return and β risk delivers a positive expected premium) does not hold. The authors argue in 
their findings that expected return is not only explained by β but also by other variables, such as firm’s 
size (market capitalization), book equity (BE) data and the ratio of BE with market equity (ME).  
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Fama and French (1996) support the usage of intertemporal CAPM (ICAPM) or the arbitrage pricing 
theory (APT) is strengthen, since expected market return, common time-series variation in returns and 
market premium are accounted. 
Kaplan, P and Peterson, J (1998) state in their paper that, although FF presented arguments against 
CAPM, there are no “theoretical justified alternative model” that can be easily applied. Giving reasons 
to many practitioners to deepen their studies on CAPM.  
The authors also present other two different ways to use the β for companies that operate in a single 
industry or in several.  The first concept is the beta of the pure-play portfolio. βeta of pure-play 
portfolios are applied for firms that are specialized in a single industry. To rise to a proper value of β, 
the authors suggest that calculation should be done to a group of pure-plays that operate in the same 
industry, division or project that is being done, in this way statistic noise is reduced.  
Conglomerates are not included in this group since they operate in different businesses. For this group 
the authors illustrate that through the usage of full-information industry beta estimation it can be 
reached the value of β. This model is done through the weighted average of company individual 
businesses betas coefficients, having into account the firm-specific betas and the percentage of sale (of 
each firm) of each industry the companies operate, in order to get the observable betas of the 
conglomerates.  
3.1.3.4. Risk Premium  
The equity risk premium (2.9) reflects how much risk analysts attributed to the market and price 
attached to that risk; the risk premium influences the expected return and the value of any risky 
investment (Damodaran, 2011).  Being the equity risk premium the price for taking risk, the premium 
only considers the risk that is added to the diversified portfolio (unsystematic/market risk), risk that can 
be measured and compensated.  
The equity risk premium determinants are economic risk, information, liquidity, risk aversion and 
catastrophic risk, whereas the first three factors play a major role. Information asymmetry is related to 
the quantity and quality of information available to investors. Yee (2006) states that information 
asymmetry and incomplete information are two relevant points, in CAPM, and they should not be 
misunderstood. If all information is public, equity risk may be influenced by the poor-earnings quality 
which creates incomplete “information environment in the market”. Poor-earnings quality by itself may 
affect the cost of capital.  
One of the most used methodology to estimate risk premium is through historical premium approach 
(Damodaran, 2011). This has into account the estimation of actual returns earned on stocks for a long 
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period of time and actual returns of a riskless asset, normally a treasury security, the value of actual 
return of the two assets are compared and computed (differential) on annual basis. To assess to the 
historical risk premiums one can use the available indexes of rating companies (S&P, Moody’s and 
Fitch) of the market (Damodaran, 2002). 
Since some markets are volatile and short (Emerging markets and European Equity markets) the 
accurate way to measure historical premiums is to find the country risk, having an unreliable parameter. 
For this reason it’s crucial to estimate the country risk premium and add it to the premium of a mature 
equity market (Damodaran, 2002).  
                                                                          
(2.9)
 
Important to bear that only the country risk that is not diversifiable by the marginal investor should be 
accounted (Damodaran, 2011), reflecting an extra risk in a specific market.  
3.1.4. Mergers and Acquisitions  
“A merger or acquisition happens when two or more companies join, often to share costs, increase 
efficiency or gain market power”, (Ullah et al., 2010), and more precisely to create synergies.  
Accordingly, Damodaran (2005) states that the added value that a firm will get after merging or 
acquiring a new firm is the defined as synergy. This added value wouldn’t be reached if both companies 
continue operating solely. 
3.1.4.1. Types of Mergers 
There are four types of mergers. The type of mergers is associated to the market that the merged 
companies are operating. For instance: 
Horizontal mergers happen when companies operate in the same market and are direct competitors. 
These companies tend to sell products that can be substitutes. 
Vertical mergers occur between companies that can operate or actually operate in the same value chain, 
having the potential to have a buyer-seller relationship.   
Conglomerate Mergers may occur between companies that might share some parts of the value chain, 
like marketing and distribution channels and in some cases the production.  
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Last, Congeneric mergers happen when two companies operate in the same industry but have different 
clients and suppliers. The companies engage in this type of mergers have no relation with each other.  
3.1.4.2. Sources of Synergy   
Aswath Damodaran presents two main groups of synergies, where different sources can explain the 
appearance of synergy within the merged companies. 
Operating Synergies, as the name already says, is one of the sources of synergy and it affects the 
operations of the company. It will cause an increase in growth and/or an increase in operating income 
from existing assets. Operating Synergies can be seen as: 
 Economies of Scale – the combined firm increases cost-efficiency and profitability. 
 Increase of Pricing Power - the combined firm reduce competition and increase their market share by 
forming a single company, this combination will deliver higher operating income and higher 
margins. 
 Different combination of functional strength – when the combined companies can transfer functional 
strengths between the two businesses. It can be observed in a vast variety of mergers. 
 Higher growth increases the capability of the combined firm to generate more sales of products. 
The first two Operational Synergies will be achieved only when the two combined companies are from 
the same business, named as Horizontal Mergers. 
Financial Synergies are more specific comparing with the previous synergy. This source of synergy can 
deliver higher cash flows and/or a lower discount rate. The different types of this synergy are: 
 Cash Slack or Excess Cash – when one company has excess of cash but poor or limited investment 
opportunities combine with another that it is in the opposite situation, a company with limited cash 
and “high-return projects”. When combining both companies higher value will be created. 
 Debt Capacity – the combined firm will have a higher debt level than if they were operating solely. 
Earnings and cash flows also become more certain and stable, allowing the new company to borrow 
higher amounts than they could before as separate entities, having in turn tax benefits. 
 Tax Benefits – can be enhanced if companies are acquired or merged to take “advantage of tax laws 
to write up the target company’s asset or from the use of net operating losses to shelter income”. 
 Diversification- “most controversial source of financial synergy” due the fact that are easier and 
cheapest ways to do it. But in case of a private or closely held firm, the acquire firm can achieve 
potential benefits.  
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Although Damodaran presents different sources of synergies, he concludes that companies enter in 
mergers to create synergies but only a small part of them can deliver “substantial synergy”. These 
findings suggest that synergies can be achieved but are very arduous to be put into practice. 
3.1.4.2.1. Valuing Synergies  
Before describing briefly the way mergers should be valued, it is important to distinguish two concepts 
that may be mistaken. Damodaran (2005), states that the value of control is the added value that a 
company can achieve by running the company in its maximum efficiency. This value is believed to be 
achieved by the acquired company without the merger, the buyer firm believes that changing 
management objectives and strategies and applying better investments, the company will increase its 
value. In the end, companies compare the value achieved in a changed scenario (if it was managed at its 
maximum efficiency and with the merger) with the status quo. 
In the same findings, Damodaran presents how the valuation should be done. The method applied in the 
findings is: 
 Value the firms involved in the merger independent. 
 Estimation of company value with a different management, a management that would yield the 
maximum value of company (value of control). 
 Estimate the value of the combine company, without the added value of synergy. 
 Estimate the value of the combine company with synergy. The difference with the previous 
valuation is the value of synergy. 
3.1.4.3.  M&A does pay?  
According to some practitioners and studies M&A on average does pay, but there is some skepticism on 
the market. 
For Mark Sirower and Sumit Shani (2006) companies don’t do an average acquisition. They reinforce 
the idea saying that it is important that executives and boards of the company that make the decisions 
and monitor investments, have the proper tools to help them distinguish between the good and the bad 
deals. 
Sirower and Shani in their findings also support that initial reactions of the market are a good signal of 
the acquirer’s operating performance in the future. The first year after the deal is established is crucial to 
deliver promises, it is a signal of the credibility of those promises. 
The authors concluded in their paper that: 
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           24 |  
 On average, acquirers underperform their industry peers – the average return to acquires acquisitions 
deal around the announcement days were -4.1%, where only 36% of the deals were seen as positive 
and 64% were perceived as bad deals. 
 Initial reactions are persistent and indicative of future returns” – one year later deals that started with 
a negative and positive reactions maintained their performance (-9.2% to -9% and 5.7% to 4.9%, 
respectively). 
 Delivering results after a good start pays off big – deals that start in a good path and deliver results 
outperform the ones that started badly. 
 Price matters - the average premium paid to companies were around 36%. An average premium of 
38.4% was paid by initially negative group and 30.7% paid by the positive group. The same results 
were intact one year later 
 Cash deals outperform stock deals – cash deals on average outperform stock deals by 4%, results 
from one year later shows a wider gap between the two, 8.3%. 
 Sellers are the biggest beneficiaries of M&A transactions – sellers win on average with the deals, 
20% of the pre-adjusted return was earned. 
 M&A transactions create value at the macroeconomic level – In general there is a value creation of 
1% at the announcement, the combination of both seller and buyer market capitalization adds value 
for the merger. 
Robert Bruner (2004) also supports that M&A does pay. According to his findings shareholders of 
selling firms earn abnormal returns from M&A, and the combination of the returns of the seller and 
buyers earn significant positive returns. Buyers, on the other side, earn the rate of return on the 
investments.  The author also supports the argument that M&A deals are not homogeneous; each 
transaction is local, so depending on different circumstances different outcomes will be achieved.  
The author concluded in his study (sample of 12.023 deals) that the average adjusted return to buyers 
was positive in 1.1%, this value is low due to the unprofitability of some big deals. The losses occurred 
in 87 deals out of the total sample. This cases also happened during 1998 and 2001, a hot M&A market.  
Although it was clear for Sirower that mergers do create add value for the companies and for the 
economy, his paper also presents some skepticism of investors. Many reasons put investors on hold in 
relation to mergers.  
When deciding to enter in this type of deal it’s required a full payment upfront and it’s crucial  to 
achieve synergies when acquires promised otherwise it will influence negatively the expected net 
present value of the investment.  
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Share price of both companies (seller and buyer) reflect the significant performance improvements, 
named as the base case, even without paying an acquisition premium, on which gains will be built. 
Synergies will only occur if the acquirer can surpass the base case. 
Many practitioners and researchers think that mergers come for free but it doesn’t. According to Sirower 
there is always a financial cost associated with achieving synergies (revenue or cost synergies), the 
synergy matching principle. 
The authors also states that majority of managers that integrate in a bad mergers they tend to invest 
more money in the hope of saving the deal, showing investors that it was unnecessary to invest in the 
business. The major concern is that these businesses usually involve large amounts of money and 
dissolving them it’s extremely expensive, so managers believe they can solve it by investing more. 
Stock deals also deliver two significant signals to investor. It shows that it’s the best time to issue new 
shares since they are overvalued. So the buyer should question the sellers’ motive to sell the company. 
Paying with stock shows that sellers are not confident with the deal, otherwise they would pay with 
cash, paying with debt, requiring confidence and discipline to pay it.  
3.1.4.4. Premium Metrics  
Premium value is the the added value that is going to be augmented to the base case of the company 
acquisition value. 
Sirower and Sahni present methodologies to be used as tool to compare with the reality. These tools are 
not replacements to the previous methodologies presented.  
Shareholder Value at Risk (SVAR) methodology is a “straightforward starting point for assessing the 
materiality of a deal whether it is paid for with cash or with stock”. In other words, it is a good tool to 
access which proportion of the value of the company will be at risk if synergies are not achieved after 
the merger. This methodology  (2.10) demonstrates that the higher the value of the seller company 
comparing to the buyer, and the higher the premium percentage paid to sellers, higher will be the 
SVAR.  
      
                                     




The Equity Market Value (2.11) is a tool used to check the integration of the companies after the 
merger. This value should be a multiple (P/E) of its after-tax earnings (E).  
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           ⁄  
(2.11)
 
As reality check the Premium offered to the acquired company should be a percentage of MV.  
The authors also stated that synergies must be reached exclusively by cost reductions and revenue 
increase. For this reason it is possible to compute cost synergies (2.12) required to earn the offer 
premium for any merger, a measure to support the acquirer premium. 
        
 
   
             
(2.12)
 
Where п is the pre-tax margin, P is the premium and %SynR is the benefits of the expected percentage 
of revenue synergies. 
The above equation yields the “Meet the Premium (MTP) line”, which is the combination of %SynC 
and %SynR to create pre-tax synergies to equalize the value of premium imposed and pre-tax margin. 
Deals should occur all above the MTP line. In Sirower et al. paper it was proposed a 35% premium on a 
target with an 18% pre-tax margin, with this parameters the decrease necessary in costs to achieve 
enough pre-tax profit improvement, to break even and justify the premium would be 7,7%
23
. 
3.1.4.5. The Era of Cross- Border on M&A 
The breakdown of barriers between countries has made many companies to look for goods, services and 
products in different countries or regions with better quality and price. Many emerging countries have 
become “targets” and partners of major companies in developed countries on market integration (Zenner 
at al., 2008). 
According to the study of cross-border era, the current crisis caused markets to accelerate demand for 
goods more quickly in order to reduce the competitiveness of markets; to survive the fall of the dollar, 
high valuations for companies in emerging markets and the increase of sovereign wealth funds. 
Since 2003 Cross-Border transactions have been exceeding domestic transactions and in 2007 it 
accounted for 12 out of 15 biggest non-private M&A deals.  
Long-term drivers of Cross-border M&A such as globalization, geographic diversification and 
deregulation are mention as factors to be maintained in the future, this long-term catalysts are stated by 
the author as a consequence of the current market situation. Due to the free markets, innovation and 
competition, the long-term drivers were predictable.  
                                                          
23 The 7,7% is achieved by doing                   ⁄   
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On the other side, the author also presented a group of short-term catalysts that he considers a powerful 
driver’s in today’s M&A markets. These drivers may not persist in the future but they do complement 
the long-term catalysts. The short-term drivers are the major currency shifts/weak U.S dollar, 
purchasing power of a unit of BRICM (Brazil, Russia, India, China and Mexico), sovereign wealth 
funds and reduced competition from financial sponsors and strategic domestic buyers.  
3.1.4.6. Skepticism of Investors 
Although it was clear for Sirower that mergers do create add value for the companies and for the 
economy, his paper also presents some skepticism. Many reasons put investors on hold in relation to 
mergers.  
When deciding to start an acquisition process, full payment upfront is required and it is crucial to 
achieve synergies when acquires promised otherwise it will influence negatively the expected net 
present value of the investment.  
Stock prices of both companies (seller and buyer) reflect the significant performance improvements, 
even without paying an acquisition premium, on which gains will be built. Synergies will only occur if 
the acquirer can surpass the base case. 
Many practitioners and researchers think that mergers come for free but they don’t. According to 
Sirower there is always a financial cost associated with achieving synergies (revenue or cost synergies), 
the Synergy matching principle. 
The authors also states that majority of managers that integrate in a bad mergers they tend to invest 
more money in hope of saving the deal, showing investors that it was unnecessary to invest in the 
business. The major concern is that these businesses usually involve large amounts of money and 
dissolving them it’s extremely expensive, so managers believe they can solve it. 
Stock deals also deliver two significant signals to investor. It shows that it’s the best time to issue new 
shares since they are overvalued. So the buyer should question the sellers’ motive to sell the company. 
Paying with stock shows that sellers are not confident with the deal, otherwise they would pay with 
cash, paying with debt, requiring confidence and discipline to pay it.  
3.1.4.7. Misleading Arguments 
Robert Bruner (2004) presents a group of arguments defended by researches that does not support the 
occurrence of mergers. According to the author, conventional wisdom supports the idea that M&A is a 
loser’s game; where failure is the most common result of mergers but the evidences about M&A are 
meanly supported by scientific prove. Another common though is that M&As’ are “homogeneous” but 
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from different authors so far it’s was clear that exists different types of deals. Aswath Damodaran 
(2005) introduces arguments that are presented to overpay the transaction. 
 Deal-makers are normally the ones that decide whenever a company should undertake in such deals. 
Their fees are attached to the occurrence of the agreement and not if it is appropriate to the company. 
In this sense, Deal-makers tend to undertaken in such agreements no matter the price that would be 
necessary to pay; these phenomenon is named as Biased Evaluation Process. 
 Managerial Hubris is a another argument designated in Damodaran findings but firstly presented by 
Roll (1986) where it is characterized as a self-belief that managers do not make mistakes, so they 
over evaluate companies (and synergies) in the companies they pretend to purchase.  
 Lastly, the Failure to plan for synergy occurs when companies tend not to map the delivering 
synergy plan before the acquisition and realize that there is no synergy. 
The author also presents other dubious arguments, the Accretive Acquisition, where the target company 
needs to have lower P/E than the purchaser. This line of though supports that after the acquisition the 
target company will reach an EPS equal to the purchaser. This though makes no sense since the target 
company had lower ratios for factors (low growth and high risk, for example) and that cannot be 
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4. Performance in the Stock Market 
Stocks Markets are a good way to evaluate the performance of business and industries. As mention 
previously, the pharmaceutical industry is a very controlled industry set by high governmental 
regulations which make it very sensitive to changes in the market and the 2007/08 financial crisis was 
one of the examples. 
 Merck and Schering-Plough were no exception following the trends of the market; they have been 
clearly affected by financial crisis. Merck shares price start declining in the 4
th
 quarter of 2007, dropping 
from a value of $61.62 to $32.46 in the 4
th
 quarter of 2008; in one year the value of shares dropped by 
half; this evidence can lead to a conclusion that pharmaceutical industry although important to the 
society because they create and produce medicines they are influenced by market fluctuations.  
Schering-Plough share price had a slight growth in 2007, reaching a price of $33.34 in the 2
nd
 quarter, 
$13.34 higher than in the following year. In 2008, the shares price dropped to its normal levels, around 
$20 reflecting the crisis effect. 
In the last quarter of 2008, Merck had shares price of $32.46 and Schering-Plough $18.48. Even with 
the financial crisis the difference between the price of shares of both companies remained equal.  
 
Figure 10: 5-year Historical Stock Price of Merck &Co and Schering-Plough 
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5. Valuation of Entities Independently  
5.1. Performance Forecast 
To evaluate the merger and its benefits to the companies it is necessary to perform firstly an individual 
valuation to merging companies. In this valuation, companies are valued as if they are optimally 
managed during the forecast years, in order to observe how a company would perform without the 
merger and the add value they would create when merging with another company. 
For individual valuation of both companies, one will take into account analysts’ considerations about 
the industry and the companies, to optimize their performance as if they were operating alone. It is 
crucial to have consistency in the results presented. 
Thus, valuation will be done through two different methodologies: APV and Relative Valuation. 
Although the valuations methodologies are different the results should complement each other. APV 
valuates companies as individuals and relative valuation compares a company with its peer group, in 
this sense the reader can have a better understanding how the company is doing. The first method to be 
used will be APV and after relative valuation will be used to complement the first method. The 
valuation model will consider the historical performance to observe trends and the company strategic 
objectives in order to forecast the company performance.   
Historical information about companies was collected from 2004 to 2008, since the merger happened in 
2008. Being the valuation of pharmaceutical companies it is crucial to have a long time period of 
forecast, since the research, development and production (R&D) of medicines normally last 10 years 
and majority of the products that go to the approval of Food and Drug Administration Organization 
(FDA) are rejected or take months to be approved. Another reason that supports the forecast period is 
the product portfolio, more specifically the stage of life that the medicines may be; some medicines will 
be losing their patent early and others were introduced recently to the market, so it is important to 
capture their different trends. 
The Free Cash Flows to the Firm will be forecast every year until 2018. The terminal value of the 
company will be forecasted from 2018.  
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5.1.1. Merck 
The objective of valuation is to find the company expected cash flows and discount them to the present 
so one can have the value of the company today and the estimation of cash flows will be calculated in 
nominal values.  
To calculate the value of cash flows (4.1) we need to forecast EBIT, CAPEX, Depreciation, Net 
Working Capital and other assets. During the analysis of historical information, there was a concern to 
know and have into account which elements of the company are more important to the business, in order 
to do a better forecast. 
                                                                                  
(4.1)
 
Merck has been trying to establish itself as one of the best pharmaceutical companies in the world, 
aiming to be in the top 10 in the last years. Until 2008, the growth strategy of Merck was to invest in 
strategic markets, such as Japan and Latin American countries but continuing to have a great focus on 
the US market.  
5.1.1.1. Revenues 
Merck presents its sales information according to two segments, as seen previously: Pharmaceutical 
Segment and Vaccines and Infectious Diseases segment. The pharmaceutical segment is the one driving 
the business of the company, being in 2008 5x
24
 higher in terms of sales in 2008 than the Diseases and 
Infectious Segment. According to the European Federation of Pharmaceutical Industries and 
Associations (EFPIA)
25
, the pharmaceutical medicines (segment) will always be the prevailing segment. 
An estimation of revenues by product segments has to be carefully forecasted and have a clear 
distinction between the segments.  
This estimation of revenues is also crucial since revenues will have a direct and indirect impact on 
several costs, for instance Material and Production costs which dependent directly on the level of sales 
and Research and Development that would be reduced in case the level of sales of a company reduce 
every year.  
The revenue forecast can also be presented by geographic segments. Merck presents this alternative way 
to view/analyze the business and one considered very useful since diverse regions of the globe are in 
                                                          
24 Revenue of Pharmaceutical Segment (08)/ Revenue of Vaccine and Infectious Disease Segments (08) = 19.382,9 / 4.237 = 
4,57  
25 EFPIA (2008) “The Pharmaceutical Industry in Figures” 
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different phases of growth, even in this business. EPFIA, IMSH Health and other institutions present 
important data that supports the forecast by geographic segments. The forecast by geographic segments 
can illustrate to readers how a company can perform in each segment and built an appropriate strategy 
to the upcoming years. For this reason, Merck’s forecast is going to be presented by the segmentation 
discussed last. 
Merck’s presents four segments in its reports, North America region, Europe, Middle East and Africa 
region, Japan region and Other region, the last region includes Latin America and Asia countries. 
Revenues Forecast Inputs 
According with the references given by Alexandre Tavares
26
, the revenue forecast has to take into 
consideration four factors, the evolution of the pharmaceutical market in terms of the number of 
patients, the evolution of pharmaceutical price, the market share of the company in terms of global sales 
and the projections made by the company for the future.  
The data collected was from the following segments: Asia/Africa/Australia, Europe, Latin America and 
North America; segmentation was provided by IMS Health
27
. The institution provides us with growth 
rates by regions (segments) which will allow a comparison with Merck forecasted growth rates for each 
segment (Table 3).  
                 Table 3: IMS Health Pharmaceutical Market Growth Prognosis 
 
Related to the evolution of the market in terms of number of patients, the objective was to relate the 
number of patients with the spending per patient. Therefore, it was taken into account the 
pharmaceutical industry spending, the GDP evolution and the population evolution (Appendix 7). 
According to the IMS Health
28
 the pharmaceutical expenditure will increase in the following years 
between 5 to 8 % due to the increase of world population and the improvement on health care. This 
information provided by IMS Health leads us to the conclusion that patients market will increase and 
one will support this information with proper data.  
                                                          
26 Finance Director of Amgen Portugal 
27 Total Unaudited and Audited Global Pharmaceutical Market by region, IMS Health Market Prognosis, March 2009 





2009 -0,5% 3,5% 11,5% 4,5% 9,5%
2010 4% 4,0% 14,0% 1,0% 11,0%
2011-2015 1,5% 3,5% 12,5% 3,5% 12,5%
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The evolution of pharmaceutical price is related to the governmental policies and economic conditions 
of each country, pharmaceutical companies have little maneuver to manage the retail price (Appendix 
7). According to the report
29
 of World Health Organization the global tendency is towards a reduction of 
pharmaceutical prices so that all patients can have access to medicines.  
The market share during forecast has to be maintained, at maximum (Appendix 8). Regardless of the 
company’s goals for the future, the market share should never be reduced the current level, the objective 
of the company is not to lose market share.  And the current market share will serve as reference to the 
sales forecast. 
Merck contributed in its report with expectation of growth for the upcoming years. Therefore, one had 
into consideration this expectations, it was seen if those were realistic in relation to past performance 
and market projections by IMS Health (Appendix 8). This element while taking into consideration the 
company’s data, one revalued in order to project the revenues, in this sense it is considered as an 
assumption.  
United States of America 
The first segment has always been the greatest segment in Merck’s portfolio (Appendix 9), with the 
highest sales level.  In 2008, this geographic location represented 56
30
 percent of the company revenues 
and one assumed that it will continue to represent a big portion of the company revenues in the future. 
According to the EFPIA 2008 Study
31
, USA is the number one in R&D investment with higher 
investment in Research and Development (R&D) and greater consumption of medicines being some of 
the reasons for their number one market position.  
The United States segment has presented a grow rate of (5), 8, 7 and (9) percent, in 2005 to 2008, 
respectively. Although it is the biggest segment, the forecasted growth rate is very small. On average the 
United States segment will grow at a rate of 1% per year and this low rate is justified by the lower 
growth forecasted by EPFIA and other institutions and the modest expectations of Merck for the upon 





                                                          
29 The World Medicines Situation 2011, Medicines Prices, Availability and Affordability, Geneva 2011. 
30 13370,5/23850,3 = 0,561 
31  EFPIA (2008) “The Pharmaceutical Industry in Figures” 
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Europe, Middle East and Africa 
Europe, Middle East and Africa segment always represented the second biggest market segment. From 
2005 to 2008 the sales growth rates were (4), (4), 4 and 12 percent, respectively. From 2007 to 2008 the 
company had a significant growth comparing to the previous years and according to the company’s 
report this is due to great investment that was made in Africa and Middle East countries.  
In 2008, it had 24 percent of the total revenue. According to the EPFIA 2008 study
32
, Europe is 
considered a big threat to U.S. and if applied the right strategies, it can overcome the United States 
segment. According to the same study, European countries are seen as technologically prepared to 
receive a great investment in the business as United States but due to different and tougher regulations 
this market segment has difficulty to be as big as the U.S. market. Africa is integrated in the 
Asia/Australia/Africa segment of IMS Health that the expects the pharmaceutical market in those 
regions in those regions to grow on an average rate of 13 percent per year and the United Nations also 
projects that population Africa and Middle East will continue to grow at an average rate of 12 percent. 
Although a very optimistic estimations about the market, with the company projections one estimates a 
growth of 4 percent, on average (Appendix 9). 
Japan 
According to the company’s annual report, this segment is separated from the other two segments since 
it is a very specific market and the company relies on it to transact certain medicines such as Cozaar, 
with a strong performance in Japan and Singulair with a high volume growth. The segment growth rates 
for 2005 to 2008 were (2), (10), 4 and 19 percent, respectively, and the average growth rate estimated 
for 2009 to 2018 is 3 percent.  
The forecasted growth rate of 2 percent (average) is influenced by the company projection of 0.2 
percent to grow each year in the segment, the 2.77 percent of market share in sales and the average 
growth rate of 0.1 percent on price evolution until 2018 (Appendix 9).  
Other 
The last segment is represented by the remaining countries that are not included in the first three groups. 
Such countries are the Australia, Singapore, South Africa, Latin American countries, Brazil, India, 
China, and others. This segment although with low sales due to the weak presence of the company in 
such countries, it has high potential to grow, since those countries are becoming more developed.  
                                                          
32 EFPIA (2008) “The Pharmaceutical Industry in Figures” 
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The growth rates of this segment were 2, (0.03), 17 and 2 percent, from 2005 to 2008, respectively. 
Merck’s sales market share is 2 percent and the company projects to grow each year 2 percent. These 
estimations and the price growth rate evolution until 2018 gives a growth rate for 2009 to 2018 of 6 
percent, on average (Appendix 9). 
5.1.1.2.  Costs 
From this chapter, the forecast will be presented in a consolidated way; the separation in segments is not 
necessary since the costs will not be significantly different once the products produced will be the same 
all over the world and the company business is highly focused on the US market.  
Material and Production 
This type of costs is highly related with manufacture of products. In this specific case, the manufacture 
of medicines represented, in the last 4 historical years, 25 percent of sales revenue, on average 
(Appendix 10). According to the 2008 form 10-K  a small percentage of material and production cost (3 
percent) is related with the depreciation of planned sale or closure of some of the company’s 
manufacturing facilities and asset write-offs, associated with the 2008 and 2005 Restructuring Program; 
this percentage of costs will be reflected in the cost of material and production until 2011.  
For the forecast one assumes that cost of material and production will be 25 percent of sales revenue 
since the average rate from 2005 to 2007 was 25 percent. 
Marketing and Administrative 
Marketing and Administrative expenses represented 34, 31 and 30 percent of the level of revenue, in 
2006, 2007 and 2008, respectively (Appendix 10); since the percentage has been around 34 and 30 
percent, so I will assume an average between the three years to forecast the Marketing and 
Administrative costs. Therefore, 32 percent will be proportion spent with this cost. Marketing in this 
industry can’t be compared with the others, since in the Pharmaceutical Industry medicines can’t be 
advertised, regulators control everything that a pharmaceutical company says about their medicines to 
the public.  
According to the 2008 form 10-K, in this cost is also included an average amount of $100 million 
corresponding to legal defense costs reserves of products. This reserve is for litigations that the 
company might have. According to the company, Merck has “various claims and legal proceedings” that 
are considered as normal due to the nature of the industry. Some examples are: product liability, 
intellectual property and commercial litigation and antitrust actions. 
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 Research and Development 
In 2008, Merck reduced its level of costs of R&D by 2 percent (Appendix 10) in comparison to the 
previous year. This reduction was due to the 2008 restructuring program that had the objective of 
reducing costs. In 2007, in contrary with 2008, the cost of R&D increased by 2 percent due to the 
increase of compound entering clinical trials.  
According to EPFIA 2008 Study
33
 the majority of pharmaceutical companies have a level of R&D 
correspondent to 15.9 percent of sales revenue. Since there is no information how this cost is projected, 
one will assume that the R&D would be forecasted based on revenues, like EPFIA presented the level of 
R&D.  
The level of R&D, in the last 3 historical years, was correspondent to 20 percent of revenues and since it 
has been stable one will assume this level to forecast R&D. 
Restructuring Costs 
As mentioned previously this cost was created to fulfill the needs of the 2005 and 2008 Restructuring 
Program. According to 2008 Form 10-K it is expected that in 2011 this cost will no longer be incurred. 
From 2009 to 2011, the company expects to spend $1.6 billion to $2.0 billion, for the cost forecast one 
will assume the maximum ($2.0 billion) and distributed equally in the three years.   
Equity Income 
This cost is associated with the joint ventures and partnerships the company does with other companies. 
Although this element is addressed in the cost section, Equity Income, like the name already says it is 
normally a positive income obtained through the partnerships and joint ventures. Due to the 2005 and 
2008 Restructuring Program some joint ventures and partnerships are being reevaluated in order to see 
if it compensates to maintain them in the company portfolio. The respiratory joint-venture of $105 
million done with Schering-Plough was terminated in 2008; therefore the company had to pay to the 
partner in the same year $43 million of charges and the remaining will be amortized until 2016 (patent 
life of Zetia). I will assume that from 2009 to 2016 the value that is going to be amortized will always 
be equal. 
Table 4: Respiratory Joint-venture 
 
                                                          
33 “EPFIA (2008) “The Pharmaceutical Industry in Figures” 
Equity Income 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total
  Respiratory Joint-venture -43 7,75 7,75 7,75 7,75 7,75 7,75 7,75 7,75 105
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Excluding the redemption made with the respiratory partnership with Schering-Plough, one will assume 
that the level of Equity Income will remain the same, since there is no conclusive information that can 
lead to a more accurate projection (Appendix 10). 
U.S. Vioxx Settlement Agreement Charge 
 
This element was only used to enter into an agreement in 2008 with law firms to resolve state and 
federal myocardial infarction and ischemic stroke claims already filed against the company in the 
United States.  
5.1.1.3. Capital Expenditures 
Capital Expenditures (Capexs) are an important element in the pharmaceutical industry. In fact, this 
element may be considered as one of the barriers to enter and establish in this industry. According to the 
IMS Health pharmaceutical companies require good and appropriate infrastructures which involve high 
investments upfront. At the same time companies face a problem of new technology appearing and 
making the one they have obsolete. Pharmaceuticals are differentiated by investments made on 
infrastructures, company size are correlated with the investment made in this area, meaning that the 
highest the company size the higher will be the infrastructure cost.  
Pharmaceutical companies tend to invest more in developed countries, where regulations and 
government policies regarding the pharmaceutical industry are clear and known. United States is 
nowadays the biggest attraction due to its high development and investment in the pharmaceutical 
industry.  
Merck by no exception follows this investment trend; United States accounted for 73 and 78 percent of 
the total CAPEX in 2008 and 2007, respectively. However, a new investment trend is rising due to 
saturation of developed markets which require companies to look for new locations to invest. Countries 
such as the BRIC countries are showing high growth levels making companies desire for new 
investment locations.  
According to Merck 2008 Form 10-K, the company is engaged in Environmental Matters, in this sense, 
during the years it has been enrolled in activities that help the environment. In 2008 the company 
estimated that they spent $89.5 million in environmental matters, since the beginning of this project, and 
this cost is included in Capital Expenditure. The company stated that in the limit they except to spent in 
the future $70.0 million with environment actions.  
For 2009, the company was expecting to have a capital expenditure of $1.6 Billion; one will assume this 
estimation for 2009 and assume that environmental matters are already included in this forecast. 
Merck does not provide any information about how they project and decide the amount they will invest 
each year, for that reason one relied on peers’ information, more precisely Amgen information about 
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how they forecast their CAPEX. According the 2009 Form 10-k, Amgen CAPEX is associated with 
manufacturing capacity and site expansion. Since, Merck does not provide concrete information about 
their strategies; I cannot estimate the expansion of sites. Therefore, one will forecast CAPEX in relation 
to manufacturing (Sales – Cost of Sales) (Appendix 11).  
From 2004 to 2009, Merck’s represented 10, 8, 6, 6, 7 and 8 percent of the company’s manufacturing, 
respectively. One assumed that Capital Expenditure maintained the same percentage over the 
company’s manufacturing, 8 percent, from 2010 to 2018.  
5.1.1.4. Depreciation 
Merck states that the company uses the straight-line method to depreciate their tangible and intangible 
assets. Although they provide this information they do not present the description about the assets they 
have in the company and intentions to purchase more. Therefore, it is quite complicated to forecast 
depreciation only with outside information. 
Therefore, one calculated the percentage that depreciation represented on net assets
34
 (table 5). From 
2004 to 2008, Merck’s’ Depreciation and Amortization has been very unstable (Appendix 11). In 2004 
the company had a ratio of 7 percent and in the following year the ratio increased to 9 percent then to 13 
percent, dropping to 9 percent in 2007 (Table 5).  
   Table 5: Percentage of Depreciation over net assets from 2004 to 2008 
 
 For the forecast, one will assume the percentage of depreciation over net assets from 2008 to estimate 
depreciation for the upcoming years.  
5.1.1.5. Working Capital 
Working capital (WC) is a measure of operating requirements of the company; it evaluates the liquidity 
of the company to fulfill its operating needs. Merck has always displayed liquidity to sustain its 
operations, the company discloses the values of working capital, been the total current assets minus the 
total current liabilities. According to Damodaran
35
, for valuation purposes the calculation of WC will 
only have Inventory, Receivables and Payables, following the general composition of WC (formula 
4.2).  
                                                          
34 Net assets  
35 http://pages.stern.nyu.edu/~adamodar/New_Home_Page/valquestions/noncashwc.htm, March 07th, 2012 
Year 2004 2005 2006 2007 2008 2009-2018
% over net assets 7% 9% 13% 11% 9% 10%
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(4.2)
 
Receivable was estimated based on a percentage of revenues, as the formula of the Cash Conversion 
Cycle
36
 (CCC) (4.3) shows. Contrary to Receivables, Inventory and Payable were forecasted having into 
the Cost of Sales.  
                
(4.3)
 
    
           
        
            
         
             
         
       
             
     
From the 2009 Form 10-K it was only possible to withdraw information about Inventory. As the 
company explains in its report the existing inventory it is related to the revenue obtained together with 
the probability of the product to have regulatory approval. Since the Cost of sales is also related to 
revenues, there was no obstruction to forecast inventory based on it. About the two remaining elements, 
there is no information that can contradict the forecast. 
For the forecast of the three elements, one had into account DSO, DIO and DPO, with those it was 
possible to achieve the number of days the company pays, receives and have products in inventory. 
With those, one assumed the number of days of 2008 to forecast the element until 2018.  
Since 2004, the CCC has been positive but dropping from 166 to 133, but in 2008 it increased to 167. 
The continuous drop, from 2004 to 2007, shows a concern to reduce the number of days between of 
Receivables, Payables and Inventory, for this reason one will assume that 2008 was an abnormal year 
and 2007 values will be the reference for the CCC from 2009 to 2018 (Table 6). 
 
Table 6: Working Capital 
 
                                                          
36 Cash Conversion Cycle measures the time period between of time payments the company does to supplies and the time the 
company will receive from clients.  
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Accounts Receivable 3,628            2,927        3,315        3,636        3,779        3,678        3,758         3,864        3,961        4,065        4,175        4,277        4,406        4,541        4,682        
Inventories 1,899            1,658        1,769        1,881        2,283        1,708        1,746         1,794        1,890        1,940        1,992        2,041        2,102        2,167        2,234        
Accounts Payable 421               471           497           625           618           567           580            596           627           644           661           677           698           719           742           
Total working Capital 5,105            4,114        4,588        4,893        5,445        4,819        4,924         5,062        5,223        5,361        5,505        5,640        5,810        5,988        6,174        
Δ Working Capital 991 -          473           305           552           626 -          106            138           161           138           144           135           170           178           186           
Days Receivables 58                 49             53             55             58             55             55              55             55             55             55             55             55             55             55             
Days Payables 31                 33             30             37             40             37             37              37             37             37             37             37             37             37             37             
Inventory Days 140               118           108           112           149           112           112            112           112           112           112           112           112           112           112           
Cash Conversion Cycle 166              133          131         130         167         130         130          130         130         130         130         130         130         130         130         
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5.1.1.6. Financial leverage 
Following the conclusion taken with the Literature Review, the terminal value of the company will be 
computed through the APV method, with an unlevered cost of equity. Some assumptions were made 
through the project so it could be possible to compute the terminal value of the company and the 
discount rates were driven from CAPM. Since one of the objectives is to find an unlevered cost of 
equity, the CAPM formula (4.4) will be used with an unlevered beta.  
                       
(4.4)
 
Risk-free (    
According to the company’s shareholder structure, Merck had up to 53 percent of the share capital 
represented by U.S investors, followed by English and German investors, representing 13 and 9 percent 
of the share capital. Therefore, the risk-free rate was taken from the United States Treasury data of 
2008, since the majority of investors are from United States (Appendix 12). The 10-year Treasury bond 
on December 31
st
 of 2008 was 2.25 percent.  
Beta (β) 
As explained in the literature review the best method to find the value of a beta (β) is through the 
estimation using proportion of excess stock return and comparing with the excess return on the market. 
For the thesis, one used the data from Damodaran website of unlevered βs; the β chosen of 1.03 is from 
the pharmaceutical industry, in order to achieve a coherent terminal value (Appendix 13).  
Risk Premium (    
According, to Damodaran the risk premium (    of U.S. in 2008 was 5 percent (Appendix 14), one 
important factor about this rate is that it does not include the Moody’s default spread and the bond 
volatility, solely the U.S historical risk-premium. According to Damodaran, U.S. in 2008 had no 
country risk; therefore the total risk premium is equal to 5 percent.  
Having all the elements of the CAPM formula it is possible to compute the value of the cost on 
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Cost of debt (    
Concluding the equity side elements to estimate the terminal value of Merck cannot be forgotten the 
valuation of the debt side, as the APV method requires. Therefore it is necessary to have a cost of debt 
and the appropriate tax rate for the business.  
Merck has presented a weighted average interest rate for borrowings of 5.8 and 1.4 percent at 31
st
 of 
December, 2007 and 2008, respectively (Appendix 15). A high discrepancy between the two years leads 
to an alternative method to achieve the cost of debt. As it is not possible to obtain a value through the 
company’s data, one has two alternatives: The first would be to collect the cost of debt of the 
pharmaceutical companies; this element is provided by data’s, Bloomberg or Damodaran data base. 
Hereby, the value found in Damodaran was 6.21 percent. Another alternative would be to adjust the cost 
of debt with the Moody’s rating of probability of default. In the case of Merck it is rated as an A3 
(Appendix 16) by Moody’s, and the spread associated is 1.65 percent. The interest coverage ratio of the 
company is 24.8x, having an AAA rating with an adjusted probability of default of 0.65 percent and one 
assumed Moody’s rating to calculate the cost of debt. Hereby, the cost of debt is 3.9 percent (1.65% + 
2.25%). 
Tax-rate (    
 In 2008, the corporate tax rate applied in the company was 20.4 percent. The effective tax rate of Merck 
has fluctuated year to year, being 28.7 and 2.8 percent, in 2006 and 2007, respectively. The unstable 
trend of the rates makes the outlook to the future all most impossible to be made. According to 
Damodaran data in 2009 the marginal tax rate of the drug industry would be 25.8 percent. 
Cost of Distress 
Finally, having into account the percentage of distress, 27 percent (for pharmaceutical companies that 
are rated between A+ and B by Moody’s), given by Korteweg research paper, the calculation of the cost 
of financial distress for Merck can be computed.  The percentage of distress will be multiplied by the 
Free Cash Flow to the Firm each year and the terminal value and discount them to the cost of debt. The 
value found will be multiplied by the probability of default. 
APV 
In this sense, through the APV method, Enterprise Value of Merck’s is $170 billion (formula 2.7 from 
the literature review), the company average market capitalization
37
 is 2x smaller than the estimated EV, 
                                                          
37 It is used the average market capitalization of companies because in 2008 were affected by the financial crisis and the market 
capitalization of the same year may not reflect the real value of the company 
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approximately, which may lead to the conclusion that the company is undervalued (Appendix 17). The 
Enterprise Value, as the formula represents, it is the sum of value of the unlevered firm plus the tax 
shields minus the financial distress (Appendix 19). 
The estimated value of the unlevered firm is $ 158 billion. The unlevered firm value is calculated by 
adding the present value FCFF from 2008 to 2018 and the terminal value of FCFF (formula 2.4). The 
FCFF is the EBIT(1 - TC) plus depreciation, Capex and variation of other assets, minus the variation of 
net working capital.  
The present value of tax shields, as formula 2.5 shows, it is the sum of the present value of interests 
multiplied by effective tax rate and the terminal value of tax shields. The value achieved is 13 billion.  
The Financial distress for Merck is equal to $1 billion and it was calculated having into account the 
value of the unlevered firm multiplied by the 1.65 percent of default spread and the 27 percentage of 
distress for a pharmaceutical company (formula 2.6). 
Share Price 
To find the share price it is necessary to calculate the value of Equity, where it is equal to present value 
of FCFE.  The Equity value is $ 143 billion, with approximately 9400 million shares, the share price is 
$15.26 and the share price on 31
st
 December 2008 was $30.4, which is good because the market 
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5.2. Schering-Plough 
Since 2003, Schering-Plough has established a long-term strategy focused on applying medical science 
to go towards unmet medical needs and have commercial value with the therapeutics created. In other 
words, the company’s strategy aims at creating therapies and medicines that responds to medical needs 
that haven’t been met yet through the meaningful investment in R&D. The company also sought to 
build long-term value for shareholders and for patients that rely on the company’s medicines.  
Although Schering-Plough has built effective strategies that brought great advantage and increased 
greatly in market, the company faces a high level of competitiveness. The pharmaceutical industry is 
highly competitive and consists of countless companies trying to discover new drugs and therapies in a 
very accelerated pace, and according to its 2008 annual report, Schering-Plough tries to be always one 
step ahead of its competitors.  
The valuation that is going to be presented with Schering-Plough will have similar structure than the 
Merck valuation, in order to compare both companies when necessary and to have an accurate 
conclusion. 
5.2.1.1.  Revenues 
Schering-Plough, as any pharmaceutical company, operates in the main segment: prescription 
pharmaceuticals, also known as pharmaceutical segment. This segment represented 77 percent of the 
company’s revenue in 2008, which can lead to the conclusion that the prescription segment is the most 
invested segment through R&D. The company is also in two other segments: Animal Health and 
Consumer Health Care, as seen previously. From all the segments, the Animal Health Segment is the 
one with the highest growth rate.  
The analysis and valuation of Schering-Plough will be done by geographic location to be in line with the 
analysis of the previous company. Therefore revenues, as the last company, will be evaluated in a 
separate basis but the remaining will be in a consolidated basis.  
As with the previous company, one will use the four factors (evolution of the pharmaceutical market in 
number of patients, evolution of the pharmaceutical price, the market share of the company in sales and 
objectives made by the company for the future), presented by Alexandre Tavares, that influence the 
sales of the company.  
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United States of America 
Contrary to what is expected by pharmaceutical companies, the United States segment is not the greatest 
segment from Schering-Plough (Appendix 20). This geographic segment represents 30% of its revenue, 
although not the greatest segment it had a significant growth (21 percent) in 2008 comparing to the 
previous year (Appendix 22). The growth felt was mainly due to the increase in sales of Nasonex, one of 
the prescription drugs with the highest revenue for the company. In the previous years, this segment 
grew 10, 17 and 12 percent, in 2007, 2006 and 2005, respectively.  
Schering-Plough has been growing in a faster way than the market, indicating that the company is 
increasing its market share in the United States.  
Having into consideration the factors influencing the forecast of revenues, one estimate that the United 
States segment will grow in 2009 and 2010, 15 and 7 percent, respectively. The grow rate will stabilized 
in 2011, and the segment will grow at a rate of 4 percent.  
Although, the growth rate of the segment will have a reduction from 2009, the growth rate will be 
always higher than the forecasted market growth rate, this shows that the company expects to continue 
to gain market share of its competitors. 
Europe and Canada 
Europe and Canada represent the largest segment accounting for 48 percent of the company’s sales 
revenue. Being, such an important segment, it presented one of the fastest and highest growth rates 
comparing with the other 3 segments. From 2004 to 2008, the Europe and Canada segment grew, 12.4, 
9.0, 24.9 and 61.9 percent. And Canada, according to the company’s report, had in the last 3 years a 
growth rate of 5 percent (Appendix 21). 
The segment is forecasted to continue to grow at a rate of 27 percent in 2009, but in 2010 the growth 
rate will decrease to 9 percent and from 2011 to 2018 the growth rate will be 5 percent. This decrease in 
the growth rate from 2009 is due to population evolution and the market evolution in term of patients. 
According to IMS Health the market will grow at approximately 4 percent until 2015, but it is expected 
that the population will grow at a rate of 1 percent until 2020, showing that the percentage of people 
with the necessity for drugs will increase comparing with the previous years.  
Latin America 
Latin America corresponds to the smallest segment of the company, with 10.74 percent of the revenues. 
This segment although small, it has been growing in a fast way; it grew 46 and 37 percent in the last two 
years (Appendix 20), 2008 and 2007, respectively. Being a rapidly growing segment one cannot neglect 
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its future’s capacity to generate more value to Schering-Plough. According to the company’s’ 2008 







, the greatest contributor to the growth of the segment was Caelyx with a growth 
rate of 25 percent from 2006 to 2007. 
As one already stated previously, the company is implementing growth strategies involving emerging 
markets being the reason why the Latin American countries by their high levels of expected growth can 
become a source of growth to the company. The growth employed to forecast the revenues are the 
following 27 percent for 2009, 15 percent for 2010, 9 percent for 2011 to 2013; and 5 percent for 2014 
to 2018.  
Asia Pacific 
The Asia Pacific segment is composed by countries from the Asian Continent like Singapore and Japan. 
Japan for instance is in the group of the top 4 foreign countries that generate 5 percent or more of 
consolidated revenues during the past 3 historical years, 2006 to 2008 (Appendix 21).  
Asia Pacific is slightly bigger than the Latin American segment, accounting for 11.11 percent of the 
total revenues of Schering-Plough in 2008. This segment increased by 67 percent between 2007 and 
2008, a significant growth comparing with the previous years. The forecasted growth rates are as stated 
before by IMS Health. In this segment, one assumed that Japan is equally important as the remaining 
countries of Asia Pacific segment since it generates significant revenues for the company. Therefore the 
growth rate estimated for this segment is 34, 30, 12 and 8 percent, from 2009, 2010, 2011 to 2012 and 
2013 to 2018, respectively.  
5.2.1.2. Costs 
From this chapter on the analysis will be done in a consolidated basis, as undertaken previously with 
Merck. Due to scarcity of information provided by the company it was not possible to analyze and 
evaluate the cost by segment. Although not optimal this would make the analysis more coherent with 
the previous one. 
 
 
                                                          
38 Pegintron Powder is an injection to treat hepatitis C 
39 Claritin is a drug used to treat allergies. Schering-Plough only marketed outside of U.S. 
40 Caelyx is medicine for a treatment of ovarian cancer, metastatic breast cancer and Kaposi’s sarcoma.  
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Material and Production 
Through the composition of the elements that make part of material and production cost was possible to 
verify that it is divided in two sub-groups of costs, in other words, this cost come from two sources.  
Normally, 70 percent of the value of material and production cost is related to the sales of medicines 
and the remaining 30 percent are related to other costs of production; for example, the amortization of 
inventory or amortization of acquired intangible assets, elements that one can’t predicted in the analysis 
but it should be noted so that readers can better understand this cost (Appendix 23).  
Although, the cost of material and production is sub-divided into parts, since 2005 this cost always 
followed the same trend, accounting for 35 percent of the revenues. In 2008, it was the only year in 
which this percentage had a small rise due to the “amortization of fair value of primarily inventories” 
and “intangible assets acquired as part of the OBS acquisition”. For further estimations about this cost, 
it will be assumed the percentage of 35 percent since during the last three historical years it remained 
intact. 
Marketing and Administrative 
This cost, as the previous one, is composed by two sub-groups:  the first one is sales related and the 
second group is related to administrative issues such as “contractually defined costs for physicians and 
promotion spending” and “ongoing investments in Emerging Markets”. These two groups, although not 
directly related, persist into the future and are somehow dependent on sales; since the company is 
engaging in expanding its business to other markets it is obvious that sales will rise and the cost on 
promotion spending and investments will also rise. Therefore, it will be used a percentage of sales as 
directly or indirectly all sub-groups of this element are dependent on sales. Through the calculations, it 
was possible to realize that from 2005 to 2007 the average for marketing and administrative costs 
accounted for 45 percent of sales, and in 2008 this percentage had a reduction of 8 percent due to the 
acquisition of OBS (Appendix 22 and 23). According to the company’s report there was a cost synergy 
in this element, the reason for the reduction of it. Hereby, one will assume the rate of 37 percent to 
estimate this cost by 2018.  
Research and Development 
In different pharmaceutical companies the cost of Research and Development (R&D) can be 
proportional to different elements of the company, for instance the majority of pharmaceutical 
companies, as EFPIA Study
41
 explained in its research, tends to spend a certain amount (percentage) in 
relation to sales (15.9 percent) to be its costs with R&D. But this doesn’t mean that all companies 
follow the same trend, one example is Schering-Plough who tries to invest as much as possible in the 
                                                          
41 EPFIA (2008) “The Pharmaceutical Industry in Figures” 
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area. A very important quote of the company’s report was withdrawn and due to it one will establish the 
estimation of R&D.  
“For the full year 2009, Schering-Plough currently expects R&D spending to grow in the mid single-digit 
range.” 
In 2008, R&D accounted for 19 percent of revenues, in the same year this cost had a decrease compared 
with the previous years. From 2005 to 2007, the proportion of R&D to revenues was around 21 percent, 
but since the company stated that it expects to have an increase in this value of 5 percent, one will 
assume this proportion and raise the value to 24 percent. This increase of 5 percent is understandable 
since the company acquired OBS in 2008, increasing its therapeutic areas to two new therapeutic areas, 
Women Health and Central Nervous System. Being important to understand these areas very well, this 
increase in expenditure makes total sense. 
 
Special and Acquisition-related Charges 
As the name by itself states this cost is related to charges driven by acquisitions. In the case of Schering-
Plough it was charges related to OBS acquisition.  
According to the report this charges will continue until 2013 and the forecast will be done until that 
year. Since there is no information about the future spending with this cost, one will assume the amount 
of 2008, to be charged until 2013, $329 million. 
Equity Income 
As with the Merck, this element represents the joint ventures and partnerships of the company, in the 
case of Schering-Plough as mention in the previous section the partnerships were taken only with 
Merck.  
According to both reports, the respiratory joint-venture between the two companies was terminated, so 
Schering-Plough equity income dropped 8.7 percent (Appendix 22), reaching a value of $1.879 million. 
Due to lack of information about the company objectives relative to joint-ventures in the future, one 
cannot predict future trends of the equity income. For this reason one will assume that Equity Income 
will remain the same until 2018.  
 
 
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           48 |  
5.2.1.3. Capital Expenditures (Capex) 
Capital Expenditures, in the case of Schering-Plough, it has presented an unstable growth during the last 
5 historical years; (2), (4), 35 and 21 percent in 2005, 2006, 2007 and 2008, respectively (Appendix 24).  
According to the 10-k report, Schering-Plough have two commitments related to capital expenditure that 
must be fulfill of $106 million and $1 million in 2009 and 2010, respectively, but besides this 
information there is no further reference on the future. 
Therefore, one will forecast Capex having into account how Amgen does it. As seen previously, Amgen 
relates Capex with the manufacturing production, so the same was done to Schering-Plough to forecast 
its Capex. 
From 2004 to 2006 the ratio of Capex/Manufacturing Production has been dropping 100 basis points, 
from 9 percent to 7 percent in 2006. From 2006 to the last historical year the company had a stable ratio. 
Here by, one will assume the percent of the last three years and forecast Capex.  
In 2009 and 2010 it was made the proper adjustments to include the commitments that the company 
had.  
5.2.1.4. Depreciation and Amortization 
Similarly to the previous company the depreciation of assets will be estimated over net assets. Since 
there is no inside information about investments on tangible assets made by the company in order to 
understand how depreciation was calculated it is quite difficult to forecast this element. Contrary to 
depreciation, Schering-Plough gives estimation for amortization during 2009 to 2013.  
“Annual amortization expenses related to these intangible assets for the years 2009 to 2013 is expected to 
be approximately $570 million.” 
 
Due to lack of information about amortization estimation from 2013 to 2018, and once the company 
estimated for 5 years one will assume the same level ($570 million) until 2018. 
However, since there is no information about the value of each element of the cost, amortization and 
depreciation, it’s not possible to forecast each element separately. Therefore, one will use the estimation 
method used in the previous company, Merck, and still have into account the value of the amortization.  
From 2004 to 2008 the Depreciation/Net assets ratio has been increasing (table 7), in the first four years 
the increase was minor but in 2008 the ratio had a significant growth, an increase of 13 percent. This 
trend demonstrates an increase in investments (tangible and intangible assets) by the company during 
these 5 years, mainly in 2008 when the company felt a higher ratio. For forecast purposes, one will 
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assume a ratio of 21 percent, assuming that an asset was bought in 2008 and it has at least 15 years to 
depreciate/amortize. 
Table 7: Percentage of Depreciation over net assets from 2004 to 2008 
  
5.2.1.5. Working Capital 
Schering-Plough, does not display in its reports the value of working capital (WC); therefore one had 
into account the general formula to calculate the WC (4.2) (page 40); thus there is a large coherence 
with the previous forecast made of Merck working capital. The working capital of the 5 historical years 
demonstrates that Schering-Plough has always displayed liquidity to sustain its operations (table 8).  
Since 2004, the CCC has been positive, dropping from 134 days in 2004 to 104 days in 2006, but in 
2007 it bucked the tendency, increasing to 237 days. In 2008, the three elements had a reduction in the 
time period. 
Although the company has always displayed capacity to fulfill its necessities, WC has been presenting 
very unstable during the years. In 2008 the value of WC dropped again after a huge recovery in 2007.  
According to the 2008 Form 10-K, Schering-Plough entered in an agreement to reduce the number of 
inventory days
42
. Therefore, one assumed the number of days of 2008 to forecast the WC until 2018. 
Since there is no more information about the other elements, Receivables and Payables, one assumed 
the days of 2008 to forecast them, in this way those two elements will be in accordance with Inventory.  




                                                          
42 “Schering-Plough’s agreements with the major U.S. pharmaceutical wholesalers address a number of commercial issues, such as product 
returns, timing of payment, processing of chargebacks and the quantity of inventory held by these wholesalers. With respect to the quantity of 
inventory held by these wholesalers, these agreements provide a financial disincentive for these wholesalers to acquire quantities of product in 
excess of what is necessary to meet current patient demand. Through the use of these agreements, Schering-Plough expects to avoid situations 
where Schering-Plough’s shipments of product are not reflective of current demand.” 2008 Form 10-K of Schering-Plough. 
Year 2004 2005 2006 2007 2008 2009-2018
        % net assets 6% 7% 7% 8% 21% 7%
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Accounts Receivable 1,407        1,479        1,804        2,841        2,816        3,496        3,903        4,138        4,390        4,634        4,870        5,119        5,381        5,657        5,949        
Inventories 1,580        1,605        1,676        4,073        3,114        3,426        3,825        4,055        4,303        4,542        4,773        5,016        5,273        5,544        5,830        
Accounts Payable 978           1,078        1,254        1,762        1,677        1,845        2,060        2,184        2,317        2,446        2,570        2,701        2,840        2,986        3,140        
Total working Capital 2,009        2,006        2,226        5,152        4,253        5,078        5,668        6,009        6,376        6,730        7,072        7,433        7,814        8,215        8,639        
0% 11% 131% -17% 19% 12% 6% 6% 6% 5% 5% 5% 5% 5%
Δ Working Capital 3 -              220           2,926        899 -          825           591           341           366           354           342           361           381           402           424           
Days Receivables 62             57             62             82             56             56             56             56             56             56             56             56             56             56             56             
Days Payables 116           118           124           146           84             84             84             84             84             84             84             84             84             84             84             
Inventory Days 188           175           165           337           156           156           156           156           156           156           156           156           156           156           156           
Cash Conversion Cycle 134         114         104         273         127         127         127         127         127         127         127         127         127         127         127         
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5.2.1.6. Financial Leverage 
In order to compute the terminal value of Schering-Plough by APV methodology some assumptions 
need to be taken for the estimation of the company’s value. Therefore, the estimation of cash flows was 
straight forward.  
As already explained, the APV has a great benefit compared to other methods of assessment; the 
valuation is divided into two parts, one that assessed the company as if it were 100% equity financed 
and the second part refers to the debt of the company, which is not the case when discounting at the 
WACC with the FCFF method. 
Risk-free (  ), Beta (β) and Risk Premium (  )  
As it was mentioned before, the value of the risk-free (    was taken the U.S. Treasury data from 2008, 
since it was the last year one had information about the company. In the case of Schering-Plough, one 
assumed that the majority of investors were in US. This assumption was made since the company is part 
of Merck and there is no information about the investors base in 2008. 
 The value of the risk-free rate (   , beta (β) and risk premium (    are 2.25, 1.03 and 5 percent, 




Cost of debt  
For the debt side valuation it is necessary two main important aspects, the return on debt (  ) required 
by the debt holders and the tax rate of the pharmaceutical industry. In 2008, Schering-Plough interest 
rate varied from 5.3 to 6.5 percent,  for borrowings due in 2013 and 2033, respectively, with the specific 
adjustments necessary according to the additional interest rate set forth by Moody’s and S&P. Since the 
company had in this period of time different borrowings with different interest rates it becomes slightly 
difficult to compute or even to choose the most appropriate rate through the company information. 
Therefore, one could use the rate withdrawn from the Damodaran data base, correspondent to 6.21 
percent. Alternately, one could use the data according to the probability of default from Moody’s.  
In line with the previous company, one will use the data from Moody’s rating. According to the 
company’s 2008 Form 10-K, Moody and S&P rating for Schering-Plough is Baa1 and A-, respectively. 
The spread associated with the rating of Baa1 is 2%. Using the approached described in the literature 
                                                          
43     = 2.25% + 1.03*5% 
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review, the cost of debt will be the sum of the risk-free and the default spread, the cost of debt is equal 
to 4.25 percent ( 2.25% + 2% ) 
Another important aspect to retain is that capital structure that is being imposed in the company, the 
company seeks to have capital structure of 40 percent of debt but from 2004 to 2008 this level has been 
very unstable. For the forecast, one will use in 2009 a capital structure of 35 percent of debt and from 
2010 one will use 40 percent as mentioned in the company reports. 
Tax-rate (  ) 
To obtain the value of the tax shields one will multiple the net debt by the cost of debt and by the 
effective tax rate. According to the Damodaran data base the effective tax rate will be 25.75 percent. 
Cost of distress 
As with the Merck, the cost of financial distress is 27%, meaning that in case of distress the Schering-
Plough would lose 27% of its value. Although this percentage seems high, in reality when accounted in 
the firm’s value one will have to multiply the cost of financial distress with the default spread, which in 
case of Schering-Plough is 2 percent, reducing the cost drastically. 
APV 
Having into account all the three components of APV, Schering-Plough enterprise value is $58 billion 
(formula 2.7). The estimated enterprise value of Schering-Plough is approximately 2x greater than its 
market capitalization. Likewise Merck, this means that the company is undervalued (Appendix 26).  
Having into consideration the APV method to calculate the different parts of the firm’s value, one found 
that the value of the unlevered firm is $36 billion, the value of the tax shields is $13 billion and 
Schering-Plough value of the financial distress is $ 435 million. (Appendix 28) 
Share Price 
Schering-Plough share price was computed the same way as Merck. The first objective was to compute 
the value of equity then the share price. The Equity value found is $36 billion and with approximately 
5343 shares; the company’s share price is $6.75. Compared with the market price of Schering-Plough 
shares, $17.03, the company is well perceived by the market.  
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5.3. Relative Valuation 
According to the literature review, one could easily conclude that it is crucial to have a complementary 
analysis when using WACC or APV methods. APV or even WACC methods are good methodologies 
but alone they only look for the companies individually. Using the relative valuation, it will be 
compared Merck and Schering-Plough with their peers and evaluate their performance. 
The choice of the peer group had some important criteria in order to have a coherent peer group. The 
first criterion was to include only pharmaceutical/biotechnology companies, companies that may 
compete with the Merck and Schering-Plough with “unique pharmaceutical/biotechnology talent”.  It is 
important to retain that the companies in the peer group should compete directly with the Merck and 
Schering-Plough and be exposed to the same environment, research-driven and regulatory. The second 
criterion is that the companies of the peer group may vary in size, which in normal conditions would be 
an exclusion factor, but since it is established the first criterion it wouldn’t be appropriate to exclude 
companies by size otherwise the focus would not be on talent basis and the group would be very small 
and would not have all the competitors. The third and last criterion is considered at least 15 competitors 
of the both companies.  
When choosing the proper peer group it  had to be into consideration the peer group presented by the 
companies, more specifically the peer group presented by Merck in its “Notice of Annual Meetings and 
Proxy Statements” of 2011. 
Table 9: Peer group data 
 
Since Merck didn’t provide enough competitors for the peer group, one had into account other sources 
to complete the group.  







P/E P/Book P/Sales EV/EBIT EV/EBITDA EV/Sales
Abbott Labs. United States 53.37          82,853.35      89,219.02      16.08             4.74                  2.79               15.67             10.73          3.02         
Amgen United States 57.75          60,464.25      60,264.25      12.89             2.90                  4.12               11.56             9.59            4.02         
AstraZeneca PLC UK/Sweden 41.03          59,219.41      66,704.41      9.74               3.72                  1.88               8.31               5.72            2.11         
Biogen Idec United States 47.63          14,158.16      13,067.87      13.34             2.44                  3.40               10.75             6.05            3.19         
Boston Scientific United States 7.74            11,622.66      16,726.66      9.68               0.88                  1.44               10.36             7.95            2.08         
Bristol-Myers Squibb United States 23.25          45,895.50      45,895.50      15.60             3.75                  2.59               8.04               10.47          2.59         
Lilly (Eli) United States 40.27          45,784.92      50,323.22      10.02             6.80                  2.16               3.86               7.57            2.47         
GlaxoSmithKline ADR United Kingdom 37.27          97,111.16      112,502.00    14.50             8.40                  2.74               7.04               6.66            2.49         
Johnson & Johnson United States 59.83          165,680.00    164,719.00    13.15             3.90                  2.63               28.07             8.67            2.58         
Novartis AG ADR Switzerland 49.76          112,964.00    114,360.00    13.89             2.25                  2.73               12.06             9.55            2.76         
Pfizer Inc. United States 17.71          119,472.00    113,281.00    7.32               2.08                  2.47               6.64               5.12            2.35         
ROCHE Switzerland 38.28          132,072.00    125,205.00    15.58             3.15                  3.06               9.73               8.17            2.96         
Sanofi-Aventis France 32.16          82,696.72      85,466.29      15.44             1.32                  2.16               9.76               5.36            2.11         
Takeda Japan 51.40          42,117.73      25,708.65      11.91             1.84                  3.08               5.08               6.44            2.13         
Wyeth United States 37.51          49,946.57      47,140.58      10.63             2.60                  2.19               10.67             5.93            2.06         
Average 74,803.90$       75,372.23 12.65 3.38 2.63 10.51 7.60 2.59
Median 60,464.25$       66,704.41 13.15 2.90 2.63 9.76 7.57 2.49
St. Deviation 33,652.74$       34,643.34 2.08 1.37 0.44 3.22 1.49 0.37
Merck & Co. United States 30.4 64,073.79 67,236.59 8.89 3.42 2.72 7.13 6.08 2.82
Schering-Plough United States 17.03 27,690.78 34,988.78 9.36 3.45 1.50 13.92 7.46 1.89
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5.3.1. Merck 
Although Merck in terms of Market Capitalization is not one of the biggest companies of the group, 
when looking to the five multiples computed it is clear that the company is in line with the average of its 
peers. For the average of the ratios, it is considered an upward and downward adjustment for the target 
price calculation. 
The first multiple, price-earnings ratio, shows that Merck is transacting at a lower multiple of earnings 
than its competitors. P/E shows that Merck should invest more to create more growth for the company. 
Since, the companies of the peer growth may had different expected growth rates it seemed crucial to 
compute PEG ratio, since it takes into account the expected growth of the companies. According to this 
multiple, Merck is trading at a premium when compared with peers. In relation to the price-to-book 
multiple, Merck reveals that its stock is overvalued, this comes into accordance with the PEG ratio with 
reveals a higher growth rate for the company. Regarding the price-to-sales ratio, the company shows a 
lower value than its peers. The equity multiples, although good, they may be manipulated by the 
company, therefore it is important to use the enterprise value multiples.  
The two first enterprise multiples are considered better than the EV/Sales, since it takes into 
consideration not only the sales but also the costs of the company. The Enterprise Value to EBIT 
(EV/EBIT) and the Enterprise Value to EBITDA (EV/EBITDA) are below the average of the peers; but 
the difference between with the averages is much smaller with the first ration than the EV/EBITDA in 
relation to the average of the peers. Through the results, the average of the peers, one could observe that 
depreciation and amortization plays an important role for some of the peers, but not as much for Merck. 
Contradicting the last two multiple, Enterprise Value to Sales (EV/Sales) is slightly above the peers 
average.  
For all the above reasons, EV/EBIT seems the most appropriate multiple to find the target price of 
Merck. 
Table 10: Merck relative valuation results 
 
The relative valuation is very useful since it can complement the previous valuation, APV method, or it 
can be used solely to calculate the target price of a company. Through this valuation, EV/EBIT ratio 
seemed the best one to calculate the target price since it presents fewer constraints likewise P/E ratio. 
The target price found with EV/EBIT ratio is $34.76 with a downward adjustment. With the 
EV/EBITDA ratio, the price found is $25.14, with a downward adjustment, this ratio would be given 
P/E P/Book P/Sales EV/EBIT EV/EBITDA EV/Sales PEG
Mean 46,05              12,32     9,57             38,24           27,66         9,45     5,87    
Median 47,86              10,54     9,57             35,53           27,54         9,08     7,87    
Min 41,86              11,20     8,70             34,76           25,14         8,59     5,34    
Max 50,66              13,55     10,53           42,06           30,42         10,39   6,46    
Merck Price per share
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more relevance if wanted to have into account the effect of depreciation and amortization in the target 
price.  Comparing with the real share price of $30.4, one can say that Merck is well priced. 
Having into account the share price found through APV, the EV/EBIT with a downward adjustment 
gives a closer approximation to the value that was found.  
5.3.2. Schering-Plough 
Schering-Plough, comparing with the company from the peer group, has the smallest market 
capitalization. However, it is well positioned in terms of the relative valuation.  The first ratio computed 
(P/E) reveals that the company is trading below the average of the market, with the growth adjustment 
Concerning the P/Book ratio, Schering-Plough is slightly above the average and the median of the group 
with 3.4x. The same trend can be seen with other ratios; P/Sales, EV/EBITDA and EV/Sales with 1.5x, 
7.46x and 1.89x, respectively. The EV/EBIT ratio contradicts all the other ratios with a value of 13.94x, 
a value greater than the average and median of the peer group.  
Likewise with Merck, certain ratios, for instance P/E suggest that the Schering-Plough should use more 
its earnings in investing in the company to generate higher growth.  
In computing the share price of Schering –Plough an upward and downward adjustment of 10% were 
made (Table 11). 
Table 11: Schering-Plough relative valuation results 
 
Looking to the target prices calculated through the multiples, there is no similar value to the real share 
price of Schering-Plough. The target price calculated with the median of P/E is the one that can be 
considered closer to the real share price, with a value of $14.20. 
Having into account the share price calculated with the APV method, the EV/EBITDA ratio presents a 
share price very close, $9.58. Having into consideration the adjustments, EV/EBITDA with an upward 
adjustment and EV/EBIT with downward adjustment present closer values to the price found with APV 
method, with $10.54 and $10.31, respectively. 
 
P/E P/Book P/Sales EV/EBIT EV/EBITDA EV/Sales PEG
Mean 13,66              3,66       2,84             11,35           8,21           2,80     1,74    
Median 14,20              3,13       2,84             10,54           8,17           2,69     2,34    
Min 12,42              3,32       2,58             10,31           7,46           2,55     1,58    
Max 15,03              4,02       3,12             12,48           9,03           3,08     1,92    
Schering-Plough Price per share
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6. Valuation of the Merged Entity  
As referred in the literature review, according to Ullah et al., (2010), when two companies join, their 
objective is to gain market power, share costs or increase efficiency, and Damodaran (2005) states that 
when two companies merge they create an added value for the new entity, also named as synergies. 
Damodaran (2005), also states that to observe the added value in the merged entity is necessary to 
evaluate it without the added value (the sum of the values of the two firms evaluated independently) and 
after the merged entity with synergies.  
Hereby, it is fundamental to create a new valuation where Merck and Schering-Plough are jointly 
estimated and later evaluate the synergy created with the merger. The valuation will be the sum of 
valuation of Merck and Schering-Plough done in the chapter 6. Although, the objective is to create a 
new model for the merged entity assumptions made previously will not change, only in the departments 
or areas where synergies will be created.  
The first approach will be to join Merck and Schering-Plough with no value added, the value obtained 
must be equal to the sum of both firms valuated independently. The second approach will be to reflect in 
the model the added value achieved with the merger.  
6.1. Valuation of the merged entity without Synergies 
In order to have a clear notion of the synergies created by a merged entity it is important to have the 
model of the merged entity without synergies. In this case, the assumptions considered in the standalone 
performance forecast of Merck and Schering-Plough will be used in to create the valuation of the 
merged entity. Since no synergies will be accounted, the enterprise value of the new is the sum of all 
elements of each firm, Merck and Schering-Plough, valued independently.   
The income statement, balance sheet and the base-case cash flows are the sum of the respective 
statements of Merck and Schering-Plough and can be seen in appendix 29, 30 and 31.  
The APV model was the only model used to estimate the enterprise value of the merged entity. The 
relative valuation for this scenario is not an appropriate method since it is not possible to estimate the 
enterprise value through it.  
6.1.1. Revenues and Costs 
The merger of Merck and Schering-Plough will enhance the presence of the new entity in the different 
markets. The new entity will have five geographic segments, United Stated, Europe, Middle East and 
Africa, Asia, Japan and Other, where Latin American countries are included.  
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Both firms will enter in new areas of expertise which will leverage their potential in the market. For 
Merck the new segment areas are the therapeutic area and animal health area. For Schering-Plough the 
new segment is the vaccines and infectious 
diseases area.  
In appendix 32, the revenue of sales is 
distributed by product segments, where 
prescription pharmaceutical segment, still 
represents the greater segment with 80% of 
the company sales revenue.  
 
              Figure 9: Merged company sales geographic distribution 
The cost section was valued the same way as the revenue and all costs from both companies were 
considered. The same happened in the computation of the balance sheet of the merged entity. In the 
financial leverage of the merged entity the FCFF, the tax-shields and the financial distress were the sum 
of the ones of Merck and Schering-Plough since.   
Conclusions: Enterprise Value of the company $ 228 billion, exactly the sum of EV of Merck and 
Schering-Plough. The equity value of the merged entity is $179 billion and the share price would be 
$12.17 (Appendix 31). 
6.2. Valuation of the merged entity with synergies 
The merger between Merck and Schering-Plough will provide the new entity opportunities that each 
company could not achieve individually. One example, one of the segments that Schering-Plough is in, 
is the animal health segment, where Schering-Plough is performing very well and according to the 
company it has the best R&D team and pipeline; for Merck to enter into a segment that is already 
structured and doing very well is a great advantage.  
According to the literature review, two companies when enter into merger they can have two types of 
synergies, Operating Synergies and Financial Synergies, and the objective in this chapter is to identify 
the different synergies that will be created with the merger of Merck and Schering-Plough.   
The merger between two pharmaceutical companies that operate in the same segments will provide to 
the new entity a strong and complementary portfolio, opportunity to enhance R&D efforts and pipeline 
and expand global presence in a faster way. And the new entity will benefit from a strong balance sheet 
that both companies, Merck and Schering-Plough, will provide. 
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A stronger and complementary portfolio will be increased by a greater number of products and scope of 
clients. Enhancing R&D efforts and pipeline will increase the sustainability of the company, the 
increase of medicines in the pipeline rise the probability of having more medicines passing in the FDA 
approval; consequently having more medicines in the market. Expanding global presence, as mention 
previously, will provide the new entity with a broader group of clients.  
The market is characterized by many companies which try to deliver the best medicines, for unmet 
needs trying to spend as low as possible. Bringing companies with different capabilities will reduce the 
cost and increase the probability of having economies of scale and enhance competition in the market.  
Concluding, the merger will create costs synergies and financial synergies, since the new entity can 
have a greater debt capacity. Important to bear in mind, is that the majority of changes that will be done 
in this chapter are assumptions. Most of the assumptions will have a support (company or industry), but 
different assumptions can be withdraw from industry and company insight.  
6.2.1. Synergies 
 
6.2.2. Operating Synergies 
According to the Merck investor presentation (2009), the merged entity will have reductions in three 
elements of the company. The company states that it expects to have costs reductions of 15 percent, 
whereas 40 percent of reductions will happen in the cost of sales and R&D and 60 percent in marketing 
and administrative elements and research and development. In ones point of view, a reduction of 15 
percent is very optimistic since both companies bring different cultures and operate in different 
segments (animal health, consumer health care and vaccines and infectious diseases) probably the 
reduction will not be as high. One will consider a more conservative position with a cost reduction of 8 
percent, this percentage of reduction will be distributed in the main three costs according to ones 
expectation of reduction.  
Material and Production (Cost of Sales) 
The merger between Merck and Schering-Plough will allow the merged entity to have costs reductions, 
since the production of the majority of the medicines is very similar and each company individually will 
make the best use of its resources and capacities. According to Danzon et al. (2007) one of the stronger 
reasons for pharmaceutical companies to enter into a merger is to have economies of scale and scope. 
This objective is supported since this industry has high levels of expenditure.  
One believes that both companies will manage their resources in the best way in order to optimize their 
capacity. The proportion of cost of sales of Merck working independently is 23 percent, one believes 
that it will be higher (in comparison with Merck). Once both company will provide with its expertise in 
production in the different segments, the merged entity will achieve economies of scale but being a 
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greater company due to the increase of  segments (in the point of view of each standalone company) the 
reduction will  greater to achieve the same percentage of costs of the companies working independently.  
Concluding, material and production element represents without the synergy 30 percent of sales 
revenue, since one it is expecting economies of scope in this element, one assumed that the new entity 
will have this element representing 28 percent of sales revenue.  
 
Marketing and Administrative Costs 
Marketing and administrative costs represent in the merged entity without synergies 34 percent of sales 
revenue. One expects that the greatest decrease in costs will happen in this area since the marketing and 
administrative do not need to as specialized as in the production of medicines and R&D. The reduction 
in this area will result in economies of scale since it is expected that this cost for the merged entity will 
be the same as Merck working independently (in percentage).  
Nonetheless, one also had into consideration the level of marketing and administrative costs in relation 
to sales of Merck and Schering-Plough operating individually when deciding to reduce the level of this 
element.  
For Merck and Schering-Plough, marketing and administrative costs represented 32 and 37 percent, 
respectively. Marketing, as one mentioned in chapter 5.2.1.2, is not as strong as in other industries due 
to the specifications of the industry
44
.  
Administrative costs, one believes that they will not increase with the merger. There will be costs 
associated with exempting personnel and disposing assets, but those will be treated with higher detail in 
following section.  
Concluding, one assumes there will be an effort to maintain this level as low as possible, therefore, 
assuming the level of 30 percent, slightly lower than the Merck’s level performing individually.  
Research and Development Cost 
For any pharmaceutical company R&D is very important, in fact, as referred in the chapter 5.2.1.2, the 
pharmaceutical industry is the one with highest expenditure in this area. Therefore, one assumes that the 
merged entity will achieve economies of scale, once both companies have an interest in maintaining 
                                                          
44 For example, in the pharmaceutical industry medicines can’t be advertised as it is done in the shoe industry. There are plenty 
rules that govern the limits of marketing in the pharmaceutical industry. Marketing in this industry is more targeted to doctors, 
where public relations of the different companies try to promote their medicines.  
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high levels of investment in R&D; the new entity will not have economies of scope. Merck operating 
independently had a level of 16 percent (in relation to sales revenue), a percentage that is very close to 
the industry average, 15.6 percent. In contrary, Schering-Plough operating independently, had a level of 
24 percent, this is in accordance with their objective to invest as much as possible in this area.  
The merged entity without synergies has 20 percent of R&D expenditure, in relation to sales revenue. 
One assumed that the level would decrease percent to 18%, since both companies had the objective to 
invest more than the industry average. The slight decrease is also justified by the fact that Schering-
Plough R&D is very developed and it has a strong R&D work force, therefore, the investment in R&D 
in relation to sales revenue could not be lower. 
Concluding, in overall one achieved a reduction of 8 percent in the three areas, whereas the cost of sales 
and marketing and administrative cost had a higher reduction in relation to R&D.  
6.2.3. Financial Synergies 
 Financial synergies are arduous to find and only companies that have a well structure plan to integrate 
the companies can achieve. According to Damodaran (2005) companies have to combine their financial 
capacity optimally in order to find synergies. In this section, one will analyze the four sources of 
financial synergies, previously referred in the literature review, cash slack or excess cash, debt capacity, 
tax benefits and diversification.   
The first source of financial synergy, cash slack or excess of cash, can be achieved when in the merger 
one company has limited investment opportunities, but has excess cash, and the other has “high-return 
projects”, but in the other hand it is limited by cash. In the case of Merck and Schering-Plough, this 
synergy does not apply since as it is seen in their financial statements; both companies have proper 
conditions to invest in projects. The purchase of Organon BioSciences by Schering-Plough is an 
example that the company has conditions to invest. The cash levels of both companies are very similar 
and one will assume that for the merged entity it will be the sum of each entity standalone. Therefore it 
won’t be considered as a cash synergy.   
The second source of synergy can be achieved through the Debt Capacity. Damodaran (2005) refers that 
when two companies merge they can benefit from having higher levels of debt ratio. Since the merged 
entity will become more stable, debtholders will lend higher amounts of money due to their increase of 
confidence in the company. This synergy applies to the merger of Merck and Schering-Plough since the 
merged entity will benefit from slightly higher amount of debt. The merged entity without the financial 
synergy has a debt to capital ratio of 60 percent. Merck had in 2008 a ratio of 60 percent and Schering-
Plough 63 percent. One will assume a conservative position in this synergy since the in one’s opinion 
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the ratio is quite high. Therefore, the increase considered is 3 percent; the merged entity will have a debt 
ratio equal to Schering-Plough before the merger.  
According to the market regulators and debtholders in this industry, pharmaceutical companies can have 
a debt to capital ratio of 60 percent. Therefore, the merged entity will benefit from this higher level to 
invest in the entity projects.  
The third source of synergy, tax benefits, is a way of the merged entity to take advantage of tax laws in 
order to reduce the tax payments. Although a good way to have synergies, Merck and Schering-Plough 
cannot benefit from it, since they don’t have operating losses. An alternative way to increase tax 
benefits is through the increase of the company depreciation, decreasing the taxable income. One 
considered that depreciation would not be increased. The last source of synergy, diversification, is 
considered to be the hardest to account and the most “controversial” in a merger. Both companies will 
have the diversification factor, since both companies will enter in new market segments, but one does 
not consider this diversification as a synergy.  
Concluding, the merged entity will benefit from a slightly greater debt ratio, which corresponds to 
financial synergy of 2 Billion. 
6.2.4. Merger Restructuring Costs 
Although, the merged entity realizes cost reductions in different areas, it also has costs related to the 
merger. The merged entity will be much bigger than each company individually, meaning that it will 
need higher resources than each company operating individually. In the other hand, it will require fewer 
resources than the merged entity without synergies.  At the same time due to the integration of both 
companies some required costs will arise for better adaptation and consolidation of Merck and Schering-
Plough.  
Legal Support 
For this type of deals it is crucial legal support by laws companies in order to protect and defend the 
interests of both parties. Since mergers are normally great transactions, high amount of moneys are 
involved in the process and are complex process, law firms are very costly since it is not a simple deal.  
Integration of Synergies 
It is important that companies not only observe where the synergies may happen but also apply them on 
their strategy and in the company. Beside the reductions mention in the previous chapters, there are 
three more costs reductions that must be taken into consideration. 
Labor cost  
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Labor cost in a merger is one of the most sensitive elements. After a merger is established it is expected 
that some employees of both companies will be dismissed.  The concern is that the companies need to 
layoff the proper number of employees and in the right departments.  
According to the Richard T. Clark, Merck’s chief executive in 2008, Merck expected to reduce the 
company’s work force by 15 percent. Having into account that both companies have approximately 
100.000 workers, one assumed that 15.000 will be dismissed. In this process the merged entity will pay 
compensation to their 15.000 employees for dismissing them.  
Property 
The merged entity in 2008 will have approximately $19 billion in properties, whereas Merck 
contributed with 64 percent and Schering with the remaining 34 percent.  The majority of Merck’s and 
Schering-Plough’s properties are located in the United States of America, the first company has 76 
percent and the last has 39 percent. One believes that some of their properties in this region will be sold.  
Consulting Support 
To best integrate both companies, creating proper strategies to integrate them and create a strategy for 
the merged entity to enter in the market. 
Re-branding 
The merged entity has to invest in creating and advertising the re-branded company, the new image of 
the company, their values and objectives. This advertisement has to be internal and externally, since 
collaborators can be demotivated or even damaged in the merger process.  
 
In fact, restructuring costs related to a merger are quite difficult to be estimated without both companies 
inside information about the deal. For a better adaptation of two companies in a merger it is important 
that both companies have an equal structured plan to have an optimal integration. According to 
PriceWaterHouseCoopers
45
 (PwC) there are seven tenets for a successful integration in a merger. The 
first tenet is to “Accelerate the transition” since it maximizes shareholder value, longer transitions 
destroy stakeholders expectation and profit, and slows growth; “Define the integration strategy”, must 
be well defined in order to create value; “Focus on priority initiatives” like limitations that may exist in 
the merged entity must be a priority; “Prepare for Day One”; “Communicate with all stakeholders” 
regularly to explain the reasons behind this deal and address all the concerns they may have; “Establish 
leadership at all levels” it’s crucial at the earliest stage of the transition to avoid uncertainty in the roles 
and define the authority in each department and “Manage the  integration as a business process”, 
                                                          
45 PwC created a report where it explains various steps to have a successful integration process – Advisory Services,  “How to 
complete the M&A integration process, minimize disruptions, and achieve  desired synergies” 
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companies must look at mergers as a business deal and threat it as one, in this way they will be creating 
value to the merged entity.  
Although one knows how the integration process should be processed, there is no inside information 
about how costly it will be.  According to Basil Peters (2010), the pharmaceutical industry is the one 
with the highest restructuring costs in a merger process. The author says in his book that this cost tend 
to be 15 percent of the merged entity sales. According to the investor presentation of the Merck and 
Schering-Plough merger, Merck expects to have restructuring costs until 2013. One also agrees with the 
time length to have restructuring costs, therefore the 15 percent of this cost will be distributed equally 
during the 5 years (2008-2013) since there is no information to allocate costs differently.  
6.2.5. Account Synergies 
Once decided the areas that synergies might happen, the following phase is to incorporate and account 
them in the new structured of the merged entity. The value of synergies created will be the enterprise 
value of the merged entity with synergies minus the enterprise value of the merged entity without 
synergies. 
Although it is important to account the value of synergies created it is also important to account the 
value of synergy generated in each area. Therefore, one will present the synergy value created in each 
area of the merged entity, incorporate them separately into the model of the new entity without 
synergies and compare with the with the enterprise value of the merged entity with no synergies. 
Restructuring costs will be the last to be incorporated into the valuation of the merged entity and later, 
one will present the value that it represents. 
6.2.5.1. Value of Synergies 
After accounting all operating and financial synergies, one achieved a total synergy value of $ 83 
billion. The estimated enterprise value of the merged entity with all synergies is $311 billion; this value 
considers the restructuring costs. In the table below it is possible to observe where and the synergy 
value created in each area.  
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Table 12: Synergies Value of the merged entity 
The restructuring costs are integrated in the merged entity enterprise value, so the total synergy value 
reflects the impact of this cost. Having into account the Basil Peters input the estimated restructuring 
cost is equal to $8 billion dollars. As mention previously, the percentage of restructuring costs (15 
percent) was equally distributed during the 5 years that it is supposed to last and multiplied by the 
revenues.  
 
Table 13:Merged entity restructuring costs 
The estimated enterprise value of the merged entity accounting with the restructuring costs is equal to 
$311 billion (Appendix 34).  
Operating Synergies are the greatest source of costs reductions, since it is the easiest and fastest way to 
achieve efficiency. The merger of Merck and Schering-Plough was no exception to this rule. According 
to John L. LaMattina
46
 (2001), mergers in the pharmaceutical industry are “attractive” since they reduce 
costs, remove duplication and produce synergies. Removing duplication happens when companies that 
are going to merge have similar medicines and when merged they focus on only one that is better for 
patients. Efficiency is automatically achieved, bringing together the best collaborators and consequently 
providing a better work and performance. The estimated operating synergies are equal to $60 billion 
(Table 12).  
                                                          
46 Online article: The impact of mergers on pharmaceutical R&D. John L. LaMattina is the former President of Pfizer 
Global Research and Development, and is currently Senior Partner at Puretech Ventures, Boston, Massachusetts 02116, USA. 
 
Reduction/Increase
Operating Synergies 54,097 8%
Material and production 4,325 3% 232,762
Marketing and administrative 29,422 3% 257,860
R&D 20,351 1% 248,788
Financial Synergies 2,317 3%
Debt 2,317 3% 230,755
Restructuring Costs 7,911 15% *
Total Synergies 82,536 11% 310,974
* percentage over sales
(Millions)
Synergies
EV without Synergy EV with Synergy
228,437.87
Year 2008 2009 2010 2011 2012 2013
Sales
    Total 42352 47446 50655 52899 55202 57502
Restructuring Costs 1423 1520 1587 1656 1725
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Finally, financial synergies were only on Debt. This synergy is equal to $2 billion and the increase of 
the debt ratio may create opportunities to invest in new projects. 
6.2.5.2. Distribution of Synergy 
Frequently in mergers, synergies tend to be generated by one company that brings unique capabilities. 
In the merger of Merck and Schering-Plough synergies are only created because both companies merge 
and both bring their unique skills in different areas of expertise, for instance production and material 
synergy was only achieved because both companies will merge and bringing their expertise in the area it 
will be possible to reduce this cost.   
Research and development is the only area that both companies have very different knowledge since 
Schering-Plough invest in animal health and consumer health products and Merck doesn’t. 
Unfortunately, due to lack of inside information it is not possible to separate what each company 
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7. The Acquisition 
The form of integration between two companies can be made in various ways. The merger between 
Merck and Schering-Plough will not be a fusion between the two companies, whereas both parties pay 
to have a portion of the company of the other party.  
Due to the great discrepancy between the enterprise values of the two companies the appropriate way in 
this merger is for the biggest company to acquire the smallest. Merck estimated enterprise value is 
approximately 3x greater than the enterprise value of Schering-Plough, which means that Merck should 
be the one acquiring Schering-Plough. The size of the company it is not the only reason that supports 
this acquisition; there are several reasons that supports the acquisition of Schering-Plough and one will 
present some of them.  
 Firstly, Merck and Schering-Plough have been involved in several partnerships during the years the two 
companies have been reinforcing their partnerships and positioning in the market. Mergers and 
acquisitions are a characteristic of this market, since funding is quite difficult it is much easier for small 
companies to have access to funding through an acquisition.   
Secondly, the pharmaceutical market is a very competitive market mainly due to the increase of market 
share of Generics. Pharmaceutical and biotechnological companies are in a position that they need to 
produce even better medicines, but they have a disadvantage in comparison to generic companies since 
they spend high expenditures in R&D. Having the possibility to diversify to a different segment like 
animal health and human health care is a great opportunity for the companies to maintain competitive in 
the market. 
One will assume that the deal process will begin on 3
rd
 of January, 2009 with the announcement of the 
deal and it will end 12 months later. Since it is a big deal it is important to account everything and 
appeal to outside consultants to have the best acquisition and integration of both companies. 
7.1. Approaching Shareholders 
The way companies decide to approach shareholders of the acquired company is extremely important 
since different ways to approach them can have different impacts on the shareholders reaction to the 
acquisition and the market also reacts differently.  
For Damodaran (2005) the best way to approach target firms is through a tender offer, a friendly offer, 
and the acquisition should be cash-based, preferentially, because it shows to the market and to 
shareholders of the target company that the acquirer company believes in the potential of the company.   
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The proposal for the acquisition should be done directly to Schering-Plough shareholders with the price 
they intend to buy the outstanding stocks. By doing the proposal directly to shareholders, Merck will be 
showing that it is willing to negotiate with the Schering-Plough and find the best way to acquire it. 
According to Damodaran (2005) tender offers premiums tend to be higher than in hostile acquisitions 
and on mergers.  
About the reaction of Merck and Schering-Plough shareholders
47
, one will assume that it is positive and 
both companies are willing to become part of each other, with at the best deal.  
7.1.1. Premium offered to Schering-Plough shareholders 
The average market capitalization of Schering-Plough from 2005 to 2008 was $34 billion. Through the 
valuation done in chapter 5.3 one found an equity value of Schering-Plough is $36 billion, which leads 
to a positive potential of 8 percent (see appendix 35 for further detail). The company new equity with 
synergies is $69 billion, comparing with the standalone equity value, it is an upside potential of 92 
percent. As previously referred in the literature review, depending on the premium offered to the 
acquired company can be perceived as a good or bad deal. Bruner (2004) suggest that the deals with 
premiums around the 30.7 percent are perceived as a good deal. The real premium paid to Schering-
Plough shareholders was 34%
48
, this value shows that the company and its synergies are overvalued. 
For this analysis one will take into consideration the literature review, but being more conservative than 
the suggested premium; therefore the premium chosen for Schering-Plough shareholders is 30 percent. 
7.2. Payment Method 
As explained in the literature review, the different method the acquirer company choses to finance the 
acquisition of a company can give different signals to the market. Consequently, the market reaction to 
the acquisition by the market and the acquired company shareholders will also vary according to the 
method of payment used. According to the literature review it is crucial that the Merck choses a method, 
cash-based, that shows to Schering-Plough shareholders that the company believes in the deal and are 
committed to the Schering-Plough. The decision of the method of payment has also to take into 
consideration the capability of the Merck to finance the deal.  
                                                          
47 Since the acquisition happened in 2009, there is no information about the reactions of Merck’s and Schering-Plough’s 
shareholders. The information one had is that on August, 2009 99 percent of Merck’s shareholders accepted the merger of $41 
billion.  Reference: http://www.dailyfinance.com/2009/08/07/merck-schering-plough-shareholders-approve-the-merger/ 
48
 Merck & Schering-Plough Merger: Investor Presentation, March 9  
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Having into account the market capitalization of Merck ($85 billion) and the equity value of the 
standalone valuation ($143 billion) it is clear that the company is undervalued by 68 percent (appendix 
35), this means that if Merck decided to finance with stocks the company would have an issuing price 
lower than the fair value so it is possible that Merck will try not to finance entirely with stocks. The 
choice between cash or stocks has to be considered in attention to the company’s capital structure and 
its credit rating. In one opinion, the acquisition should be financed firstly by cash and debt and lastly by 
stocks, but maintaining the company rating.  
7.3. Financing Sources and the Offer  
The acquisition price is the Equity Value of Schering-Plough with synergies, $70 billion. One will 
assume that the company decided to finance the deal with the three possible sources. 
Firstly, financing with cash is extremely important in this deal, so one will assume that Merck will 
finance $12 billion with cash, taken in the cash equivalents and the investments account of the company.  
Secondly, debt will be the second source chosen by Merck. Financing with debt it is also perceived as 
good indicator of commitment by the acquirer company, but at the same time the acquirer company will 
want to preserve its credit rating, so it’s important to calculate how much it can finance through debt. 
According to Damodaran interest coverage ratio calculation, a company with an A- rating should have 
an interest coverage ratio between 3x and 4.25x and having into account that the merged entity with 
synergies have a Net Debt/Ebitda ratio of 2.22x, Merck can reach this ratio at maximum (see table 14). 
Merck can finance $22 billion with debt (Appendix 36). 
 
Table 14: Merged entity Debt Capacity 
After having into account all the restrictions and best practices that Merck should follow, the amount 
financed by shares is $35 billion, corresponding to 50 percent of the total financing (Appendix 37). 
Although it was followed requirements to finance the acquisition of Schering-Plough, the fact that half 
of the acquisition will be financed by shares can raise concerns and mistrust by Schering-Plough 







Cash 4.482 4.188 8.670 8.670
Net Debt 12.017 5.573 28.840 35.687
Ebitda 10.113 3.566 13.680 16.088
Interest Costs 1.135 783 1.918 1.308
Ebit 8.440 2.650 11.100 13.498
Interest coverage 7,43 3,39 5,79 10,32
Net Debt/Ebitda 1,19 1,56 2,11 2,22
*Data are from 2009, since the synergies were calculated from 2009. Merck is rated as A3 
(Moody's rating), equivalent to the A- of S&P rating.
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Merck to finance through shares will have to value higher than the market price. One assumed that the 
premium of 30 percent (the real premium offered) to reach the price offered by the company to 
Schering-Plough (see table 15 for more information). In this sense, Merck will have to issue 1.576 
million shares.  
 













Shares Financing* Current Share Price (2008) Offered Price Issued Shares*
34.891                       17,03 22,14               1.576                
*million
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8. Conclusion 
The high level of worldwide competition between pharmaceutical companies increases the pressure for 
companies to position themselves strategically and be very efficient in researching and developing 
medicines for unmet necessities. For many pharmaceutical companies a way to strengthen their presence 
in the market is to enter in new segments through mergers.   
The consolidation between Merck and Schering-Plough will leverage the competitive position of new 
entity, increasing the efficiency of the company due to the complementary factor that will rise with the 
merger. The new entity will operate in more segments than Merck and Schering-Plough operating 
independently and the combination of both companies expertise will make this new entity much 
stronger, taking advantage of new opportunities that shall rise. 
 The pharmaceutical industry is characterized for having the highest level of R&D of all industries, great 
pressure to reduce costs and for being a very competitive market. Pharmaceutical companies try to 
reduce the costs as much as possible but at the same time they aim to create the best medicines in the 
market. Therefore, the merger of Merck and Schering-Plough is benefiting since Schering-Plough is 
very R&D oriented and Merck already had a very good pipeline. On the other hand, the high levels of 
costs in this industry make companies like Merck and Schering-Plough merger in order to reduce them.  
The merger of Merck and Schering-Plough is reasonable and it was a natural process since both 
companies have long cooperated in various projects and their relation has been strengthening during the 
years. Merck with the merger will benefit from entering in new segments that Schering-Plough has very 
strong position, animal health and human care segments. Schering-Plough, in the other hand, with be 
part of the 10
th
 greatest pharmaceutical companies, it will have access to financial resources to invest in 
projects  and be part of a company with a great pipeline.  
The two sources of synergies in this merger are cost reductions and financial benefits. Costs are 
mentioned by practitioners as the most reliable source of synergies and the company will have a 
reduction of 8 percent. Financial benefit was all on the increase of the debt capacity by 3 percent. 
Nevertheless, restructuring costs were also included to account the integration process costs.  
Merck, being the biggest company will make the offer for the acquisition of Schering-Plough directly to 
shareholders of the company. The acquisition will be financed by three sources, 17 percent of the 
acquisition will be with cash, 32 percent with debt and 51 percent with shares. 
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9. Appendixes 
Appendix 1: Global Pharmaceutical Market by Region (Total Unaudited and Audited Companies) 
 
Appendix 2: Total Market Composition, June 2007 
 
Appendix 3: Distribution Margins and VAT rates 
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Appendix 4: R&D 
Phases of Research and Development Process 
 
Primary reasons for the high costs with R&D is highly are associated with the great failures rates, costs of clinical 
trials and the required resources necessary to get approval by regulatory entities. Another reason are seen in promising 
products that reach advanced stages of clinical trials but have to be abandon because they don’t meet all requirements 
established by regulatory entities. The probability of a new substance to become a market pharmaceutical product is 
very low, so as soon a company receives approval to market a new product on the market it has to launches to 
generate cash flows and recover the investment made in R&D. 
 
Estimated Full Cost of Bringing a New Chemical 
or Biological Entity to Market ($ Million – Year 
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Changes in Research Site (2001-2008) 
 
Allocation of R&D Investments by Function (%) 
 
 
Origin of the 25 New Molecular (Chemical and Biological) 
Entities Launched on the World Market in 2007 
 
Number of New Active Substances Launched on the World 
Market over the Last Five Years 
 
 
Pharmaceutical R&D Expenditure Value & Annual Growth Rate (%) 
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Appendix 5: Merck Corporation 
Appendix 5.1: Merck Research Pipeline in February 2009 
Source: Annual Report Merck 2008 
Appendix 5.2: Product Sales Performance 
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(million) Year 2004 2005 2006 2007 2008
Current Liabilities:
Total current liabilities 5.166 4.659 4.162 6.043 5.193
Long-term liabilities
Total long-term liabilities 3.189 3.423 4.001 12.728 12.395
Shareholder's Equity 7.556 7.387 7.908 10.385 10.529
Total liabilities and equity 15.911 15.469 16.071 29.156 28.117
D/A 53% 52% 51% 64% 63%
E/A 47% 48% 49% 36% 37%




Appendix 6: Schering-Plough Corporation 
Appendix 6.1: Organon BioSciences N.V. 
Organon BioSciences N.V. was purchased from Akzo Nobel in 2007. Organon was a global pharmaceutical company 
that operated in human and animal therapeutic treatments and it was presence in 120 countries. This purchase enhanced 
Schering-Plough in several aspects: 
 Key new pipepline projects; 
 Key products in therapeutic areas – Women’s Health and Central Nervous System; 
 A proposition as a leader in Animal Health by combining Schering-Plough Animal health with Intervet; 
 A leardership position in animal vaccines at Interver and early-stage innovation capabilities in human vaccines 
at Nobilion; 
 Addition state-of-the-art biologics capabilities; 
 A substantial expansion to the Company’s geographic footprint; and 
 Significant Talent, including in key research and development functions 





Appendix 6.2: Capital Structure 
 
(million) Year 2004 2005 2006 2007 2008
Current Liabilities:
Total current liabilities 11.753          13.304      12.723      12.258      14.319      
Long-term liabilities
Total long-term liabilities 13.541          13.626      14.287      17.908      14.119      
Shareholder's Equity 17.288          17.917      17.560      18.185      18.758      
Total liabilities and equity 42.582          44.846      44.570      48.351      47.196      
D/A 59% 60% 61% 62% 60%
E/A 41% 40% 39% 38% 40%
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 Appendix 7: Market Indices (Market Evolution)
 
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
11.5 14 12.5 12.5 12.5 12.5 12.5 12.57142857
Global 0.7% 0.5% -0.2% 0.0% -0.2% 0.3% -0.4% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10%
North America 8.8% 5.6% 9.3% 4.1% 1.8% 5.2% 2.7% 3.6% 4.0% 4.0% 4.0% 4.0% 4.0% 4.0% 4.0%
Europe 6.7% 4.1% 3.9% 3.9% 4.7% -2.1% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9%
Asia/Africa/Australia 8.1% 9.2% 10.0% 10.6% 11.2% 11.5% 12.0% 10.4% 11.3% 11.2% 11.0% 11.2% 11.1% 11.1% 11.1%
Japan 2% 4% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2%
Latin America 5.0% 5.2% 5.1% 5.1% 4.9% 4.8% 5.2% 5.0% 5.0% 5.1% 5.0% 5.0% 5.1% 5.1% 5.1%
Global 6.1% 5.6% 6.0% 5.2% 5.0% 4.4% 5.2% 5.0% 5.3% 5.3% 5.3% 5.3% 5.3% 5.3% 5.3%
North America 1,047,497 701,275 1,245,650 571,539 254,298 731,063 386,088 537,328 624,388 648,855 677,623 711,343 748,201 788,184 830,303
g -33% 78% -54% -56% 187% -47% 39% 16% 4% 4% 5% 5% 5% 5%
Europe 654,782 416,034 419,426 482,707 639,434 -255,363 474,066 511,490 490,857 502,679 515,959 530,166 544,928 559,977 575,441
g -36% 1% 15% 32% -140% -286% 8% -4% 2% 3% 3% 3% 3% 3%
Asia/Africa/Australia 844,355 962,147 1,042,413 1,104,958 1,167,503 1,198,775 1,250,896 1,081,578 1,177,083 1,169,852 1,142,838 1,163,258 1,158,649 1,154,915 1,158,941
g 14% 8% 6% 6% 3% 4% -14% 9% -1% -2% 2% 0% 0% 0%
Japan 95,161 167,610 77,722 104,562 113,265 120,260 124,871 136,113 145,563 148,329 150,309 153,950 158,031 161,971 166,053
g 76% -54% 35% 8% 6% 4% 9% 7% 2% 1% 2% 3% 2% 3%
Latin America 109,555 138,163 159,341 189,165 210,639 193,543 254,814 283,161 290,480 307,830 323,655 342,041 362,931 384,393 407,921
g 26% 15% 19% 11% -8% 32% 11% 3% 6% 5% 6% 6% 6% 6%
North America 11,853,250 12,622,950 13,377,200 14,028,675 14,291,550 13,938,925 14,526,550 15,094,025 15,609,697 16,221,378 16,940,567 17,783,568 18,705,028 19,704,590 20757566.74
g 6% 6% 5% 2% -2% 4% 4% 3% 4% 4% 5% 5% 5% 5%
Europe 9,772,868 10,147,173 10,754,503 12,377,114 13,604,971 12,437,820 12,155,543 13,115,131 12,586,076 12,889,212 13,229,718 13,593,991 13,972,509 14,358,376 14754899.16
g 4% 6% 15% 10% -9% -2% 8% -4% 2% 3% 3% 3% 3% 3%
Asia/Africa/Australia 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132 10,424,132
g 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Japan 4,655,823 4,571,867 4,356,750 4,356,347 4,849,185 5,035,141 5,488,424 5,869,471 5,980,997 6,060,834 6,207,665 6,372,229 6,531,077 6,695,692 6,864,456
g -2% -5% 0% 11% 4% 9% 7% 2% 1% 2% 3% 2% 3% 3%
Latin America 2,191,101 2,656,990 3,124,341 3,701,854 4,298,752 4,032,149 4,900,267 5,613,501 5,792,499 6,052,087 6,410,966 6,773,269 7,170,343 7,606,790 8,069,803
g 21% 18% 18% 16% -6% 22% 15% 3% 4% 6% 6% 6% 6% 6%
Global 42,136,202 45,571,189 49,342,423 55,677,539 61,166,629 57,760,763 63,074,924 69,659,626 71,896,504 75,522,071 79,504,622 83,940,909 88,743,877 94,028,240 99,627,267
6% 6%
North America 3.5% 6.5% 6.0% 4.9% 1.9% -2.5% 4.2% 3.9% 3.4% 3.9% 4.4% 5.0% 5.2% 5.3% 5.3%
Europe 4.7% 3.8% 6.0% 15.1% 9.9% -8.6% -2.3% 7.9% -4.0% 2.4% 2.6% 2.8% 2.8% 2.8% 2.8%
Asia/Africa/Australia 9.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Japan 2.7% -1.8% -4.7% 0.0% 11.3% 3.8% 9.0% 6.9% 1.9% 1.3% 2.4% 2.7% 2.5% 2.5% 2.5%
Latin America 6.0% 21.3% 17.6% 18.5% 16.1% -6.2% 21.5% 14.6% 3.2% 4.5% 5.9% 5.7% 5.9% 6.1% 6.1%




Market Evolution (dependent on 
the evolution of the number of 
patients)




GDP                             
Source: IMF 
GDP                             
Source: IMF 
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Appendix 8: Company Evolution – Company’s Market Share 
 
 
North America 9.1% 5.9% 9.9% 4.3% 1.8% 5.1% 2.8% 3.7% 4.1% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2%
Europe (epfia 2010) 7.0% 4.3% 4.1% 4.5% 5.2% -1.9% 3.8% 4.2% 3.7% 4.0% 4.0% 4.0% 4.0% 4.0% 4.0%
Asia/Africa/Australia 8.8% 9.2% 10.0% 10.6% 11.2% 11.5% 12.0% 10.4% 11.3% 11.2% 11.0% 11.2% 11.1% 11.1% 11.1%
Japan (Total) 2% 4% 2% 2% 3% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5%
Latin America 5.3% 6.3% 6.0% 6.1% 5.7% 4.5% 6.3% 5.8% 5.2% 5.3% 5.3% 5.3% 5.4% 5.4% 5.4%
Global 6% 6% 6% 6% 5% 4% 5% 5% 5% 5% 5% 5% 5% 5% 5%
1990 1995 2000 2005 2010 2015 2020 2025 2030
North America 281,162.0 295,749.0 313,289.0 329,231.0 344,529.0 359,639.0 374,394.0 388,472.0 401,657.0
g 5% 6% 5% 5% 4% 4% 4% 3%
Europe 720,497.0 727,422.0 726,777.0 730,736.0 738,199.0 742,067.0 744,177.0 743,890.0 741,233.0
g 1% 0% 1% 1% 1% 0% 0% 0%
Asia/Africa/Australia 3,855,262.0 4,213,170.0 4,553,167.0 4,880,650.0 5,213,123.0 5,549,192.0 5,873,784.0 6,178,254.0 6,462,770.0
g 9% 8% 7% 7% 6% 6% 5% 5%
Japan 122,251.0 124,487.0 125,720.0 126,393.0 126,536.0 126,072.0 124,804.0 122,771.0 120,218.0
g 2% 1% 1% 0% 0% -1% -2% -2%
Latin America 443,032.0 482,647.0 521,429.0 557,038.0 590,082.0 622,437.0 652,182.0 678,778.0 701,606.0
g 9% 8% 7% 6% 5% 5% 4% 3%
Global 5,306,425.0 5,726,239.0 6,122,770.0 6,506,649.0 6,895,889.0 7,284,296.0 7,656,528.0 8,002,978.0 8,321,380.0
g 8% 7% 6% 6% 6% 5% 5% 4%
Market Evolution (dependent on 





2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
North America 262.33 277.29 293.09 305.99 311.80 323.8 335.1 343.5 348.6 353.9 359.2 364.6 370.0 375.6 381.2
g 6% 6% 4% 2% 6% 3% 3% 2% 2% 2% 2% 2% 2% 2%
Europe 190.77 202.98 215.97 231.31 247.50 263.9 253.2 259.5 268.6 278.0 287.7 297.8 308.2 319.0 330.2
g 6% 6% 7% 7% 5% -4% 3% 4% 4% 4% 4% 4% 4% 4%
Asia/Africa/Australia 85.77 86.94 88.14 89.46 90.80 106.6 129.7 145.9 164.2 184.7 207.8 233.7 262.9 295.8 332.8
g 1% 1% 2% 2% 2% 22% 13% 13% 13% 13% 13% 13% 13% 13%
Japan 68.26 70.11 72.00 75.02 76.60 95.0 102.3 107.9 111.7 115.6 119.7 123.8 128.2 132.7 137.3
g 3% 3% 4% 2% 8% 8% 6% 4% 4% 4% 4% 4% 4% 4%
Latin America 28.80 32.46 36.58 41.26 46.50 47.9 54.3 60.5 68.1 76.6 86.2 97.0 109.1 122.7 138.1
13% 13% 13% 13% 11% 13% 12% 13% 13% 13% 13% 13% 13% 13%
Global 605 650 694 742 782 837 875 917 961 1009 1061 1117 1178 1246 1320
g 7.4% 6.8% 6.9% 5.4% 7.0% 4.5% 4.9% 4.8% 4.9% 5.1% 5.3% 5.5% 5.7% 5.9%
United States 5% 5% 5% 5% 4%
Europe, Middle  East and Africa 2% 2% 2% 2% 2%
Japan 2% 2% 2% 2% 2%
Other 8% 7% 7% 7% 6%
Global 4% 3% 3% 3% 3%
United States 1% 1% 1% 2% 2%
Europe and Canada 2% 2% 2% 2% 4%
Asia Pacific 0% 1% 1% 1% 1%











Company  Evolution  (dependent 
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Merck Information 
Appendix 9: Merck Income Statement 
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Sales
United States 13321.1 13,472             12,767        13,777            14,691                     13,371               13,504             13,545             13,667             13,790            13,941                14,095             14,250             14,406             14,565             14,725                  
Europe, Middle  East and Africa 5341.3 5,441               5,204          4,977              5,159                       5,774                 6,022               6,299               6,620               6,892              7,174                  7,468               7,700               8,093               8,505               8,939                    
Japan 1637.9 1,668               1,638          1,479              1,533                       1,824                 1,883               1,932               1,991               2,032              2,074                  2,117               2,161               2,206               2,251               2,298                    
Other 2403.9 2,358               2,404          2,403              2,815                       2,883                 3,064               3,236               3,433               3,642              3,865                  4,100               4,351               4,616               4,897               5,196                    
    Total 22485.9 22,939             22,012        22,636            24,198                     23,850               24,474             25,011             25,711             26,356            27,054                27,781             28,461             29,321             30,219             31,158                  
growth 0                      (0)                0                     0                              (0)                       0                      0                      0                      0                     0                         0                      0                      0                      0                      0                           
Costs
Material and production 4,960               5,150          6,001              6,141                       5,583                 5,577               5,699               5,857               6,169              6,332                  6,502               6,662               6,863               7,073               7,293                    
Marketing and administrative 7,239               7,156          8,165              7,557                       7,377                 7,932               8,104               8,327               8,534              8,757                  8,990               9,208               9,483               9,770               10,071                  
R&D 4,010               3,848          4,783              4,883                       4,805                 4,405               5,002               5,142               5,271              5,411                  5,556               5,692               5,864               6,044               6,232                    
Restructuring Costs 107                  322             142                 327                          1,033                 667                  667                  667                  -                      -                          -                      -                      -                      -                      -                           
Equity Income (1,008)              (1,717)         (2,294)             (2,977)                     (2,561)                (2,561)             (2,553)             (2,545)              (2,537)             (2,530)                 (2,522)             (2,514)             (2,506)             (2,499)             (2,394)                  
U.S. Vioxx  Settlement Agreement Charge -                       -                  -                      4,850                       -                         -                      -                      -                       -                      -                          -                      -                      -                      -                      -                           
Oher (Income) Expense, net (338)                 (15)              7                     403                          (1,814)                15                    15                    15                    16                   16                       17                    17                    18                    18                    19                         
   Total 14,970             14,743        16,804            21,184                     14,423               16,034             16,933             17,464             17,452            17,987                18,543             19,064             19,721             20,407             21,221                  
EBIT 7,969               7,269          5,832              3,014                       9,428                 8,440               8,078               8,247               8,903              9,067                  9,237               9,397               9,600               9,812               9,938                    
Interest/ Expense 6                      95               389                 357                          380                    1,135               1,160               1,193               1,223              1,256                  1,290               1,321               1,361               1,403               1,446                    
EBT 7,975               7,364          6,221              3,371                       9,808                 9,575               9,238               9,440               10,127            10,323                10,527             10,718             10,961             11,215             11,384                  
Taxes @ 20,38% 2,161               2,733          1,788              95                            1,999                 2,467               2,380               2,432               2,609              2,659                  2,712               2,761               2,824               2,889               2,933                    
Net income 5,814               4,631          4,434              3,275                       7,809                 7,108               6,859               7,008               7,518              7,664                  7,815               7,957               8,137               8,326               8,452                    
EBITDA 7,969               7,269          5,832              7,606                       11,059               10,113             9,789               10,005             10,706            10,917                11,137             11,343             11,605             11,879             12,069                  
Income Statements
Historical Information Forecasting
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Appendix 10: Merck costs disaggregated (Historical information) 
 




2005 2006 2007 2008
Cost of Sales 5149.6 6001.1 6140.7 5582.5
 - Restructuring costs (2008 &2005) 736.4 483.1 123.3
 - Amortization of inventory adjusted to fair value
Total 736.4 483.1 123.3
 - Manufacturing related 5149.6 5264.7 5657.6 5459.2
% over sales 23% 23% 23% 23%
% all cost sales over sales 23% 27% 25% 23%
% manufacturing related 
over cost of sales
88% 92% 98%
Marketing and Administrative 8165.4 7556.7 7377
 - Reserves for future Vioxx legal defense 673 280 62
 - Reserves for Fosamax Litigation 48 0 40
 - Insuranc e arbitration - Vioxx 455 0
Total 721 735 102
 - Manufacturing related 0 7444.4 6821.7 7275
% over sales 0% 31% 28% 31%
% all cost sales over sales 0% 34% 31% 30%
% manufacturing related 
over cost  mark & adm
91% 90% 99%
Research and Development 4782.9 4882.8 4805.3
 - Closure or sale of facilit ies (Rest Program) 56.5 0 128.4
 - Research Expense 762.5 325.1 0
Total 819 325.1 128.4
 - Manufacturing related 3963.9 4557.7 4676.9
% over sales 16% 19% 19%
% all cost sales over sales 20% 20% 20%
% manufacturing related 
over cost of sales
83% 93% 97%
Restructuring Program 327.1 1032.5
2008 Rest Program 735.5
  - Separation Costs 684.9
2005 Rest Program 297
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Supplemental data
Depreciation and Amortization 1,259      1,554      2,268    1,988       1,631        1,674     1,711       1,758       1,803    1,850     1,900    1,947     2,005      2,067      2,131        
% of growth 23.5% 46.0% -12.4% -18.0% 9.8% 9.6% 9.4% 9.2% 9.0% 8.8% 8.6% 8.4% 8.2% 8.0%
% over net assets 7% 9% 13% 11% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9% 9%
Capital expenditures 1,726      1,403      980       1,011       1,298        1,600    1,635       1,681       1,709    1,755     1,802    1,846     1,901      1,960      2,021        
% Capex/ (Sales - Cost of sales) 10% 8% 6% 6% 7% 8% 8% 8% 8% 8% 8% 8% 8% 8% 8%
Δ Net working capital 3,178      (991)        473       305          552           (626)       106          138          161       138        144       135        170         178         186           
Δ Other assets 1,400      794         (704)      5,650       (4,196)       962        185          240          188       239        248       233        294         307         321           
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Appendix 12: Treasury Yield Curve Rates 
 
Source: US Treasury 
Appendix 13:  Levered and Unlevered Betas by Industry 
 
Source: Damodaran website 
Appendix 14:  Country Risk Premium 
 
Source: Damodaran website 
 
Date 1 mo 3 mo 6 mo 1 yr 2 yr 3 yr 5 yr 7 yr 10 yr 20 yr 30 yr
01-02-2008 3.09 3.26 3.32 3.17 2.88 2.89 3.28 3.54 3.91 4.39 4.35
01/31/08 1.64 1.96 2.07 2.11 2.17 2.27 2.82 3.19 3.67 4.35 4.35
02/29/08 2.07 1.85 1.83 1.77 1.65 1.87 2.50 2.96 3.53 4.37 4.41
03/31/08 1.22 1.38 1.51 1.55 1.62 1.79 2.46 2.88 3.45 4.30 4.30
04/30/08 1.17 1.43 1.64 1.85 2.29 2.49 3.03 3.34 3.77 4.49 4.49
05/30/08 1.98 1.89 2.01 2.22 2.66 2.93 3.41 3.68 4.06 4.74 4.72
06/30/08 1.60 1.90 2.17 2.36 2.63 2.91 3.34 3.61 3.99 4.59 4.53
07/31/08 1.55 1.68 1.89 2.27 2.52 2.81 3.25 3.56 3.99 4.63 4.59
08/29/08 1.63 1.72 1.97 2.17 2.36 2.60 3.10 3.45 3.83 4.47 4.43
09/30/08 1.02 0.92 1.60 1.78 2.00 2.28 2.98 3.38 3.85 4.43 4.31
10/31/08 0.12 0.46 0.94 1.34 1.56 1.80 2.80 3.29 4.01 4.74 4.35
11/28/08 0.02 0.01 0.44 0.90 1.00 1.27 1.93 2.35 2.93 3.71 3.45
12/31/08 0.11 0.11 0.27 0.37 0.76 1.00 1.55 1.87 2.25 3.05 2.69







Bank 476 0,71 183,05% 25,97% 0,30 12,61% 0,35
Beverage 40 0,96 19,03% 16,21% 0,83 3,25% 0,86
Biotechnology 107 1,26 9,98% 3,25% 1,15 10,63% 1,29
Chemical (Basic) 18 1,26 28,67% 19,25% 1,02 8,21% 1,12
Chemical (Diversified) 32 1,23 27,63% 25,35% 1,02 7,92% 1,10
Chemical (Specialty) 87 1,19 35,48% 18,85% 0,92 5,79% 0,98
Drug 341 1,17 14,52% 5,90% 1,03 10,70% 1,15
E-Commerce 53 1,50 11,29% 12,60% 1,36 23,33% 1,78
Educational Services 33 0,84 2,27% 20,44% 0,82 7,99% 0,89
Electrical Equipment 82 1,38 23,79% 14,06% 1,14 9,38% 1,26
Electronics 172 1,31 45,68% 11,78% 0,93 24,77% 1,24
Entertainment 83 1,67 79,88% 16,90% 1,01 7,21% 1,08
Environmental 78 1,12 49,93% 15,13% 0,78 2,27% 0,80
Financial Svcs. (Div.) 295 1,27 522,77% 17,99% 0,24 11,57% 0,27
Food Processing 108 0,80 35,37% 21,62% 0,63 3,14% 0,65
Food Wholesalers 17 0,73 59,86% 27,00% 0,51 5,93% 0,54
Healthcare Information 28 1,05 19,92% 16,00% 0,90 13,72% 1,04
Insurance (Life) 34 1,17 43,42% 26,62% 0,89 34,66% 1,36
Insurance (Prop/Cas.) 77 0,91 3,78% 20,53% 0,89 4,36% 0,93
Manuf. Housing/RV 17 1,31 51,79% 13,67% 0,90 27,78% 1,25
Maritime 55 1,30 186,85% 7,14% 0,48 7,95% 0,52
Medical Services 159 1,10 54,69% 18,25% 0,76 15,06% 0,90
Medical Supplies 251 1,17 13,46% 12,45% 1,05 7,66% 1,13
Natural Gas (Div.) 33 1,22 58,59% 23,99% 0,84 2,26% 0,86
Natural Gas Utility 24 0,69 90,76% 24,32% 0,41 2,82% 0,42
Pharmacy Services 18 0,94 23,50% 20,26% 0,79 2,38% 0,81
Reinsurance 10 0,91 21,12% 8,19% 0,76 32,39% 1,12
Restaurant 67 1,27 25,59% 20,11% 1,05 3,25% 1,09
Securities Brokerage 31 1,36 924,55% 22,87% 0,17 21,13% 0,21
Telecom. Services 139 1,43 51,38% 15,80% 1,00 5,70% 1,06
Thrift 233 0,66 19,42% 17,12% 0,57 21,11% 0,72
Tobacco 11 0,71 17,69% 22,09% 0,63 5,73% 0,66
Toiletries/Cosmetics 22 0,95 38,64% 22,76% 0,73 7,45% 0,79
Public/Private Equity 9 2,08 389,77% 6,90% 0,45 7,51% 0,49
Funeral Services 5 1,41 67,74% 32,54% 0,97 4,83% 1,01
Total Market 6753 1,19 65,71% 16,57% 0,77 10,43% 0,86
Country Region Long-Term Rating Adj. Default Spread Total Risk Premium Country Risk Premium
Albania Eastern Europe & Russia B1 650 14,75% 9,75%
Belarus Eastern Europe & Russia B1 650 14,75% 9,75%
Belgium [1] Western Europe Aa1 70 6,05% 1,05%
Brazil Central and South America Ba1 300 9,50% 4,50%
China Asia A1 140 7,10% 2,10%
Denmark Western Europe Aaa 0 5,00% 0,00%
Dominican Republic Caribbean B2 750 16,25% 11,25%
Ecuador Central and South America Ca 260 8,90% 3,90%
France [1] Western Europe Aaa 0 5,00% 0,00%
Germany [1] Western Europe Aaa 0 5,00% 0,00%
Greece [1] Western Europe A1 140 7,10% 2,10%
Ireland [1] Western Europe Aaa 0 5,00% 0,00%
Isle of Man Financial Center Aaa 0 5,00% 0,00%
Israel Middle East A1 140 7,10% 2,10%
Italy [1] Western Europe Aa2 100 6,50% 1,50%
Japan Asia Aa3 120 6,80% 1,80%
Luxembourg [1] Financial Center Aaa 0 5,00% 0,00%
Netherlands [1] Western Europe Aaa 0 5,00% 0,00%
New Zealand Australia & New Zealand Aaa 0 5,00% 0,00%
Portugal [1] Western Europe Aa2 100 6,50% 1,50%
Russia Eastern Europe & Russia Baa1 200 8,00% 3,00%
Saudi Arabia Middle East A1 140 7,10% 2,10%
Singapore Asia Aaa 0 5,00% 0,00%
Slovakia Eastern Europe & Russia A1 140 7,10% 2,10%
South Africa Africa A2 160 7,40% 2,40%
Spain [1] Western Europe Aaa 0 5,00% 0,00%
St. Vincent & the Grenadines Caribbean B1 650 14,75% 9,75%
Suriname Caribbean Ba3 525 12,88% 7,88%
Sweden Western Europe Aaa 0 5,00% 0,00%
Switzerland Western Europe Aaa 0 5,00% 0,00%
United Arab Emirates Middle East Aa2 100 6,50% 1,50%
United Kingdom Western Europe Aaa 0 5,00% 0,00%
United States of America North America Aaa 0 5,00% 0,00%
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Appendix 15: Long-term debt of Merck ar December 31 
 
Source: Merck 2008 Form 10-K 
 
Appendix 16: Cost of debt, Interest Coverage ratio and Default spread  
            
  





4.75% notes due 2015 1.078,3$     1.068,1$     
4.375% notes due 2013 530,0 524,4
6.4% debentures due 2028 499,3 499,3
5.75% notes due 2036 497,8 497,7
5.95% debentures due 2028 497,2 497,1
5.125% notes due 2011 273,7 258,8
6.3% debentures due 2026 248,0 247,9
other 319,0 322,5
3.943,3$     3.915,8$     
Market Value 2004 2005 2006 2007 2008 average
Merck 70.985,65    69.407,00    94.515,45  126.244,14  64.073,79  85.045,21  
source: Bloomberg
Re = Rf + β (Rm - Rf) 7.40%
Rf 2.25%
β 1.03
Rp = Rm - Rf
5.00%






Interest Coverage ratio 24.79
probabilty of default 0.65%
 % CFD for Health 
Industry 27%
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Appendix 18: Merck Balance Sheet 
 
Appendix 19: Base- Case Value 
Year 2.004           2.005      2.006      2.007      2.008      2.009      2.010       2.011      2.012      2.013      2.014      2.015      2.016      2.017      2.018      
Current Assets
Cash and Equivalents 2.879            9.585        5.915        5.336        4.368        4.482        4.581         4.709        4.827        4.955        5.088        5.213        5.370        5.535        5.707        
Short-term investments 4.211            6.052        2.798        2.895        1.118        1.147        1.173         1.205        1.236        1.268        1.302        1.334        1.375        1.417        1.461        
Accounts Receivable 3.628            2.927        3.315        3.636        3.779        3.678        3.758         3.864        3.961        4.065        4.175        4.277        4.406        4.541        4.682        
Inventories 1.899            1.658        1.769        1.881        2.283        1.708        1.746         1.794        1.890        1.940        1.992        2.041        2.102        2.167        2.234        
Deferred Income taxes 859               826           1.433        1.297        7.756        7.959        8.134         8.361        8.571        8.798        9.034        9.256        9.535        9.827        10.133      
Total Current Assets 13.475          21.049      15.230      15.045      19.305      18.975      19.391       19.934      20.484      21.027      21.591      22.120      22.788      23.487      24.217      
Investments 6.727            1.108        7.788        7.159        6.491        6.661        6.807         6.998        7.173        7.363        7.561        7.746        7.980        8.225        8.480        
Property, at cost
Land 367               433           409           406           386           396           405            416           427           438           450           461           475           489           504           
Buildings and improvements 8.874            9.480        9.746        10.048      9.767        10.023      10.243       10.529      10.794      11.080      11.377      11.656      12.008      12.376      12.760      
Equipment 11.926          12.785      13.172      13.554      13.104      13.446      13.741       14.126      14.480      14.864      15.263      15.637      16.109      16.603      17.119      
Construction in progress 1.642            1.016        882           796           871           894           913            939           963           988           1.015        1.039        1.071        1.104        1.138        
Total 22.809          23.714      24.210      24.803      24.128      24.759      25.302       26.010      26.663      27.370      28.104      28.793      29.662      30.571      31.522      
Less accumulated depreciation 8.095            9.315        11.015      12.457      12.129      12.446      12.719       13.075      13.403      13.758      14.127      14.473      14.910      15.367      15.845      
Property, net 14.714          14.399      13.194      12.346      11.999      12.313      12.584       12.936      13.260      13.612      13.977      14.319      14.752      15.204      15.676      
Goodwill 1.086            1.086        1.432        1.455        1.439        1.476        1.509         1.551        1.590        1.632        1.676        1.717        1.769        1.823        1.880        
Other intangible assets, net 679               519           944           713           525           539           551            566           581           596           612           627           646           666           686           
Other assets 5.892            6.686        5.982        11.632      7.436        8.398        8.583         8.823        9.011        9.250        9.498        9.731        10.024      10.332      10.653      
Total assets 42.573          44.846      44.570      48.351      47.196      48.362      49.424       50.807      52.099      53.480      54.915      56.260      57.959      59.735      61.592      
768           785            807           794           815           837           857           883           910           938           
-               -                -               -               -               -               -               -               -               -               
(million) Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Liabilities:
 Loans Payable and current 
portion of long-term debt 2.181            2.972        1.285        1.824        2.297        2.357        2.409         2.476        2.538        2.606        2.676        2.741        2.824        2.911        3.001        
Accounts Payable 421               471           497           625           618           567           580            596           627           644           661           677           698           719           742           
5.288            5.381        6.653        8.535        9.174        9.414        9.621         9.890        10.138      10.407      10.686      10.948      11.278      11.624      11.985      
Income taxes 3.021            3.649        3.461        444           1.426        1.464        1.496         1.538        1.576        1.618        1.661        1.702        1.754        1.807        1.863        
Dividends Payable 841               830           827           831           804           824           843            866           888           911           936           959           988           1.018        1.050        
Total current liabilities 11.753          13.304      12.723      12.258      14.319      14.626      14.947       15.366      15.768      16.186      16.620      17.027      17.542      18.079      18.641      
Long-term liabilities
Long-term debt, net current portion 4.692            5.126        5.551        3.916        3.943        4.046        4.135         4.251        4.358        4.473        4.593        4.706        4.848        4.996        5.152        
Deferred income taxes 6.442            6.093        6.330        11.585      7.767        7.970        8.145         8.372        8.583        8.810        9.046        9.268        9.548        9.841        10.146      
Minority Interests 2.407            2.407        2.406        2.407        2.409        2.472        2.526         2.597        2.662        2.732        2.806        2.874        2.961        3.052        3.147        
Total long-term liabilities 13.541          13.626      14.287      17.908      14.119      14.488      14.806       15.220      15.602      16.015      16.445      16.848      17.357      17.889      18.445      
Total debt 25.294          26.929      27.010      30.166      28.437      29.114      29.753       30.586      31.370      32.201      33.066      33.876      34.899      35.968      37.086      
Shareholder's Equity 17.288          17.917      17.560      18.185      18.758      19.248      19.671       20.222      20.729      21.278      21.849      22.385      23.061      23.767      24.506      
Total liabilities and equity 42.582          44.846      44.570      48.351      47.196      48.362      49.424       50.807      52.099      53.480      54.915      56.260      57.959      59.735      61.592      
D/A 59% 60% 61% 62% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60%
E/A 41% 40% 39% 38% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40%
ASSETS
Liabilities and Shareholders Equity
 Accruded compensation 
other accruded liabilities 





Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
EBIT 7.968,7 7.268,5 5.832,2 3.013,9 9.427,7 8.439,5 8.077,9 8.246,8 8.903,4 9.067,1 9.237,5 9.396,7 9.599,8 9.812,5 9.937,9
Taxes 2.159,5 2.696,6 1.673,8 84,4 1.923,3 2.174,0 2.080,9 2.124,4 2.293,5 2.335,7 2.379,6 2.420,6 2.472,9 2.527,7 2.560,0
EBIT (1-t) 5.809,2 4.571,9 4.158,4 2.929,5 7.504,4 6.265,5 5.997,1 6.122,4 6.609,9 6.731,4 6.857,9 6.976,1 7.126,9 7.284,8 7.377,9
Depreciation 1.258,7 1.554,2 2.268,4 1.988,2 1.631,2 1.673,8 1.758,5 1.802,6 1.900,0 1.946,6 2.005,3 2.066,8 2.131,0 1.946,6 2.005,3
Operating Cash Flow 7.067,9 6.126,1 6.426,8 4.917,7 9.135,6 7.939,3 7.755,5 7.925,0 8.509,9 8.677,9 8.863,2 9.042,9 9.257,9 9.231,3 9.383,3
Δ Net working capital 3.178,1 -990,7 473,3 305,1 551,9 -625,9 137,7 160,7 138,4 143,9 134,9 170,3 178,0 143,9 134,9
Capital Expenditures 1.726,1 1.402,7 980,2 1.011,0 1.298,3 1.600,0 1.681,0 1.709,2 1.754,5 1.801,6 1.845,7 1.901,5 1.959,8 1.801,6 1.845,7
Δ Other assets -18.599,7 794,1 -704,2 5.650,3 -4.196,3 962,5 240,3 187,7 238,8 248,3 232,7 293,9 307,2 248,3 232,7
Free Cash flow of assets 20.763,4 4.920,0 5.677,5 -2.048,7 11.481,7 6.002,8 5.696,6 5.867,4 6.378,2 6.484,2 6.650,0 6.677,2 6.813,0 7.037,6 7.170,0
Base-Case Cash Flows
Base-Case Value
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCFF 11.481,7 6.002,8 5.696,6 5.867,4 6.378,2 6.484,2 6.650,0 6.677,2 6.813,0 7.037,6 7.170,0
Terminal Value 98.587,88           
PV CF 5.589,17        4.938,64        5.867,42        6.378,19       6.484,16           6.649,99        6.677,19        6.812,99        7.037,55        102.099,25         
Base-case value 
(total)
158.534,55$       
Interest Tax Shields
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Interest tax shield 77,6 292,5 298,9 307,3 315,2 323,5 332,2 340,3 350,6 361,3 372,6
Terminal Value of 
tax shields
9.864,82             
PV tx shields 281,51           276,89           273,96           270,43          267,18              290,67           260,37           293,43           256,09           10.118,96           
Total  PV, tx 
shields
12.589,50$         
Cost of Financial Distress
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
CFD 51,2 26,7 25,4 26,1 28,4 28,9 29,6 29,7 30,4 31,4 31,9
Terminal Value 845,74                
PV CF 25,74 23,51 23,30 24,38 23,86 23,55 22,76 22,35 22,22 876,48
Total  PV, CF 1.088,15$           
Adjusted Present 
Value
170.035,90$    
Value of Equity
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCFE 9.318,2 7.131,7 6.188,8 6.115,3 6.666,8 6.789,8 6.905,4 7.112,9 7.047,8 7.185,8 7.257,9
Terminal Value 99.796,08           
PV CF 6.640,34 5.365,36 4.936,36 5.010,69 4.751,52 4.499,51 4.315,36 3.981,24 4.059,23 99.677,80
Value of Equity 143.237,42$    
# of shares 9386,3
Share Price 15,26$                
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Schering-Plough Information 
Appendix 20:  Schering – Plough segments weight 
 
 
Appendix 21: Sales of foreign countries with ≥ 5% consolidated net sales 
 
Source: Schering-Plough 2008 Form 10-K 
 
 











Total International net sales 6.402,00$        60% 8.093,00$        64% 12.946,00$       70%
France 809 8% 965 8% 1369 7%
Japan 669 6% 70 6% 1008 5%
Germany 408 4% 473 4% 835 5%
Canada 478 5% 578 5% 774 4%
20082006 2007
Year 
Sales % Total Sales growth % Total Sales growth % Total Sales growth % Total Sales growth % Total Sales
United States 3,219 39% 3,589 11% 38% 4,192 17% 40% 4,597 10% 43% 5,556 21% 52%
Europe and Canada 3,595 43% 4,040 12% 42% 4,403 9% 42% 5,500 25% 52% 8,903 62% 84%
Asia Pacific 676 8% 995 47% 10% 1,009 1% 10% 1,234 22% 12% 2,056 67% 19%
Latin America 782 9% 884 13% 9% 990 12% 9% 1,359 37% 13% 1,987 46% 19%
    Total 8,272 100% 9,508 15% 100% 10,594 11% 100% 12,690 20% 120% 18,502 46% 175%
20082004 2005 2006 2007
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2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Sales
United States 3,219 3,589 4,192 4,597 5,556 6,373 6,819 7,092 7,376 7,671 7,977 8,296 8,628 8,973 9,332
Europe and Canada 3,595 4,040 4,403 5,500 8,903 11,310 12,328 12,908 13,514 14,149 14,814 15,511 16,240 17,003 17,802
Asia Pacific 676 995 1,009 1,234 2,056 2,763 3,592 4,023 4,505 4,866 5,255 5,675 6,129 6,620 7,149
Latin America 782 884 990 1,359 1,987 2,526 2,905 3,166 3,451 3,762 3,950 4,148 4,355 4,573 4,801
    Total 8,272 9,508 10,594 12,690 18,502 22,972 25,644 27,188 28,846 30,448 31,997 33,630 35,352 37,169 39,085
0 0 0 0 0 0 0 0 0 0
Costs
Material and production (cost of sales) 3,070 3,346 3,697 4,405 7,307 8,040 8,975 9,516 10,096 10,657 11,199 11,771 12,373 13,009 13,680
Marketing and administrative 3,811 4,374 4,718 5,468 6,823 8,471 9,457 10,026 10,638 11,228 11,800 12,402 13,037 13,707 14,413
R&D 1,607 1,865 2,188 2,926 3,529 5,513 6,155 6,525 6,923 7,307 7,679 8,071 8,485 8,921 9,380
Acquired in-process R&D 0 0 0 3,754 0 0 0 0 0 0 0 0 0 0 0
Special and acquisition-related charges 153 294 102 84 329 329 329 329 329 329 0 0 0 0 0
Equity Income -347 -873 -1,459 -2,049 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870 -1,870
Oher (Income) Expense, net 58 18 -10 -533 -130 -161 -180 -191 -203 -214 -225 -236 -248 -261 -275
   Total 8,352 9,024 9,236 14,055 15,988 20,322 22,865 24,335 25,913 27,437 28,583 30,137 31,776 33,505 35,329
EBIT -80 484 1,358 -1,365 2,514 2,650 2,778 2,853 2,933 3,010 3,414 3,493 3,576 3,664 3,756
Interest 88 -13 125 150 -465 783 885 938 995 1,050 1,104 1,160 1,219 1,282 1,348
EBT 8 471 1,483 -1,215 2,049 3,432 3,663 3,791 3,928 4,061 4,518 4,653 4,795 4,946 5,104
Taxes @ 779 228 340 258 146 884 944 977 1,012 1,046 1,164 1,199 1,235 1,274 1,315
Net income -771 243 1,143 -1,473 1,903 2,548 2,719 2,814 2,916 3,015 3,354 3,454 3,560 3,672 3,789
Ebitda 373 970 1,926 -504 4,689 3,566 3,802 3,938 4,084 4,225 4,691 4,835 4,987 5,147 5,316
Forecasting
growth
Pro Forma Income Statements
Historical Infomation
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           85 |  
Appendix 23: Schering-Plough Costs disaggregated (Historical information) 
 
 
Appendix 24: Supplement data 
 
2005 2006 2007 2008
Cost of Sales 3,346 3,697 4,405 7,307
 - Manufacturing streamlining actions 146
 - Amortization of inventory adjusted to fair value 258 889
 - Amostization of acquired intangible assets 65 527
  - Incremental depreciation on property 3 33
  - Purchasing account adjustments 1,400 326
 - Cost Saving from manufacturing streamlining -100
 - Amortization related to other intangible 47 107 570
Total 0 193 1,733 2,345
 - Manufacturing related 3,346 3,504 2,672 4,962
% over sales 35% 33% 21% 39%
% all cost sales over sales 35% 35% 35% 39%
% manufacturing related over cost of sales 95% 61% 68%
Marketing and Administrative 4374 4718 5468 6823
 - Contractually definied costs for physician 204 242 223
- OBS acquisition related 1,706
- addition in 2004 fourth quarter of Bayer sales representatives 656
- Promotion spending, ongoing investments in EMA 377 875
Total 656 581 1,117 1,929
- Manufacturing related 3,718 4,137 4,351 4,894
% over sales 39% 39% 34% 26%
% all mkt and administrative over sales46% 45% 43% 37%
% manufacturing related over mkt and admin85% 88% 80% 72%
Research and Development 1865 2188 2926 3529
- Upfront payments related to licensing transactions 197
0 0 995 741
Total 0 0 1,192 741
- Manufacturing related 1,865 2,188 1,734 2,788
% over sales 20% 21% 14% 15%
% all R&D over sales 20% 21% 23% 19%
% manufacturing related overR&D 100% 100% 59% 79%
Special and acquisition-related charges 294 102 84 329
- Integration-related 61 54
- termination costs (productivity Transformation Program) 23 275
- Changes in Manufacturing operations (U.S. and Puerto Rico) 102
Total 0 102 84 329
- Manufacturing related 294 0 0 0
% over sales 3% 0% 0% 0%
% all SARC over sales 3% 1% 1% 2%
% manufacturing related over SARC 0% 100% 100% 100%
Costs
- Clinical trials, building greater breath and capacity to 
suppor pipeline (increase the value cost)
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Supplemental data
Depreciation and Amortization 453 486 568 861 2,175 917 1,023 1,085 1,151 1,215 1,277 1,342 1,411 1,483 1,560
        % of growth 7% 17% 52% 153% 57% 57% 57% 56% 56% 56% 56% 56% 55% 55%
        % net assets 6% 7% 7% 8% 21% 7.0% 7.0% 7.0% 7.0% 7.0% 7.0% 7.0% 7.0% 7.0% 7.0%
Capital expenditures (sales growth) 489 478 458 618 747 1,140 1,155 1,224 1,298 1,370 1,440 1,514 1,591 1,673 1,759
CAPEX/(Sales - Cost of sales) 9% 8% 7% 7% 7% 7%
Δ Net working capital -3 220 2,926 -899 825 591 341 366 354 342 361 381 402 424
Δ Other assets -54 110 562 28 -385 244 75 80 77 75 79 83 88 93
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Re = Rf + β (Rm - Rf) 7.40%
Rf 2.25%
β 1.03
Rp = Rm - Rf 5.00%




Appendix 25: Estimated Parameters 


















Market Value 2004 2005 2006 2007 2008 average






Interest Coverage ratio -5.406
probability of default 1.40%
 % CFD for Health 
Industry 27%
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Appendix 27:  Schering-Plough Balance Sheet 
 
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Assets
Cash and Equivalents 4,984       4,767        2,666        2,279        3,373        4,188        4,675        4,957        5,259        5,551        5,833        6,131        6,445        6,776        7,125        
Short-term investments 851          818           3,267        32             5               6               7               7               8               8               9               9               10             10             11             
Accounts Receivable 1,407       1,479        1,804        2,841        2,816        3,496        3,903        4,138        4,390        4,634        4,870        5,119        5,381        5,657        5,949        
Inventories 1,580       1,605        1,676        4,073        3,114        3,426        3,825        4,055        4,303        4,542        4,773        5,016        5,273        5,544        5,830        
Deferred Income taxes 309          294           266           349           435           540           603           639           678           716           752           791           831           874           919           
Prepaid expenses and other current assets 872          769           744           1,272        1,228        1,525        1,702        1,805        1,915        2,021        2,124        2,232        2,346        2,467        2,594        
Total Current Assets 10,003     9,732        10,423      10,846      10,971      13,182      14,715      15,601      16,553      17,471      18,360      19,297      20,286      21,328      22,428      
Property, at cost
Land 79            67             67             326           377           468           523           554           588           620           652           685           720           757           796           
Buildings and improvements 3,198       3,238        3,387        4,634        4,551        5,651        6,308        6,688        7,095        7,489        7,870        8,272        8,696        9,143        9,614        
Equipment 2,999       3,131        3,240        4,503        4,504        5,592        6,243        6,619        7,022        7,412        7,789        8,187        8,606        9,048        9,515        
Construction in progress 809          761           627           891           1,008        919           1,026        1,088        1,154        1,218        1,280        1,345        1,414        1,487        1,563        
Total 7,085       7,197        7,321        10,354      10,440      12,630      14,099      14,948      15,859      16,740      17,591      18,489      19,436      20,435      21,488      
Less accumulated depreciation 2,492       2,710        2,956        3,338        3,607        4,478        4,999        5,300        5,624        5,936        6,238        6,556        6,892        7,246        7,620        
Property, net 4,593       4,487        4,365        7,016        6,833        8,151        9,099        9,647        10,236      10,804      11,353      11,933      12,544      13,189      13,869      
Goodwill 209          204           206           2,937        2,778        2,268        2,660        2,820        2,992        3,158        3,318        3,488        3,666        3,855        4,054        
Other intangible assets, net 371          365           286           7,004        6,154        6,892        7,693        8,157        8,654        9,134        9,599        10,089      10,606      11,151      11,726      
Other assets 735          681           791           1,353        1,381        996           1,240        1,315        1,395        1,472        1,547        1,626        1,709        1,797        1,890        
Total assets 15,911     15,469      16,071      29,156      28,117      31,488      35,407      37,539      39,828      42,039      44,178      46,433      48,811      51,319      53,965      
-               -               -               -               -               -               -               -               -               -                
719           674           715           758           800           841           884           929           977           1,028        
(million) Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Liabilities:
Accounts Payable 978          1,078        1,254        1,762        1,677        1,845        2,060        2,184        2,317        2,446        2,570        2,701        2,840        2,986        3,140        
1,569       1,278        242           461           245           304           340           360           382           403           424           445           468           492           518           
Income taxes 896          213           323           617           183           227           254           269           285           301           316           333           350           368           387           
Accruded compensation 443          632           794           995           1,010        1,254        1,400        1,484        1,575        1,662        1,747        1,836        1,930        2,029        2,134        
other accruded liabilities 1,280       1,458        1,549        2,208        2,078        2,580        2,880        3,054        3,240        3,420        3,594        3,777        3,971        4,175        4,390        
Total current liabilities 5,166       4,659        4,162        6,043        5,193        6,211        6,933        7,351        7,799        8,232        8,651        9,092        9,558        10,049      10,567      
Long-term liabilities
Long-term debt, net current portion 2,392       2,399        2,414        9,019        7,931        6,662        7,693        8,157        8,654        9,134        9,599        10,089      10,606      11,151      11,726      
Deferred income taxes 111          117           122           1,701        1,551        1,926        2,150        2,279        2,418        2,552        2,682        2,819        2,964        3,116        3,276        
Other long-term liabilities 686          907           1,465        2,008        2,913        3,617        4,037        4,281        4,542        4,794        5,038        5,295        5,566        5,852        6,154        
Total long-term liabilities 3,189       3,423        4,001        12,728      12,395      12,204      13,880      14,716      15,614      16,480      17,319      18,203      19,135      20,118      21,156      
Shareholder's Equity 7,556       7,387        7,908        10,385      10,529      13,073      14,593      15,472      16,416      17,327      18,209      19,138      20,118      21,152      22,242      
Total liabilities and equity 15,911   15,469    16,071    29,156    28,117    31,488    35,407    37,539    39,828    42,039    44,178    46,433    48,811    51,319    53,965    
D/A 53% 52% 51% 64% 63% 58% 59% 59% 59% 59% 59% 59% 59% 59% 59%
E/A 47% 48% 49% 36% 37% 42% 41% 41% 41% 41% 41% 41% 41% 41% 41%
Short-term borrowings and 
current portion of long-term 
debt
ASSETS
Liabilities and Shareholders Equity
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Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 4,634 1,304 1,508 1,524 1,591 1,654 1,923 1,949 1,976 2,139 2,177
Terminal Value 33,998





Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Interest tax shield -33 202 228 242 256 271 284 299 314 330 347
Terminal Value 10,581
PV tx shields 193 219 228 237 245 252 260 268 276 10,810
Total  PV, tx 
shields
12,989
Cost of Financial Distress
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 25.02 7.04 8.14 8.23 8.59 8.93 10.38 10.52 10.67 11.55 11.76
Terminal Value 358.15






Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCFE 5,413 673 -401 1,080 1,057 1,206 1,591 1,596 1,601 1,606 1,611
Terminal Value 25,161
PV CF 627 -374 1,006 984 1,123 1,481 1,486 1,491 1,495 26,772
Value of Equity 36,091$   
(million)
#shares 5343
Price per share 6.75$         
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
EBIT (80)                484               1,358           (1,365)              2,514                  2,650         2,778                     2,853        2,933                3,010           3,414        3,493            3,576         3,664          3,756                     
Taxes (7,790)           234               311              290                  179                     683            716                        735           756                   775              879           900               921            944             968                        
EBIT (1-t) 7,710            250               1,047           (1,655)              2,335                  1,967         2,063                     2,118        2,177                2,235           2,535        2,593            2,655         2,720          2,789                     
Depreciation 453               486               568              861                  2,175                  917            1,085                     1,151        1,215                1,277           1,342        1,411            1,483         1,277          1,342                     
Operating Cash Flow 8,163            736               1,615           (794)                 4,510                  2,884         3,148                     3,269        3,392                3,512           3,877        4,004            4,138         3,997          4,130                     
Δ Net working capital -                    (3)                 220              2,926               (899)                    825            341                        366           354                   342              361           381               402            342             361                        
Capital Expenditures 489               478               458              618                  747                     1,140         1,224                     1,298        1,370                1,440           1,514        1,591            1,673         1,440          1,514                     
Δ Other assets -                    (54)               110              562                  28                       (385)           75                          80             77                     75                79             83                 88              75               79                          
Free Cash flow of assets 7,674            315               827              (4,900)              4,634                  1,304         1,508                     1,524        1,591                1,654           1,923        1,949            1,976         2,139          2,177                     
Base-Case Cash Flows
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Without Synergy 




Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Tax (10-K Info) 20.4% 26% 26% 26% 26% 26% 26% 26% 26% 26% 26%
growth
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Sales
United States 18,927 19,877 20,364 20,758 21,165 21,612 22,072 22,546 23,035 23,538 24,058
Europe, Middle  East and Africa 14,677 17,332 18,627 19,528 20,406 21,324 22,283 23,211 24,332 25,508 26,741
Asia 2,056 2,763 3,592 4,023 4,505 4,866 5,255 5,675 6,129 6,620 7,149
Japan 1,824 1,883 1,932 1,991 2,032 2,074 2,117 2,161 2,206 2,251 2,298
Other (Latin America) 4,870 5,590 6,141 6,599 7,094 7,627 8,051 8,498 8,971 9,470 9,998
    Total 42,352 47,446 50,655 52,899 55,202 57,502 59,777 62,091 64,673 67,388 70,244
Costs
Merger Costs
Material and production 12,890 13,617 14,674 15,373 16,265 16,989 17,701 18,432 19,236 20,082 20,973
Marketing and administrative 14,200 16,403 17,560 18,354 19,172 19,986 20,789 21,609 22,520 23,477 24,484
R&D 8,334 9,919 11,157 11,667 12,194 12,718 13,235 13,763 14,349 14,964 15,612
Equity Income -4,431 -4,431 -4,423 -4,415 -4,407 -4,400 -4,392 -4,384 -4,376 -4,369 -4,264
Oher (Income) Expense -1,944 -147 -165 -176 -187 -198 -208 -219 -231 -243 -256
Others 1,362 996 996 996 329 329 0 0 0 0 0
   Total 30,411 36,356 39,798 41,799 43,366 45,425 47,126 49,202 51,497 53,912 56,550
EBIT 11,942 11,089 10,856 11,100 11,836 12,077 12,651 12,890 13,176 13,476 13,694
Interest -85 1,918 2,045 2,131 2,218 2,306 2,393 2,481 2,581 2,685 2,795
EBT 11,857 13,007 12,901 13,230 14,055 14,383 15,045 15,371 15,756 16,161 16,489
Taxes @ 20,38% 2,145 3,351 3,323 3,408 3,621 3,705 3,876 3,959 4,059 4,163 4,247
Net income 9,712 9,656 9,578 9,822 10,434 10,678 11,169 11,411 11,697 11,998 12,241
Ebitda 15,748 13,680 13,590 13,943 14,790 15,143 15,828 16,178 16,592 17,026 17,385
Supplemental data
Depreciation 3,806 2,590 2,734 2,843 2,954 3,065 3,177 3,289 3,416 3,550 3,691
Capital expenditures 2,045 2,740 2,790 2,905 3,008 3,125 3,242 3,359 3,493 3,633 3,780
Δ Net working capital -347 199 696 479 527 492 486 496 551 580 610
Δ Other assets -4,168 577 429 315 268 316 323 312 377 395 414
Pro Forma Income Statements
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Appendix 30: Balance Sheet of the merged entity without synergies 
 
 
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Assets
Cash and Equivalents 7,741        8,670         9,256        9,666        10,086      10,506      10,921      11,344        11,815        12,311        12,832        
Short-term investments 1,123        1,154         1,179        1,213        1,243        1,277        1,311        1,343          1,384          1,427          1,471          
Accounts Receivable 6,595        7,174         7,661        8,002        8,351        8,700        9,045        9,395          9,787          10,198        10,631        
Inventories 5,397        5,135         5,571        5,850        6,192        6,481        6,764        7,057          7,375          7,711          8,064          
Deferred Income taxes 8,191        8,499         8,737        9,001        9,249        9,514        9,787        10,046        10,366        10,701        11,052        
Prepaid expenses and other current assets 1,228        1,525         1,702        1,805        1,915        2,021        2,124        2,232          2,346          2,467          2,594          
Total Current Assets 30,276      32,156       34,106      35,535      37,037      38,498      39,952      41,418        43,074        44,815        46,644        
Investments 6,491        6,661         6,807        6,998        7,173        7,363        7,561        7,746          7,980          8,225          8,480          
Property, at cost
Land 763           864            927           970           1,014        1,058        1,102        1,146          1,195          1,247          1,301          
Buildings and improvements 14,318      15,673       16,550      17,217      17,889      18,569      19,247      19,928        20,703        21,518        22,374        
Equipment 17,608      19,038       19,984      20,744      21,503      22,276      23,052      23,824        24,715        25,651        26,634        
Construction in progress 1,879        1,813         1,939        2,026        2,116        2,206        2,294        2,385          2,485          2,590          2,701          
Total 34,568      37,388       39,401      40,958      42,522      44,109      45,696      47,282        49,098        51,006        53,010        
Less accumulated depreciation 15,736      16,924       17,718      18,375      19,026      19,694      20,365      21,030        21,802        22,613        23,465        
Property, net 18,833      20,464       21,683      22,583      23,496      24,415      25,331      26,252        27,296        28,393        29,545        
Goodwill 4,217        3,744         4,168        4,371        4,581        4,790        4,994        5,205          5,435          5,678          5,933          
Other intangible assets, net 6,679        7,431         8,244        8,723        9,235        9,730        10,211      10,716        11,252        11,816        12,412        
Other assets 8,817        9,394         9,823        10,138      10,405      10,722      11,045      11,357        11,734        12,129        12,542        
Total assets 75,313      79,850       84,831      88,347      91,927      95,519      99,093      102,694      106,771      111,055      115,557      
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Liabilities:
Loans Payable and current portion of 
long-term debt 2,297        2,357         2,409        2,476        2,538        2,606        2,676        2,741          2,824          2,911          3,001          
Accounts Payable 2,295        2,412         2,639        2,780        2,945        3,090        3,232        3,379          3,538          3,705          3,881          
245           304            340           360           382           403           424           445             468             492             518             
Income taxes 1,609        1,691         1,749        1,807        1,862        1,919        1,978        2,035          2,103          2,175          2,250          
Accruded compensation other accruded liabilities 12,262      13,248       13,901      14,428      14,952      15,488      16,026      16,561        17,179        17,827        18,509        
Dividends payable 804           824            843           866           888           911           936           959             988             1,018          1,050          
Total current liabilities 19,512      20,837       21,880      22,716      23,567      24,418      25,271      26,120        27,099        28,128        29,208        
Long-term liabilities
Long-term debt, net current portion 11,874    10,708     11,828    12,407    13,011    13,607    14,192    14,795      15,453      16,147      16,877      
Deferred income taxes 9,318        9,895         10,294      10,652      11,001      11,362      11,729      12,087        12,512        12,956        13,423        
Other long-term liabilities 2,913        3,617         4,037        4,281        4,542        4,794        5,038        5,295          5,566          5,852          6,154          
Minority interests 2,409        2,472         2,526        2,597        2,662        2,732        2,806        2,874          2,961          3,052          3,147          
Total long-term liabilities 26,514      26,692       28,686      29,936      31,216      32,496      33,764      35,051        36,492        38,007        39,601        
Shareholder's Equity 29,287      32,321       34,264      35,694      37,145      38,605      40,058      41,523        43,179        44,919        46,749        
Total liabilities and equity 75,313      79,850       84,831      88,347      91,927      95,519      99,093      102,694      106,771      111,055      115,557      
ASSETS
Liabilities and Shareholders Equity
Short-term borrowings and current 
portion of long-term debt
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           91 |  
Appendix 31: Base-Case of the merged entity without synergies 
 
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
EBIT 11,942 11,089 10,856 11,100 11,836 12,077 12,651 12,890 13,176 13,476 13,694
Taxes 2,102 2,857 2,797 2,859 3,049 3,111 3,259 3,320 3,394 3,471 3,528
EBIT (1-t) 9,839 8,233 8,060 8,240 8,787 8,966 9,392 9,569 9,782 10,005 10,166
Depreciation 3,806 2,590 2,734 2,843 2,954 3,065 3,177 3,289 3,416 3,550 3,691
Operating Cash Flow 13,646 10,823 10,794 11,084 11,741 12,032 12,569 12,858 13,198 13,555 13,857
Δ Net working capital -347 199 696 479 527 492 486 496 551 580 610
Capital Expenditures 2,045 2,740 2,790 2,905 3,008 3,125 3,242 3,359 3,493 3,633 3,780
Δ Other assets -4,168 577 429 315 268 316 323 312 377 395 414
Free Cash flow of assets 16,116 7,307 6,878 7,385 7,938 8,098 8,518 8,691 8,777 8,947 9,054
Base-Case Cash Flows
Base-Case Value
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 16,115.62        7,307.16          6,878.45          7,385.16        7,938.49            8,098.06        8,518.06           8,690.86        8,776.95          8,947.45       9,053.80            
Terminal Value 132,586.08        





Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Interest tax shield 44.45               494.10             526.78             548.87           571.48               594.06           616.51              639.16           664.74             691.62          719.88               
Terminal Value 20,446.20          
PV tx shields 474.90             495.91             501.61           507.24               512.23           543.14              520.52           561.54             532.44          20,929.39          
Total  PV, tx 
shields
25,578.92
Cost of Financial Distress
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 76.17               33.79               33.52               34.37             37.00                 37.82             40.01                40.27             41.02               42.90            43.70                 
Terminal Value 1,203.89$             
PV CF 32.50               31.00               30.57             31.66                 31.11             31.64                30.62             30.00               30.16            1,242.39$             





Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCFE 14,731.2 7,804.9 5,787.6 7,195.8 7,723.5 7,995.4 8,496.3 8,708.9 8,648.9 8,792.0 8,868.9
Terminal Value 124,957.1
PV CF 7,267.13 4,991.78 5,942.38 5,994.65 5,874.05 5,980.75 5,801.42 5,472.06 5,554.72 126,449.89
Value of Equity 179,328.84$    million
#shares 14729.3
Price per share 12.17$                
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With Synergy 
Appendix 32: Merged company sales by areas 
 
Appendix 31: Long-term debt increase 
 
 Appendix 32: Synergies Value and Restructuring Cost of the merged entity 
  
 
Appendix 35: Upside Potential of Schering-Plough 
 
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Without synergy 11.874      10.708      11.828      12.407      13.011      13.607      14.192      14.795      15.453      16.147      16.877      
With synergy 11.874      17.080      18.236      19.044      19.873      20.701      21.520      22.353      23.282      24.260      25.288      







Operating Synergies 60.489 -8%
Material and production 8.738 24% -2% 205.254
Marketing and administrative 27.990 31% -4% 191.968
R&D 23.761 19% -2% 231.010
Financial Synergies 72.609 3%
Debt 72.609 35% 3% 181.514
Restructuring Costs % Restructuring Cost 15% 313.934
Total Synergies 133.098 -5% 313.934
(Millions)
Synergies
EV without Synergy EV with Synergy
228.437,87




Equity w Synergy/ 
Standalone equity val 93% 42%
Nádia Teixeira                        Merger of Merck & Co and Schering-Plough Corporation           93 |  
 
Appendix 36: Merck debt financing to purchase 
Schering-Plough 
 
Appendix 37: The three sources of finance 
 
 
Appendix 38: Income Statement of the merged entity with synergies 
 
 




Debt financing Total 69.767,42$               
Cash 12.000                    17%
Debt 22.077                    32%
Shares 35.691                    51%
Financing
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Tax (10-K Info) 20.4% 26% 26% 26% 26% 26% 26% 26% 26% 26% 26%
growth
Year 2,008 2,009 2,010 2,011 2,012 2,013 2,014 2,015 2,016 2,017 2,018
Sales
United States 18,927 19,877 20,364 20,758 21,165 21,612 22,072 22,546 23,035 23,538 24,058
Europe, Middle  East and Africa 14,677 17,332 18,627 19,528 20,406 21,324 22,283 23,211 24,332 25,508 26,741
Asia 2,056 2,763 3,592 4,023 4,505 4,866 5,255 5,675 6,129 6,620 7,149
Japan 1,824 1,883 1,932 1,991 2,032 2,074 2,117 2,161 2,206 2,251 2,298
Other (Latin America) 4,870 5,590 6,141 6,599 7,094 7,627 8,051 8,498 8,971 9,470 9,998




Material and production 12,890 13,048 13,930 14,547 15,181 15,813 16,439 17,075 17,785 18,532 19,317
Marketing and administrative 14,200 14,329 15,298 15,976 16,671 17,366 18,053 18,752 19,531 20,351 21,214
R&D 8,334 8,730 9,320 9,733 10,157 10,580 10,999 11,425 11,900 12,399 12,925
Equity Income -4,431 -4,431 -4,423 -4,415 -4,407 -4,400 -4,392 -4,384 -4,376 -4,369 -4,264
Oher (Income) Expense -1,944 -147 -165 -176 -187 -198 -208 -219 -231 -243 -256
Others 1,362 996 996 996 329 329 0 0 0 0 0
Restructuring Costs 1,423 1,520 1,587 1,656 1,725 0 0 0 0 0
   Total 30,411 33,948 36,476 38,248 39,400 41,216 40,891 42,648 44,609 46,671 48,936
EBIT 11,942 13,498 14,179 14,651 15,803 16,286 18,887 19,443 20,064 20,717 21,308
Interest -85 1,308 2,045 2,131 2,218 2,306 2,393 2,481 2,581 2,685 2,795
EBT 11,857 14,806 16,224 16,782 18,021 18,592 21,280 21,924 22,645 23,402 24,102
Taxes @ 20,38% 2,145 3,814 4,179 4,323 4,642 4,789 5,482 5,648 5,833 6,028 6,209
Net income 9,712 10,992 12,045 12,459 13,379 13,803 15,798 16,277 16,811 17,374 17,894
Ebitda 15,748 16,088 16,913 17,494 18,756 19,352 22,064 22,732 23,480 24,267 24,998
Pro Forma Income Statements
Supplemental data
Depreciation 3,806 2,590 2,734 2,843 2,954 3,065 3,177 3,289 3,416 3,550 3,691
Capital expenditures 2,045 2,740 2,790 2,905 3,008 3,125 3,242 3,359 3,493 3,633 3,780
Δ Net working capital -347 199 696 479 527 492 486 496 551 580 610
Δ Other assets -4,168 577 429 315 268 316 323 312 377 395 414
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Appendix 39: Balance Sheet of the merged entity with synergies 
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Assets
Cash and Equivalents 7,741        8,670              9,256              9,666              10,086            10,506            10,921            11,344            11,815            12,311            12,832            
Short-term investments 1,123        1,154              1,179              1,213              1,243              1,277              1,311              1,343              1,384              1,427              1,471              
Accounts Receivable 6,595        7,174              7,661              8,002              8,351              8,700              9,045              9,395              9,787              10,198            10,631            
Inventories 5,397        5,135              5,571              5,850              6,192              6,481              6,764              7,057              7,375              7,711              8,064              
Deferred Income taxes 8,191        8,499              8,737              9,001              9,249              9,514              9,787              10,046            10,366            10,701            11,052            
Prepaid expenses and other current assets1,228        1,525              1,702              1,805              1,915              2,021              2,124              2,232              2,346              2,467              2,594              
Total Current Assets 30,276      32,156            34,106            35,535            37,037            38,498            39,952            41,418            43,074            44,815            46,644            
Investments 6,491        13,508            13,721            14,163            14,587            15,032            15,486            15,925            16,456            17,011            17,593            
Property, at cost
Land 763           864                 927                 970                 1,014              1,058              1,102              1,146              1,195              1,247              1,301              
Buildings and improvements 14,318      15,673            16,550            17,217            17,889            18,569            19,247            19,928            20,703            21,518            22,374            
Equipment 17,608      19,038            19,984            20,744            21,503            22,276            23,052            23,824            24,715            25,651            26,634            
Construction in progress 1,879        1,813              1,939              2,026              2,116              2,206              2,294              2,385              2,485              2,590              2,701              
Total 34,568      37,388            39,401            40,958            42,522            44,109            45,696            47,282            49,098            51,006            53,010            
Less accumulated depreciation 15,736      16,924            17,718            18,375            19,026            19,694            20,365            21,030            21,802            22,613            23,465            
Property, net 18,833      20,464            21,683            22,583            23,496            24,415            25,331            26,252            27,296            28,393            29,545            
Goodwill 4,217        3,744              4,168              4,371              4,581              4,790              4,994              5,205              5,435              5,678              5,933              
Other intangible assets, net 6,679        7,431              8,244              8,723              9,235              9,730              10,211            10,716            11,252            11,816            12,412            
Other assets 8,817        9,394              9,823              10,138            10,405            10,722            11,045            11,357            11,734            12,129            12,542            
Total assets 75,313      86,697            91,745            95,512            99,341            103,187          107,019          110,873          115,246          119,841          124,670          
0 6,847 6,914 7,165 7,413 7,668 7,925 8,179 8,476 8,787 9,113
-               -                      -                      -                      -                      -                      -                      -                      -                      -                      -                      
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Current Liabilities:
Loans Payable and current portion of long-term debt2,297        2,357              2,409              2,476              2,538              2,606              2,676              2,741              2,824              2,911              3,001              
Accounts Payable 2,295        2,412              2,639              2,780              2,945              3,090              3,232              3,379              3,538              3,705              3,881              
245           304                 340                 360                 382                 403                 424                 445                 468                 492                 518                 
Income taxes 1,609        1,691              1,749              1,807              1,862              1,919              1,978              2,035              2,103              2,175              2,250              
Accruded compensation other accruded liabilities12,262      13,248            13,901            14,428            14,952            15,488            16,026            16,561            17,179            17,827            18,509            
Dividends payable 804           824                 843                 866                 888                 911                 936                 959                 988                 1,018              1,050              
Total current liabilities 19,512      20,837            21,880            22,716            23,567            24,418            25,271            26,120            27,099            28,128            29,208            
Long-term liabilities
Long-term debt, net current portion 11,874      17,555            18,742            19,573            20,425            21,276            22,118            22,974            23,929            24,934            25,990            
Deferred income taxes 9,318        9,895              10,294            10,652            11,001            11,362            11,729            12,087            12,512            12,956            13,423            
Other long-term liabilities 2,913        3,617              4,037              4,281              4,542              4,794              5,038              5,295              5,566              5,852              6,154              
g 0               0                     0                     0                     0                     0                     0                     0                     0                     0                     0                     
Minority interests 2,409        2,472              2,526              2,597              2,662              2,732              2,806              2,874              2,961              3,052              3,147              
Total long-term liabilities 26,514      33,539            35,600            37,102            38,629            40,164            41,690            43,230            44,968            46,794            48,714            
Total debt 46,025      54,376            57,480            59,818            62,196            64,582            66,961            69,350            72,067            74,922            77,922            
Shareholder's Equity 29,287      32,321            34,264            35,694            37,145            38,605            40,058            41,523            43,179            44,919            46,749            
Total liabilities and equity 75,313      86,697            91,745            95,512            99,341            103,187          107,019          110,873          115,246          119,841          124,670          
ASSETS
Liabilities and Shareholders Equity
Short-term borrowings and 
current portion of long-term 
debt
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Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
EBIT 11,942 13,498 14,179 14,651 15,803 16,286 18,887 19,443 20,064 20,717 21,308
Taxes 2,436 3,477 3,653 3,774 4,071 4,195 4,865 5,009 5,169 5,337 5,489
EBIT (1-t) 9,506 10,021 10,527 10,877 11,732 12,091 14,022 14,435 14,896 15,381 15,819
Depreciation 3,806 2,590 2,734 2,843 2,954 3,065 3,177 3,289 3,416 3,550 3,691
Operating Cash Flow 13,312 12,611 13,261 13,720 14,685 15,156 17,198 17,723 18,312 18,931 19,510
Δ Net working capital -347 199 696 479 527 492 486 496 551 580 610
Capital Expenditures 2,045 2,740 2,790 2,905 3,008 3,125 3,242 3,359 3,493 3,633 3,780
Δ Other assets -4,168 577 429 315 268 316 323 312 377 395 414
Free Cash flow of assets 15,782 9,095 9,345 10,022 10,883 11,223 13,147 13,556 13,891 14,323 14,706
Base-Case Value
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 15,781.89           9,095.43         9,345.34           10,021.59        10,882.94        11,222.79        13,147.20       13,556.30        13,890.84          14,323.42           14,706.30                   
Terminal Value 207,665.97$                  





Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Interest tax shield 17.28 -                 336.94            526.78              548.87             571.48             594.06             616.51            639.16             664.74               691.62                719.88                        
Terminal Value of 
tax shields
20,760.69$                    
PV tx shields 324.29 487.97 489.35 490.38 490.63 490.05 488.99 489.47 490.15 21,251.71$                    
Total  PV, tx 
shields
25,493.00
Cost of Financial Distress
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCF 70.31                  40.52              41.63                44.65               48.48               50.00               58.57              60.39               61.88                 63.81                  65.52                          
Terminal Value 1,823.92$                      
PV CF 39.00 38.57 39.81 41.60 41.29 46.56 46.20 45.57 45.22 1,868.61$                      





Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
FCFE 14,731 2,294 8,187 9,581 10,420 10,865 12,868 13,321 13,466 13,857 14,195
Terminal Value 200,446$                       
PV CF 2,136 7,098 7,734 7,832 7,603 8,385 8,082 7,607 7,288 207,398$                       
Value of Equity 271,162.25$       Merck
Scherin-
Plough
#shares 14729.3 201,837.44$    69,324.81$      
Price per share 18.41$                   9386.3 5343
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